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SCOPE OF THE THESIS 
The enzymatic deiodination of thyroid hormone is an important process 
since it concerns- among other things- the regulation of thyromimetic act-
ivity at the site of the target organ. To understand the mechanism of this 
regulation it is necessary to have a detailed knowledge of the mode of action 
of the enzyme(s) involved in the metabolism of thyroid hormone. My investigat-
ions of the deiodination of iodothyronines at the subcellular level, forming 
the basis of this thesis, are described in the appendix papers. It is not 
intended to deal in extenso with the technical aspects of my studies in the 
preceeding chapters. Rather it will be attempted to give a general review of 
the literature including- with some emphasis -my own work. 
Though not directly related to the subject of this thesis, the bio-
synthesis of thyroid hormone in the thyroid gland is treated in the first 
chapter. This is done because of possible similarities between thyroid hormone 
iodination and deiodination pathways, which are suggested by the finding that 
some drugs inhibit both processes. In the same chapter the relationship 
between iodothyronine structure and biological potency is described to illu-
strate that indeed deiodination has a dramatic effect on the activity of 
thyroid hormone. Besides deiodination, other pathways of metabolism are also 
considered. 
The second chapter concerns the in vivo investigation of thyroid hormone 
deiodination under physiological and pathological conditions. This includes 
the effects of internal and external factors which affect deiodination, such 
as dietary intake, drugs, stress and illness. Since much work has been done 
to find an explanation for the effect of calorie restriction on deiodination 
at the molecular level, the role of the diet is emphasized. This appears 
particularly important since nutritional status must be considered to contrib-
ute to the change in thyroid hormone metabolism found in other situations, 
for example in systemic illness. 
The in vitro observations of the enzymatic deiodination of thyroid 
hormone are described in chapter 3. A distinction has been made between 
(early) reports on the analysis of iodide production using chromatography, 
and (more recent) studies dealing with the detection of specific metabolites, 
often by means of radioimmunoassay. My investigations which belong to the 
latter category are presented in the appendix papers. 
In the last chapter an attempt is made to relate the in vivo findings 
(described in chapter 2) to the characteristic features of the enzymatic 
12 
reactions as revealed by the in vitro experiments (described in chapter 3). 
Especially the role of glutathione is emphasized with respect to changes in 
thyroid hormone metabolism during fasting. 
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1. GENERAL INTRODUCTION 
1.1. Thyroid hormone biosynthesis 
The principal secretory products of the thyroid gland are thyroxine 
(3,3' ,5,5'-tetraiodothyronine, T4) and 3,3' ,5-triiodothyronine (T3). Under 
physiological conditions and sufficient iodine intake they are synthesized 
in the human gland in a molar ratio of about 20:1. This is much higher than 
the ratio of their blood production rates (approximately 3:1), indicating 
an additional source for circulating r 3. It is now well established that the 
extra-thyroidal monodeiodination of r4 at the 5'-position (5'-deiodination) 
is a major route of T3 production. For the isomer, 3,3' ,5'-triiodothyronine 
(reverse T3 , rT3), peripheral production by monodeiodination of T4 at the 
5-position (5-deiodination) is even more important. Thyroidal secretion of 
rT3 and probably also of the lower substituted iodothyronines is almost 
negligible. Thus, in normal persons, total production rates for T4, T3 and 
rT3 amount to about 115, 45 and 30 nmol/day, where thyroidal secretion 
accounts for 100, 20 and 6%, respectively {Chopra et al, 1978a; see Table 
1.1.). 
Table 1.1. CONTRIBUTIONS OF THYROIDAL SECRETION AND PERIPHERAL PRODUCTION 
TO TOTAL PRODUCTION RATES OF T4, T3 AND rT3a 
Iodothyronine Total production 
T4 115 
T3 45 
rT3 30 
Thyroidal secretion 
(nmol/day per 70 kg 
body weight (%)) 
115 (100) 
9 ( 20) 
2 ( 6) 
Peripheral 
production 
36 (80) 
28 (94) 
aData from Chopra, 1976; Chopra et al, l978a (see also section 2.2.). 
Thyroxine is produced by coupling of two diiodotyrosine residues within 
the thyroglobulin molecule. Thyroglobulin is a high molecular weight 
(~660 000 dalton) glycoprotein. Its tyrosyl residues are iodinated by a 
process which requires the presence of iodide, hydrogen peroxide and thyroid 
peroxidase (for a review, see DeGroot and Niepomniszcze, 1977). For the 
mechanism of enzymatic iodination two hypotheses have been put forward. Both 
models agree in that iodination does not involve the generation of a free 
species of oxidized iodide, which subsequently reacts with tyrosyl moieties 
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in thyroglobulin. Rather a ternary complex is formed composed of oxidized 
iodide, thyroglobulin and peroxidase. The first model implies the oxidation 
of iodide in the presence of H2o2 to the iodinium ion (I+), and the enzyme-!+ 
complex formed is thought to be the active species in the iodination of tyrosine 
residues. The second model implies a radical reaction. Abstraction of an elect-
ron from iodide and of a hydrogen radical from tyrosine yields two radical 
species, I· and Tyr., which combine under formation of an iodotyrosyl residue. 
6 
HO \ l 
2 
Compound 
Tyrosine (Tyr) 
3-lodotyrosine (MIT) 
3,5-Diiodotyrosine (DIT) 
R2 
HO 
NH2 
0 CH2 - ~H- COOH 
R 1 
Compound 
Thy ron; ne (T Q) 
3-lodothyronine (3-Tj) 
3' -lodothyronine (3'-T1) 
3,5-Diiodothyronine (3,5-T2) 
3,3' -Diiodothyronine (3,3 '-T2) 
3' ,5' -Diiodothyronine (3' ,5'-Tz) 
3,3' ,5-Triiodothyronine {T3) 
3,3' ,5'-Triiodothyronine (rT3) 
3,3' ,5,5'-Tetraiodothyronine (T4) 
(thyroxine) 
Rl 
H 
I 
H 
I 
I 
H 
I 
I 
I 
R2 R3 
H H 
H H 
H I 
I H 
H I 
H I 
I I 
H 
I 
R4 
H 
H 
H 
H 
H 
I 
H 
I 
Fig. 1.1. Structures of tyrosine, thyronine and iodine-substituted derivatives. 
Iodination by either model yields 3-(mono)iodotyrosine (MIT), which by 
repetition of the sequence is converted into 3,5-diiodotyrosine (DIT). These 
residues are still contained within the thyroglobulin backbone. Addition of 
two DIT moieties by a process which is not fully understood, but which is 
probably also catalysed by the peroxidase, results in the formation of T4. 
Apparently, production of T3 and rT3 by combination of MIT and DIT residues 
as well as the addition of two MIT's to form 3,3'-diiodothyronine (3,3'-Tz) 
are less preferred. (For structures, see Fig. LL). Coupling, therefore, 
largely yields T4 molecules still attached by their analine side chain to 
the remaining of the thyroglobulin molecule. They are released from the 
protein by the action of lysosomal proteases. 
The relative uniqueness of thyroidal mechanisms in the oxidation of 
iodide and its subsequent incorporation suggests that thyroid hormone 
synthesis may be blocked specifically by intervention with these reactions. 
With regard to the subject of this thesis the effects of thioureylenes on 
thyroid activity are worth mentioning. Two members of this family of com-
pounds, methimazole and propylthiouracil (PTU; for structures, see Fig. 
1.2), are frequently used in the treatment of hyperthyroidism. They block 
thyroid hormone synthesis by inhibition of thyroid peroxidase. This results 
in an impairment of both the iodination and coupling reactions. In vivo as 
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well as in vitro investigations have shown that methimazole is about 10 times 
as active as PTU (Taurog, 1976). Studies by Cunningham (1964) and Jirousek 
(1968) have shown that thioureylenes react specifically with protein-sulfenyl 
iodides. This has resulted in the hypothesis (Jirousek and Cunningham, 1968; 
Maloof et al, 1969) that iodination of thyroid hormone by thyroid peroxidase 
involves the formation of an intermediate enzyme-sulfenyl iodide (E-SI) complex. 
2-mercopto-1-
methylimidozole 
(methimazole) 
H 
Rl Rz 
5-propyl-2-thiourocil (5-PTU) C3H7 H 
6-propyl-2-thiourocil (6-PTU) H c3H7 
Fig. 1.2. Structures of methimazole, 5- and 6-propylthiouracil. 
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It has, however, been observed that thioureylenes also inhibit peroxidase 
activity in the absence of I such as in the guaiacol oxidation assay 
(Taurog, 1976). 
The mechanism of action of these antithyroid drugs appears to be complex 
and depends on the concentration of the drug relative to that of iodide. In 
the presence of high r- concentrations the inhibitor is extensively oxidized 
and inhibition is only transient, whereas at low levels of I little or no 
oxidation takes place and inhibition is persistent (Taurog, 1976; Davidson 
et al, 1978, 1979; Edelhoch et al, 1979). In the first case inhibition is 
believed to be due to competition of the drug with tyrosine for the active 
E-I species (the oxidation state of iodine in this complex is not defined; 
see above). In the second situation the inhibitor prevents this species from 
being formed. Reaction of thioureylenes with the E-I intermediate could result 
in the formation of the sulfenyl iodide (-SI) form of the drug and subsequent-
ly of other forms with oxidized sulfur, such as the disulfide (-S-S-), sul-
fenic (-SOH), sulfinic (-S02H) and sulfonic (-S03H) acid (Morris and Hager, 
1966; Davidson et al, 1979; Lindsay et al, 1979). 
(o) E- I 
(b) 
(c) 
Fig. 1.3. Formation of formamidine sulfenyl iodide (a), formamidine disulfide 
(b) and cyanamide (c) from thiourea by thyroid peroxidase-iodine 
(E-I) complex. 
The above mechanisms do only partly hold for thiourea. In the absence 
of iodide this compound is not inhibitory. In the presence of iodide the di-
sulfide is formed (via the sulfenyl iodide), which decomposes to cyanamide 
(Fig. 1.3). The latter gives rise to an irreversible inactivation of the 
peroxidase. Inhibition of peroxidase activity by thiourea is, therefore, 
twofold. Firstly, by competition for the E-1 intermediate and, secondly, by 
virtue of its conversion to cyanamide (Davidson et al, 1979). 
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The generation of the sulfenyl iodide form of the goitrogens would also 
be difficult to reconcile with the formation of an E-SI complex as an inter-
mediate in the iodination process. In that case one would expect an enzyme-
thioureylene mixed disulfide to be formed (Cunningham, 1964). 
Besides its inhibition of thyroid hormone synthesis PTU also has a pro-
nounced effect on peripheral thyroid hormone deiodination, which property 
is not shared with methimazole. Results from in vitro experiments have led 
us to suggest that enzymatic deiodination does involve the formation of an 
intermediate E-Sl complex (see chapter 3). 
1.2 Thyroid hormone action; structure-activity relationship 
Thyroid hormone is a major factor in the regulation of the resting 
metabolic rate. The measurement of oxygen consumption has been used as a 
test for thyromimetic activity of thyroid hormone analogues. Another test 
on which structure-activity relationships may be based is the prevention 
of goitre in experimental animals induced by thyroid-blocking agents (e.g. 
PTU). In this goitre prevention test the activity to inhibit the release of 
thyrotropin (negative feedback) is measured. These and other in vivo bio-
assays. are blurred in the sense that the metabolism of a substance may be 
a major determinant in the response it elicits. This is of particular im-
portance in the estimation of the effect of T4, where the metabolically more 
potent T3 is produced (for a review, see Jorgensen, 1976). 
Recent studies have provided strong evidence that the first event in 
the initiation of the response to thyroid hormone is the binding to a 
specific nuclear receptor (Oppenheimer and Dillmann, 1978; Samuels, 1978; 
Latham et al, 1978). This leads to increased transcription rates and syn-
thesis of proteins involved in the metabolic response to thyroid hormone. 
This sequence of events is similar to that reported for several steroid 
hormones, except that in case of thyroid hormone no prior binding to cytosol-
ic receptors is required for binding at the nucleus (Docter et al, 1976). 
Of all compounds tested so far, binding to the nuclear receptor has been 
associated with a metabolic effect. The affinity for the receptor may there-
fore be taken as a measure for biological potency of thyroid hormone analogues. 
A correlation of the in vivo activity of thyromimetic compounds with 
their affinity for the receptor may be obscured by differences in metabolism, 
in binding to serum proteins, in cellular uptake and in binding to intra-
!8 
cellular sites other than the receptor. Nevertheless, Koerner et al (1975) 
have demonstrated for a variety of thyronine derivatives such a correlation 
to exist. In Table 1.2. the relative in vivo potency of the various iodo-
thyronines is compared with their relative affinity for the liver nuclear 
receptor. For comparison the relative affinities for human T4-binding glob-
ulin (TBG) are also given. Of the naturally circulating iodothyronines only 
T4 and r3 appear to have significant biological activity, where r 3 is about 
5 times as active as r4. Since approximately 30% of T4 is converted into T3, 
any in vivo effect of r4 may be accounted for by its transformation into r3. 
Thyroxine may, therefore, be regarded as a prohormone with little or no 
intrinsic metabolic activity. Not only the low affinity of T4 for the 
receptor, but also the finding that 90% of the endogenous thyroid hormone-
receptor complexes contain T3, while in the remaining 10% T4 is the ligand 
(Surks and Oppenheimer, 1977), are in agreement with this concept. 
Table 1.2. BIOLOGICAL ACTIVITY OF THYRONINE DERIVATIVES AND THEIR AFFINITY 
FOR PIG LIVER NUCLEAR RECEPTOR AND HUMAN TBG RELATIVE TO T4 (%) 
Compound Biological activity Affinity 
Antigoitera o2-consumptiona Receptorb TBGC 
T4 100 100 100 100 
T3 850 500 900 9 
rT3 <0.2 <0.1 3 38 
3,5-T2 7 5 3 0.07 
3,3'-T2 0.5 <0.1 14 1.3 
3' ,5'-T2 <0.01 <0.01 0.01 0.1 
3-T1 <0.01 <0.01 0.05 
3'-T1 <0.01 <0.01 0.025 
To 0 
Data from aJorgensen (1976); bSnllth et al (1980); cSngder et a1 (1976). 
1.3 Pathways of thyroid hormone metabolism 
The following reactions have been recognized in the metabolism of T4: 
i) deiodination, ii) oxidative deamination, iii) conjugation and iv) ether 
bond cleavage (Fig. 1.4). Of these, deiodination is the most important path-
way, accounting for at least 60% of T4 turnover in humans. Similar fractions 
of T4 are converted into T3 and rT3. However, deiodination is not a random 
HOOC 0 *I *I NH2 *I *I NH2 HOGO 0 0 0 CH2- ~H-COOH -o3so 0 0 0 CH2- ~H-COOH 
HO OH 1 1 ""- conjugation / 1 I 
T4 glucuronide ~ / T4 sulphate 
*
I *I NH 1 2 oxidative 
HO 0 0 CH2-CH-COOH .. 
deommot1on 
I I 
HO~O~CH2-COOH 
I I *
I NH2 I ether 
HO CH2- CH- COOH.,.___. cleavage 
I 
DIT 
,, ""' /.iodiootio" "'. 
Tetroc 
I~~ NH 
HO-y--OYCH2- ~H'_COOH 
I 
AlA. I~ NH H~O -Q--cH2- ~H=-COOH 
I 
,, ,,, 
Fig. 1.4. Pathways of T4 metabolism 
:;:; 
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process as has previously been suggested (Surks and Oppenheimer, 1971), but 
production of r 3 and rT3 may vary independently. Both T3 and rT3 undergo 
further deiodination. The sequential deiodination of T4 in peripheral tissues 
(Fig. 1.5) is thought to be mediated by two enzymes, i.e. iodothyronine 5-
and 5'-deiodinase (Schimmel and Utiger, 1977; Visser, 1978). 
~ ~ 
-........ .....---
eoOo-0-R 
.'E. 
Fig. 1.5. Sequential 5-(~) and 5'-deiodination ('o) of T4 (note that positions 
3 and 5 are equivalent as are positions 3' and 5') 
The alanine side chain of iodothyronines is subject to the action of 
deaminating and transaminating enzymes. Oxidative deamination occurs in 
several tissues and leads via pyruvic acid intermediates to the formation 
of acetic acid derivatives (Van Middlesworth, 1974). In this way 3,3',5,5'-
tetraiodothyroacetic acid (tetrac) and 3,3',5-triiodothyroacetic acid (triac) 
are formed. There is some controversy concerning the concentrations of these 
compounds in the circulation but these are certainly much lower than those of 
T4 and T3. Of interest is the high biological activity of triac in several 
test systems and its high affinity for the nuclear receptor (Goslings et al, 
1976). The occurence of tetraiodothyroformic acid in rat liver has been 
reported, which is also produced via the pyruvic acid analogue {Ramsden et 
al, 1974). Thyroid hormone may take part in transamination reactions with 
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enzymes in rat liver and kidney cytoplasm, which show preference for T3 above 
r4. Surprisingly, the activity of these enzymes is stimulated by treatment 
of the animals with rT3 (Fishman et al, 1977). The extent to which degradation 
of the alanine side chain contributes to the elimination of thyroid hormone 
remains to be elucidated but is probably of minor importance (Pittman et al, 
1980). 
Sulfate and glucuronide conjugates of thyroid hormone are formed by the 
action of enzymes located mainly in liver but also in kidneys {Van Middles-
worth, 1974). The conjugates lack biological potency and are excreted via 
the bile. Some investigators have suggested that there is an 11 entero-hepatic 11 
circulation of these conjugates, which would involve hydrolysis and sub-
sequently reabsorption into the portal vene. The existence of such a cycle 
has, however, been contested by others. Assuming that faecal excretion of 
radioactivity after administration of labelled T4 is a measure of conjugation, 
it has been shown that in humans 10-25% and in rats a somewhat greater fract-
ion of T4 is eliminated via this route. The remainder is excreted as iodide 
into the urine, which is representative for the deiodination process. 
There is much controversy about the occurrence and possible physiological 
significance of ether bond cleavage as a pathway for thyroid hormone degradat-
ion (Van Middlesworth, 1974). Early studies of the in vitro deiodination of 
radioiodine-labelled r4 were hampered by non-specific reactions leading to 
products other than T3 and rT3. In these reactions, which even occurred in 
boiled tissue preparations, iodide was produced concomitant with destruction 
of the thyronine structure. DIT was also produced in these circumstances 
(see section 3.2.). Recently, the attention of investigators has again been 
attracted to the possible occurrence of ether link cleavage. Balsam and 
Ingbar (1978) have detected the formation of DIT in rat liver homogenate in 
the presence of the catalase inhibitor 3-amino-1,2,4-triazole. This would 
indicate that this reaction may be catalysed by a peroxidase, which is in 
agreement with previous observations. The possible inv~vement of a peroxid-
ative mechanism was also suggested from studies by Burger and Allied (1977), 
who showed that this reaction is induced in leucocytes by phagocytosis. Be 
it as it may, the consensus is that hydrolysis of the ether bond is only a 
very minor pathway of r4 degradation in the organism. 
1.4. Conclusions 
The thyroid secretes mainly T4, a small amount of T3 and a negligible 
amount of rT3. The major part of T3 and virtually all of rT3 is produced 
peripherally. Iodination of tyrosine residues in thyroglobulin and the sub-
sequent coupling of iodotyrosines to iodothyronines are both mediated by 
thyroid peroxidase. The activity of this enzyme is inhibited by thioureylenes 
(e.g. methimazole and PTU). The formation of an enzyme-sulfenyl iodide complex 
as the active species in the iodination process appears unlikely. It is more 
likely that iodination involves the production of radicals. 
In several test systems the biological potency of T3 is much higher 
than that of T4, while rT3 is devoid of activity. Most, if not all, of the 
effect by T4 can be accounted for by its conversion into T3. Besides the de-
iodination, iodothyronines are metabolised by conjugation to sulfates and 
glucuronides, by oxidative deamination and possibly to a very minor extent 
by ether bond cleavage. Of these pathways peripheral deiodination is the 
most important, accounting for at least 60% of T4 turnover. Thus, the biologic-
al effect of thyroid hormone is largely determined at the level of peripheral 
tissues. Conversion of T4 into r3 may be regarded as an activation step, 
whereas by conversion into rT3 the hormone is irreversibly inactivated. 
2. THYROID HORMONE DEIOD!NATION - IN VIVO OBSERVATIONS 
2.1. Introduction 
3,3' ,5-Triiodothyronine has been identified in thyroid extracts and plasma 
by Roche, t~ichel and coworkers and by Gross and Pitt-Rivers (Gross and Pitt-
Rivers, 1952, 1953; Roche et al, 1952; Roche and Michel, 1954). Soon after its 
isolation it was suggested (Pitt-Rivers et al, 1955) that at least part of r3 
was produced by peripheral deiodination of T4, which could not be confirmed in a 
subsequent study (Lassiter and Stanbury, 1958). However, reports on the stepwise 
deiodination of r4 have continued to appear since then. These studies also in-
cluded the possible formation from T4 of iodothyronines other than T3 after 
Roche et al (1956a) had shown the presence of rT3 and 3,3'-T2 in thyroglobulin. 
Besides the demonstration of the formation of these compounds by isolated tissue 
preparations (see chapter 3) several in vivo observations were also in line with 
the concept that deiodination of T4 is an important pathway for the production 
of T3, rT3 and lower substituted iodothyronines. Especially noteworthy in this 
respect are the studies of Flock and collaborators, who reported on the product-
ion of 3,3'-T2 from T3 (Flock et al, 1960a,b), of rT3 and 3,3'-T2 from T4 (Flock 
et al, 1961), of 3,3'-T2 and 3'-T1 from rT3 and of 3'-T1 from 3,3'-T2 (Flock et 
al, 1963) in dogs. The products were present in conjugated form in bile, plasma 
and urine of normal and hepatectomized animals, although deiodination was con-
siderably slower in the latter group. Production of 3,3'-T2 from T3 in rats had 
also been reported by Roche et al (1956b). 
Despite these reports this matter has been controversial for many years. 
This was mainly due to the lack of sensitive methods for the measurement of the 
metabolites, forcing the investigators to rely on the use of radioactive isotopes 
and cumbersome chromatographic techniques. A frequently encountered problem was 
the spontaneous deiodination during chromatography. These techniques have im-
proved in recent years and radioactive 3,3'-T2 and 3'-T1, and 3' ,5'-T2, 3,3'-T2 
and 3'-T1, together with their sulfa- and glucuroconjugates, have been isolated 
from plasma after administration to humans of T3 and rT3, respectively, labelled 
with radioactive iodine in the phenolic ring (Rudolph et al, 1978; Sakurada et 
al, 1978). 
Measurement of plasma levels of the several metabolites had to await the 
development of more specific techniques. In case of r 3 some progress had been 
made by adaption of the competitive protein binding assay for T4, in which chro-
matography, however, was still a critical step (Sterling et al, 1969). A major 
breakthrough was obtained by the introduction of specific radioimmunoassays for 
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T3 (Gharib et al, 1971) and more recently for rT3 (Chopra, 1974), 3,3' ,T2 (Wu et 
al, 1976), 3',5'-T2 (Burman et al, 1978), 3,5-T2 (Meinhold and Schurnbrand, 1978) 
and 3'-T1 (Smallridge et al, 1979). 
2.2. Deiodination under physiological conditions 
There is general agreement in the literature concerntng normal circulating 
levels of T3 in humans (Chopra et al, 1978a). Less certainty exists about con-
centrations of rT3 in the plasma of normal subjects. This is, among ather things, 
caused by the impurity of the rT3 standards used in several laboratories and by 
the cross-reactivity of endogenous T4 in the rT3 radioimmunoassay (Premachandra, 
1978; Mathur et al, 1979; Meinhold and Visser, 1980). Even greater differences 
in serum levels of 3,5-T2, 3,3'-T2 and 3' ,5'-T2 in normal individuals have been 
reported. In case of the radioimmunoassay of serum 3,3'-T2 it has been suggested 
that part of the discrepancies is due to cross-reactivity by endogenous r3 (Vis-
ser et al, 1978b). 
Calculation of the daily production of a hormone is generally carried out 
by multiplying its plasma level with the metabolic clearance rate (MCR). The 
latter is an estimate of the elimination rate of the hormone and may be derived 
by several techniques. Preferably this should be done by noncompartmental analys-
is after a single injection of radioactive hormone or by the constant infusion 
technique (Cavalieri et al, 1971; Oppenheimer et al, 1975). 
Table 2.1. 11EAN SERUM CONCENTRATIONS, METABOLIC CLEARANCE RATES (MCR) AND PRO-
DUCTION RATES (PR) OF SEVERAL IODOTHYRON!NES IN NORMAL HUMAN SUBJECTS 
Iodothyronine 
T4 
T3 
rT3 
3,5-T2 
3,3'-T2 
3' ,5'-T2 
3'-T1 
Serum concentration 
(nmol/1) 
!lOa 
1.7-2.0c 
0.22-0.92d 
O.Oll-0.14e,f 
<0.018-0.32g 
O.OJ2-0.12i,k-m 
<0.06n 
MCR PR 
(1/day) (nmol/day) 
1.osb 115 
20-26c 34-52 
82-108c 18-99 
560-930h-j <10-300 
l60-300i,m 2-36 
References: aVisser et al, 1975b; bOppenheimer et a1, 1975; cChopra et al, 1978a; 
dPremachandra, 1978; eEngler et a1, 1979; £Maciel et al, 1979a; gVis-
ser et a1, 1978c; hGavin et a1, 1978; iGeola et al, 1979; jGa1eazzi 
and Burger, 1980; kBurman et al, 1978; 1Engler and Burger, 1978; 
mFaber et al, 1979a; nSmallridge et al, 1979. 
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Mean normal plasma levels, MCR and production rates (PR) for the various 
iodothyronines as reported from several laboratories are listed in Table 2.1. 
Large variations are observed, especially for rT3 and lower substituted iodo-
thyronines, most of which appear to stem from uncertainties in normal plasma 
concentrations. If the lower reported values for serum rT3 (20 ng/100 ml; 0.3 
nmol/1) are considered to be true, total PRof this metabolite would amount to 
approximately 20 "g (30 nmol)/day. For r 3 and T4 these values are approximately 
30 "g (45 nmol)/day and 90 "g (115 nmol)/day, respectively (standardized to 70 
kg body weight). 
Thyroidal secretion rates for T3 and rT3 have been calculated assuming that 
their secretion (relative to T4) is proportional to their content in thyroglob-
ulin. Estimations of T3;r4 and rT3;r4 ratios in normally iodinated thyroglobulin 
are 0.05-0.1 (Chopra et al, 1978a) and approximately 0.015 (Chopra, 1976), res-
pectively, from which secretion rates of around 6 ~g (9nmol) r 3 and 1 ~g (2 nmol) 
rT3 per day, respectively, may be calculated. It therefore appears that direct 
secretion by the thyroid accounts for about 20 and 6% of the daily PRof r 3 and 
rT3, respectively, the remainder being derived from peripheral conversion. Based 
on similar considerations, Abrams and Larsen (1973) have calculated- using 
estimates of T3 and T4 MCR by Schwartz et al (1971) - that in rats on a normal 
iodine diet, 70% of r 3 PR is derived from peripheral monodeiodination of T4. 
Caution should be applied to the interpretation of these data since it has been 
showp that part of r 4 may be converted into r 3 and rT3 before secretion (Laur-
berg, 1980). Moreover, stimulation of the thyroid (Laurberg, 1980) and iodine 
deficiency (Abrams and Larsen, 1973; Stevenson et al, 1974) lead to a prefer-
ential secretion of r 3. 
Nevertheless, the above results are in agreement with other approaches to 
assess the importance of thyroidal and peripheral mechanisms in the production 
of iodothyronines. Firstly, similar figures were calculated by comparison of 
serum r3 levels in r4-substituted athyreotic or hypothyroid humans (Braverman et 
al, 1970, 1973; Surks et al, 1973; Nomura et al, 1975) and rats (Larsen and Fru-
mess, 1977), with those in euthyroid subjects. Normal serum concentrations and 
turnover rates of rT3 have also been measured in T4-substituted subjects (Gavin 
et al, 1977). Secondly, estimates have been based on the quantitation of radio-
active r 3 in serum of humans (Sterling et al, 1970; Pittman et al, 1971; Inada 
et al, 1975) and rats (Zimmerman et al, 1978; Boonnamsiri, 1979) after the ad-
ministration of labelled T4. Both kind of studies have yielded values for the 
fractional conversion rate of T4 into r3 of 25-35%, and thus provided evidence 
that about 80% of circulating r 3 is produced by monodeiodination of r4. Finally, 
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the above findings were confirmed by the assessments of arterio-venous gradients 
across the thyroid in humans. Westgren et al (1977a) found that T4, T3 and rT3 
were secreted in a ratio of 85:9:1, and similar observations have been made by 
Hooper et al (1978). 
Less certainty exists about turnover rates of the lower substituted iodo-
thyronines. With respect to 3,5-T2 only preliminary figures concerning plasma 
concentrations have been published. Clearance rates have as yet not been estimat-
ed. Assuming the lower reported values of 1-2 ng/100 ml (0.02-0.04 nmol/1) for 
mean normal serum 3,3'-T2 to be real, an approximate PRof 5-20 ~g (10-40 nmol/ 
1)/day may be calculated. Although most authors agree that mean normal con-
centrations of 3' ,5'-T2 should be around 5 ng/100 ml (0.1 nmol/1), a different 
figure of only 0.6 ng/100 ml (0.012 nmol/1) has been published by Engler and 
Burger (1978). In addition, MCR varies according to the author between 160-300 
1/day. Production rate of this compound may, therefore, assume any value between 
1 and 18 "g (2-36 nmol)jday. 
In analogy with r 3 and rT3 - that.is, based on their content in thyroglobul-
in - it has been suggested (Geola et al, 1979) that the diiodothyronines are 
secreted by the thyroid in insignificant quantities as compared to peripheral 
productions. From the above it is clear that this suggestion should be consider-
ed premature. Nevertheless, several other observations (see section 2.1. and 
below) point to the peripheral stepwise deiodination of T4 as an important route 
by which these compounds are produced. Among these are the measurements of serum 
levels and daily turnover rates of 3,3'-T2 and 3' ,5'-T2 in athyreotic and hypo-
thyroid subjects on T4 substitution, which were found to be comparable to those 
in healthy persons (Burman et al, 1978; Gavin et al, 1978). Moreover, production 
from their direct precursors after administration of unlabelled T3 and rT3 has 
been detected by radioimmunoassay (Wu et al, 1976; Meinhold and SchUrnbrand, 
1977; Chopra et al, 1978b; Geola et al, 1980; Laurberg and Weeke, 1980). 
Still less is known about the PRof the monoiodothyronines and thyronine 
(T0) itself. Recently, radioimmunoassays for 3'-T1 have been developed and serum 
concentrations thereof have been found to be undetectable in euthyroid subjects. 
Its concentration was shown to increase after administration of 3' ,5'-T2 (Small-
ridge et al, 1979). Production in humans of radioactive T0 from r 4 labelled in 
the phenolic ring with 14c or in the alanine side chain with 3H was suggested 
from experiments by Pittman et al (1970). Its excretion into the urine has· been 
measured recently by a combination of gas chromatography and mass-fragmentography 
(Willetts et al, 1979). The results showed that only 20% of daily r4 production 
is excreted as thyronine into the urine. The fate of the remaining 80% remains 
to be established. 
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Fig. 2.1. Approximate thyroidal and peripheral production rates (nmol/day) of 
several iodothyronines in man. 
If measurements of PR are to have any physiological significance it has to 
be assumed that the distribution and elimination of administered hormone is 
identical to that endogenously produced. For the r4 metabolites no evidence has 
as yet been presented that this is the case, and attempts have been made to 
proof the contrary (Obregon et al, 1979). It is, therefore, not excluded that in 
some compartments products of T4 metabolism are further degraded before leaving 
these so-called "hidden" pools. Considering the different ways of distribution 
between the several iodothyronines, this could mean that MCR, and therefore PR, 
of metabolites may be underestimated substantially. (For a summary on thyroidal 
and peripheral production rates of T4 , T3, rT3 and 3,3'-T2, see Fig. 2.1.). 
In vivo investigations have not yielded clear indications as to the site of 
thyroid hormone deiodination. From observations discussed in section 2.3.3. and 
chapter 3 it is suggested that the liver and kidneys are important loci, but 
contributions from other tissues cannot be excluded. In this respect findings 
reported from the laboratory of Larsen are noteworthy. These workers studied the 
relative importance of serum r 3 and T4 in the negative feedback on TSH secretion 
in rats (Larsen and Frumess, 1977). Indirect evidence was obtained for a major 
role of serum T4 by the demonstration of a predominant binding of locally produc-
ed T3 to nuclear receptors in the anterior pituitary compared with T3 taken up 
from the circulation. The reverse was found if the origin of T3 bound to nuclear 
receptors in the liver was investigated (Silva and Larsen, 1977. 1978; Silva et 
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al, 1978a; Larsen et al, 1979, 1980). Similar findings to anterior pituitary 
were reported for rat cerebral cortex and cerebellum (Crantz and Larsen, 1980). 
2.3. Factors affecting deiodination 
2.3.1. Inhibitors 
2.3.1.1. Thiouracil derivatives 
Thiourea derived compounds were introduced by Astwood (1943) as potential 
drugs in the treatment of hyperthyroidism (see also Astwood et al, 1945). Mainly 
two of these have found wide clinical application since then, i.e. methimazole 
and 6-PTU. It was soon recognized that besides their goitrogenic activity (see 
chapter 1), thiouracil (TU) derivatives also interfere with T4 action (Andik et 
al, 1949; Barker et al, 1949) and metabolism (Hogness et al, 1954; Kalant et al, 
1955). It has been repeatedly demonstrated that TU derivatives inhibit the res-
ponse (i.e. oxygen consumption, TSH suppression, glycerol-3-phosphate dehydro-
genase activity, growth hormone secretion) in rats to T4, but not to T3 (Jagiel-
lo and McKenzie, 1960; Stasilli et al, 1960; Escobar del Rey et al, 1962; Hsieh, 
1962; Ruegamer et al, 1964, 1967, 1972; Hoffman et al, 1966; Mouriz et al, 1966; 
Bray and Hildreth et al, 1967; Frumess and Larsen, 1975; Hervas et al, 1976). 
Similar observations have been made with derivatives of 2-thiohydantoin, al-
though these compounds may also inhibit the response to T3 (Marx ·et al, 1970, 
1971; Ruegamer et al, 1972; see also Tsukui et al, 1978). Generally, such an 
effect is not observed with methimazole although a conflicting report has appear-
ed (Van Pilsum et al, 1973). 
Thiouracil and derived compounds have been shown to slow deiodination of T4, 
T3 and other iodothyronines in rats (VanArsdel and Williams, 1956; Jones and Van 
Middlesworth, 1960; Hershman and Van Middlesworth, 1962; Morreale de Escobar and 
Escobar del Rey, 1962). This was concluded from the reduction in urinary excret-
ion of iodide after administration of radioiodine-labelled T4 concomitant with 
an augmented faecal loss of conjugates. Again, such effects are not seen with 
methimazole. More specifically, Flock and Bollman (1963) concluded that deiodin-
ation of T4 at the 3' and 5' positions was decreased by TU, whereas that at the 
3 and 5 positions was increased. Inhibition of the conversion of T4 into r3 by 
PTU in rats was also found by Oppenheimer et al (1972), Bernal and Escobar del 
Rey (1974) and Frumess and Larsen (1975). Similarly, a decrease in T4 deiodinat-
ion by PTU has been observed in man (Hershman, 1964; Furth et al, 1966). More 
recently, PTU administration to thyrotoxic and T4-replaced hypothyroid patients 
has been shown to decrease serum r3 levels and to increase those of rT3 (Abuid 
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and Larsen, 1974; Geffner et al, 1975; Saberi et al, 1975; Westgren et al, 1977b; 
Laurberg and Weeke, 1978; Siersbaek-Nielsen et al, 1978). In addition, PTU has 
been found in humans to lower conversion of rT3 into 3~3
1 -T2 as well as degrad-
ation of the latter (Laurberg and Weeke, 1980). Intrapituitary r4-r3 conversion 
is not affected by PTU (Larsen and Frumess, 1977; Silva and Larsen, 1978). 
2.3.1.2. $-Adrenergic antagonists. 
Many of the symptoms of hyperthyroidism appear to resemble the manifestat-
ions of catecholamine excess {Verhoeven, 1978). This is why cervical sympathetic 
chain resection has been practiced at the end of the last century as the treat-
ment of hyperthyroidism in preference to thyroidectomy (Turner, 1974). More 
recently e-blocking drugs have been added to the therapeutic assortment of the 
physician in the abatement of thyrotoxic symptoms (Turner et al, 1965; Howitt 
and Rowlands, 1966; Shanks et al, 1969; Mazzaferi et al, 1976). 
Several sites have been proposed for the interaction of the thyroid and the 
sympathetic nervous system. Despite the demonstration of sympathetic innervation 
of the thyroid (Melander, 1977), studies of the effects of a- and s-adrenoceptor 
agonists and antagonists on thyroid activity have yielded apparently conflicting 
results. A number of reports have indicated that several aspects of thyroid 
function are not affected by propranolol (Azizi et al, 1974; Wartofsky et al, 
1975; Bastomsky and Lin, 1979). 
It has been suggested that in hyperthyroidism there is an increased sensit-
ivity to catecholamines. Although earlier studies have failed to show such an 
abnormality in experimental hyperthyroidism (McDevitt, 1976, and references 
therein). more recent reports have supported this suggestion (Kunes, 1977; Hashi-
moto and Nakashima, 1978; Fregly et al, 1979). It has also been found that 
thyroid hormone has a profound effect on the number and properties of a- and s-
adrenergic receptor sites in some tissues, e.g. the myocardium (Ciaraldi and 
Marinett, 1977, 1978; Williams et al, 1977; Kempson et al, 1978; Williams and 
Lefkowitz, 1979). 
Another possibility to account for the therapeutic merits of s-adrenoceptor 
antagonists, which has been investigated, is an alteration in peripheral thyroid 
hormone metabolism induced by these agents. In rats, adrenaline accelerates the 
deiodination of T4 and r3 (Kallman and Starr, 1959). It had been shown before 
that propranolol may slow the peripheral degradation of r4 in humans (Hadden et 
al, 1969). It is now known that propranolol application to hyperthyroid subjects 
results in a decrease in serum T3 levels and an increase in those of rT3 often 
without affecting serum T4 concentrations (Nauman et al, 1974; Murchison et al, 
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1976; Verhoeven et al, 1977; Wiersinga and Touber, 1977). Similar observations 
were made in T4-maintained hypothyroid patients (Wiersinga and Tauber, 1977; 
Faber et al, 1979b; Feely et al, 1979). The changes were found to be due to a 
decreased production rate of r 3 from T4 and a decreased elimination rate of rT3 
(Lumholtz et al, 1978, 1979). It has been questioned whether the effects on 
thyroid hormone metabolism do contribute to the therapeutic value of a-adren-
ergic blocking drugs since it has been found that more selective e1-antagonists 
such as practolol (Nelson and McDevitt, 1975; Murchison et al, 1976), atenolol 
(McDevitt and Nelson, 1978; Nillson et al, 1979) and metoprolol (Murchison et 
al, 1979) are as effective as propranolol in the amelioration of thyrotoxic 
symptoms without affecting serum T3 levels. 
2.3.1.3. Glucocorticosteroids. 
Corticosteroids have been known for long to have effects on the hypothalam-
us-pituitary-thyroid axis in man (Ingbar and Freinkel ,1956). Which site of this 
axis is affected appears to be a complex function of duration, dose and route of 
administration of the glucocorticoids. Short-term administration has indicated 
that these steroids reduce thyrotropin (TSH) secretion by an effect at a supra-
hypophyseal level (Wilber and Utiger, 1969; Nicoloff et al, 1970; Haigler et 
al, 1971; Singer and Nicoloff, 1973; Otsuki et al, 1973). This was concluded 
from - among other things - the inhibitory effect of prednisolone and other 
glucocorticoids on basal but not on TSH-releasing hormone (TRH)-stimulated TSH 
secretion. The rebound phenomenon after steroid withdrawal has been applied to 
the assessment of TRH reserve in patients (Singer and Nicoloff, 1973; Singer et 
al, 1978). 
In the longer run, glucocorticosteroids appear to have an inhibitory effect 
on the pituitary as we1l (Faglia et al, 1973; Otsuki et al, 1973; Dussault, 1974; 
Re et al, 1976; Sowers et al, 1977). A decrease in TRH-induced TSH release has 
also been observed in patients with Cushing's syndrome (Otsuki et al, 1973; 
Kuku et al, 1975; Duick and Wahner, 1979; Visser and Lamberts, 1980). The im-
portance of endogenous cortisol in the regulation of thyrotroph function has 
been demonstrated by a significant increase in serum TSH after lowering of corti-
sol secretion by metyrapone administration (Re et al, 1976). Also, serum TSH has 
been found to be increased in adrenal insufficiency (Topliss et al, 1980). Dexa-
methasone does not change the response of the thyroid to TSH (Vigneri et al, 
1975). 
The effect of corticosteroids on the hypothalamus-pituitary-thyroid axis 
in rats has been difficult to assess and apparently conflicting reports have 
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appeared. Here too, the changes observed depend on duration and dose of steroid 
administration (Brown and Hedge, 1973, 1974; Ranta, 1975, 1976). Nevertheless, 
it has been demonstrated unequivocally that physiological levels of corticoster-
one play a part in the regulation of pituitary sensitivity to TRH (Pamenter and 
Hedge, 1980). 
In addition, glucocorticoid administration to humans has been shown to in-
fluence peripheral thyroid hormone metabolism. An early study by Kumar et al 
(1968) had.suggested that glucocorticosteroids primarily alter the hepatic metab-
olism of r 4. This was based on an abnormal elimination of injected radioactive 
T4. The rapid disappearance phase was slowed, and both fractional turnover rate 
and distribution volume were diminished. This seems to indicate that liver up-
take of T4 is reduced by glucocorticoids. Later studies have shown that serum T3 
is decreased and serum rT3 is temporarily increased (Duick et al, 1974; Chopra 
et al, 1975; Burr et al, 1976; DeGroot and Hoye, 1976). This has been observed 
in normals and in r-4-substituted hypothyroid subjects. Of course, secondary to 
an impaired thyrotroph function, serum T4 may also be decreased. Similar alter-
ations have been observed in patients with Cushing's syndrome (Duick and Wahner, 
1979; Visser and Lamberts, 1980) and also after administration of corticotropin 
to healthy persons (e.g. Westgren et al, 1977c). No effects have been observed 
with mineralocorticosteroids (Westgren et al, 1977c). 
Finally, glucocorticoid excess has been shown to change serum binding of 
thyroid hormone (Oppenheimer and Werner, 1966; Gamstedt et al, 1979). Binding 
capacity of TBG is decreased and that of T4-binding prealbumin (TBPA) increased 
such that the free fractions of T3 and T4 are slightly elevated. 
Due to the rapid inhibition of thyroid hormone synthesis at several loci, 
treatment with dexamethasone in conjunction with PTU has been advocated to ob-
tain early relief in thyroid storm (Croxson et al, 1977a). The effects of these 
two drugs on serum thyroid hormone levels were found to be additive. It is note-
worthy that benificial effects of dexamethasone on serum T4 were also seen in 
patients with Graves' disease (Williams et al, 1975). Figure 2.2. il1ustrates 
the multiple actions of glucocorticoids on the hypothalamus-pituitary-thyroid 
axis. 
2.3.1.4. Miscellaneous 
Several iodine-containing compounds, other than iodothyronines, have been 
reported to influence thyroid hormone deiodination in vivo (for structures, see 
Fig. 2.3.). Before T3 was ever discovered, it was shown that alkyl 3,5-diiodo-
4-hydroxybenzoates reduced the T4-stimulated oxygen consumption in mice (Barker 
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et al, 1951; Sheahan et al, 1951). Later it was found that- as with PTU- the 
response to T3 was increased (Maclagan et al, 1952). Inhibition of deiodination 
was thought to be the underlying mechanism of this action, as confinmed by a 
subsequent study (Wilkinson et al, 1954). Escobar del Rey and Morreale de Esco-
bar (1962) and Flock and Bollman (1964) have, however, provided evidence that 
this is mainly a secondary effect, caused by the augmentation of the faecal ex-
cretion of T4 conjugates. 
Recently, clinical observations have been made of the inhibition of T4-T3 
conversion and rT3 breakdown by other iodinated compounds, e.g. amiodarone, an 
antiarrythmic and antianginal drug (Burger et al, 1976; Jonckheer et al, 1978), 
and several radiographic contrast agents having a 2,4,6-triiodoaniline structure 
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(BUrgi et al, 1976; Wu et al, 1978a; Suzuki et al, 1979). The latter have been 
used in the treatment of hyperthyroidism (Wu et al, 1978c), despite the deletor-
ious effect of iodine administration in this condition (see also Costa, 1979; 
Chopra et al, 1979c). Some of these compounds also inhibit the binding of r3 to 
its receptor (DeGroot and Rue, 1979). In contrast to PTU, these X-ray contrast 
agents do block the intrapituitary conversion of r4 into r3. This leads to an 
impairment of the TSH-suppressive effect of T4 (Larsen et al, 1979; Suzuki et al, 
1979). 
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Fig. 2.3. Structures of iodine-containing inhibitors of thyroid hormone deiodin-
ati on. 
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In this respect it is worthwhile to mention that pharmacological doses of 
rT3 blunt the metabolic response to T4 (Pittman et al, 1959a,b; Pittman et al, 
1960; Coiro et al, 1980). This is most probably due to the inhibition of the 
peripheral production of T3 from T4 (Coiro et al, 1980). The physiological sig-
nificance of this effect by rT3 is doubtful because of the huge doses needed. 
It has, nevertheless, been applied in the treatment of patients with Graves' 
disease (Benua et al, 1959). 
It has been speculated that thyroid hormone may act as a neurotransmitter, 
and that deiodination may be mediated by tyrosine hydroxylase (Dratman, 1974; 
Dratman et al, 1976a,b; Dratman and Crutchfield, 1978). Indeed, T4 degradation 
in rats (Dratman et al, 1976b) and the postnatal rise of serum r3 in newborn 
lambs (Fisher et al, 1977) have been reported to be impaired by administration 
of a-methyltyrosine, a specific tyrosine hydroxylase inhibitor. Other authors, 
however, have been unable to demonstrate a significant effect of a-methyl-
tyrosine administration to humans (Dvorak et al, 1978) and to rats (Pascual et 
al, 1979) on the conversion of T4 into T3. 
Many drugs appear to affect serum thyroid hormone levels by interference 
with the binding to serum proteins. Among these is diphenylhydantoin which, in 
addition, appears to stimulate T4-T3 conversion (Cavalieri et a1, 1979, and 
references therein). Of importance are, finally, the findings of an increased 
disposal of T4 by phenobarbital treatment as a result of an enhanced biliary 
excretion and perhaps also increased deiodination (Oppenheimer et al, 1971; 
Cavalieri et al, 1973). 
2.3.2. Diet 
Numerous studies - in vivo as well as in vitro - have emphasized the role 
of nutrients in the regulation of peripheral thyroid hormone deiodination. The 
results have indicated that not only the amount of calories consumed but also 
the composition of the diet are important factors. The interest in diet induced 
alterations in T4 metabolism has been aroused by the observations by Portnay et 
al (1974) of a selective decrease in serum T3 concentrations in humans during 
starvation. These studies were extended by the demonstration of a concomitant 
rise in serum rT3 levels during fasting (Vagenakis et al, 1975; Spaulding et al, 
1976). Serum T4 remained constant during the studies, and similar effects were 
noted in normal subjects on suppressive T4 doses. These results were amply con-
firmed by others for starvation (Merimee and Fineberg, 1976; Carlson et al, 
1977), semi-starvation (Grant et al, 1978; Visser et al, 1978a) and anorexia 
nervosa (Moshang et al, 1975; Miyai et al, 1975; Croxson and Ibbertson, 1977). 
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In some of these studies it was noted that in contrast to a sustained reduction 
of serum T3, the rise in serum rT3 was transient (Carlson et al, 1977; Visser et 
al, 1978a; see Fig. 2.4.). Overfeeding has been shown to increase serum r 3 
levels (Bray et al, 1976). In subsequent investigations it has been attempted to 
more clearly define i) the importance of diet composition, and ii) the underly-
ing mechanism of these changes in T3 and rT3 levels. 
120 
BODY WEIGHT ~ (kg) 
70 
11 
T4 ~ 
(~g/dl) 
! ! 1 
6 
150 
T3 ~ (ng/dl) 
50 
35 
* 
rT3 
* * (ng/dl) 
lO 
0 2 4 6 
WEEKS ON DIET 
Fig. 2.4. Effects of a 300 kca1 diet on body weight, serum r4, r3 and rT3 (from Visser et a1, 1978a). 
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It has been demonstrated that not so much reduction of calorie intake but 
rather the selective decrease in consumption of protein and carbohydrate is res-
ponsible for the changes observed. In addition~ composition of the diet may 
affect serum r 3 and rT3 concentrations independently. Thus, feeding obese sub-jects a 800 kcal diet containing no carbohydrate resulted in a lowering of serum 
r 3 without an effect on serum rT3. On an isocaloric diet containing 50g of carbo-
hydrate the concentrations of neither T3 nor rT3 appeared to be affected (Spaul-
ding et al, 1976). Similar findings were reported by Azizi (1978), who showed 
that - after fasting - refeeding with a mixed or a 100% carbohydrate diet caused 
a return of serum r3 and rT3 to control values. In contrast, refeeding with a 
protein diet only restored serum rT3 concentrations. 
The importance of carbohydrate in supporting peripheral thyroid hormone 
deiodination has also been demonstrated by Burman et al (1979a) in a fasting-
refeeding experiment, showing the efficacy of glucose and fructose in restoring 
serum T3 and rT3 levels. A requirement for the utilization of sufficient amounts 
of glucose to support deiodinase activity was demonstrated by the increase in 
serum T3 together with unaffected T4 and slightly decreased rT3 levels after 
administration of insulin to healthy individuals (Tevaarwerk et al, 1979). In-
terestingly, Westgren et al (1977d) noted in fasted subjects an acute stimulat-
ion of peripheral T3 formation by oral but not by intravenous glucose feeding. 
These studies, therefore, emphasize the role of hepatic glucose metabolism in 
the regulation of thyroid hormone deiodination (see also Saunders et al, 1978). 
On the other hand, by studying the effect of norma- and hypercaloric diets, 
with the proportion of carbohydrate varyied between 20-80%, Davidson and Chopra 
(1979) concluded that the changes observed in serum r3 were correlated best with 
calorie intake rather than with carbohydrate intake. Otten et al (1980) compared 
four diets containing 1500 kcal composed of either 100% fat, 50% fat-50% protein 
or 50% fat-50% carbohydrate and a control, mixed diet. It was noted that the all 
fat diet induced at least the same alterations in serum iodothyronine levels as 
did fasting. Complementing the diet with either carbohydrate or protein diminish-
ed but did not prevent the increase of serum rT3, whereas addition of protein to 
the diet did not protect against the effect of fat on serum T3 concentrations. 
A negative effect of fat on thyroid hormone deiodination was proposed. 
It has been suggested _that the decrease in T 3 seen during fasting spares 
muscle protein, since adjusting serum T3 to normal (Gardner et al, 1979) or 
supranormal (Burman et al, 1979b) values resulted in increased muscle catabolism 
(see also Bray, 1977; r~oore et al, 1980). 
Metabolic clearance rates of iodothyronines have been measured to assess 
which processes are affected by a reduction of calorie intake. It was found that 
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the elimination of T3 was unaltered, pointing to a decreased PR in these circum-
stances (Vagenakis et al, 1977; Suda et al, 1978). However, no major effect of 
fasting on rT3 production was observed. Increased serum rT3 concentrations are 
primarily a result of a decreased MCR (Eisenstein et al, 1978; Suda et al, 1978). 
Clearance rate and PRof T4 have been found to be decreased (Grant et al, 1978; 
Suda et al, 1978) or normal (Vagenakis et al, 1977). A decrease may be due to 
diminished thyroid activity secondary to a lowering of TSH secretion (e.g. Carl-
son et al, 1977; Croxson et al, 1977b; Azizi, 1978; Burman et al, 1980). Over-
feeding has been shown to increase both serum concentrations and MCR of r3, ir-
respective of whether the extra calories were supplied by fat, carbohydrate or 
protein (Danforth et al, 1979). Production rates of T4 remained constant. 
The role of the diet in the regulation of peripheral T4 deiodination has 
been studied less extensively in animals. A decrease in both faecal excretion 
and deiodination has been observed in rats during fasting (Ingbar and Galton, 
1975). Consequently, serum T4 levels were doubled within 48 hours of starvation. 
In contrast, fasting has been shown by Harris et al (1978a) and Kaplan and Utiger 
(1978a) to result in a substantial decline of both serum T3 and T4. Also serum 
TSH but not its response to TRH was decreased. Refeeding after a 4 days fast 
with protein or carbohydrate resulted in a rapid increase in serum r3, whereas 
refeeding with fat had no effect. Refeeding after 6 days of starvation with any 
of the nutrients did not acutely elevate serum r 3 (Burger et al, 1980). The 
effect of semi-starvation in rats on serum r 3 concentrations depends on the 
composition of the diet. Substituting protein for carbohydrate induces a de-
crease in serum T3 without affecting r4 concentrations (Glass et al, 1978). In 
rabbits, starvation has been shown to induce a tenfold increase in circulating 
rT3 and a 50% increase in T4 levels, whereas those of T3 remained constant. The 
r~CR of T4 did not change, that of r 3 increased and in case of rT3 it decreased. 
As a result, turnover rates of all these iodothyronines were found to be increas-
ed. Since the PR of T3 exceeded that of r4, a substantial amount of the former 
appears to derive from thyroidal secretion in rabbits (Takagi et al, 1978). 
An interesting observation has been the demonstration of a decrease in the 
number of nuclear r3 receptors during starvation (Burman et al, 1977; DeGroot et 
al, 1977; Schussler and Orlando, 1978). This may be related to the finding that 
not only resting metabolic rate is decreased by fasting in humans (Grant et al, 
1978) and in rats (Wimpfheimer et al, 1979) but also the efficacy of T3 to stim-
ulate it (Wimpfheimer et al, 1979). Finally, a profound decrease in serum TBG 
and especially TBPA was observed during caloric restriction (Moreira-Andres et 
al, 1980). 
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2.3.3.1. Stress 
Major alterations in thyroid hormone metabolism have been observed to be 
induced by internal and external factors which disturb the normal functioning of 
the organism. Most attention has been paid to the effects of surgical stress, 
exposure to a cold envirnment and non-thyroidal illness, such as liver and kid-
ney disease, myocardial infarction and infection. 
Rapid elevation of rT3 and lowering of T3 serum concentration were observed 
in patients undergoing surgery (Burr et al, 1975; Brandt et al, 1976). By study-
ing the effect of epidurial analgesia it was concluded that changes in thyroid 
hormone levels .were independent of increased cortisol secretion (Brandt et al, 
1976). A lack of correlation between cortisol and T4 metabolism after surgery 
has also been reported by Presscott et al (1979). Still, Hagenfeldt et al (1979) 
proposed that adrenocortical activation and/or changes in the mode of nutrition 
may be the cause of the changes observed. A considerable reduction of serum TSH 
was noted by Keh let et a l ( 1979) , but not by Hagenfe l dt et a l ( 1979) . Concomitant 
with T3, levels of TBPA were found to decline after surgery (Ramsden et al,1978). 
Qualitatively similar changes in serum thyroid hormone levels occured after total 
and subtotal thyroidectomy (Anderberg et al, 1979; Tarnai et al, 1979; Veen, 
1980). Surgery has been found to affect thyroid hormone deiodination in rabbits 
likewise (Ramsden et al, 1979). 
Exposure of rats to cold has been known for a long time to stimulate de-
iodination and faecal clearance of T4 (Kassenaar et al, 1959; Hillier et al, 
1968a,b; Galton and Nisula, 1969). Conversion of T4 into T3 is stimulated by a 
cold environment (Ruegamer et al, 1964; Bernal and Escobar del Rey, 1975a,b). 
This is not caused by the increased food intake of the animals (Van Hardeveld 
et al, 1979a). It has been suggested that the sympathetic nervous system plays 
a role in the induction but not in the magnitude of the response to cold (Van 
Hardeveld et al, 1979b). 
In humans, short-term (30 min) elevation to 39°C and reduction to below 35°C 
of body temperature (during and after sauna bath) failed to affect serum T4 or 
T3 levels (Tuomisto et al, 1976). In contrast, elevation of body temperature to 
38.5°C - induced by moderate exercise in a hot environment - has been shown to 
reduce serum T3 and to increase serum rT3, whereas T4 levels remained unchanged 
(Epstein et al, 1979). The rapidity of the changes in r3 suggests, however, that 
not only its production but also its distribution may have been altered. A recent 
study has indicated that similar but less pronounced changes in thyroid hormone 
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metabolism as seen during fasting occur during prolonged moderate exercise. A 
relationship between r4 metabolism, and uptake and utilization of free fatty 
acids and glucose was suggested (O'Connell et al, 1979). 
2.3.3.2. Illness 
In a review, Wartofsky (1974) concluded from the existing literature that, 
as a response to infection, thyroid activity is decreased secondary to inhibit-
ion of TSH release. He suggested that - as in other types of stress - this may 
be mediated by cortisol. Binding of T4 to serum proteins is usually lowered and, 
unless the disease is associated with hepatic dysfunction, cellular uptake of 
the hormone and therefore its fractional turnover is increased. Since then an 
overwhelming amount of data has been published on the effect of acute and chronic 
non-thyroidal illness on thyroid hormone metabolism. 
Decreased serum r3, increased rT3 and normal or low T4 levels have been 
measured in a variety of sick patients and taken as indications of a reduced 5'-
deiodinase activity of the tissues (for a review, see Braverman and Vagenakis, 
1979). Such an impairment of peripheral conversion may be misleading in the diag-
nosis of hyperthyroidism, since elevated r4 levels may be accompanied by normal 
serum T3 concentrations (Britton et al, 1975; Birkhauser et al, 1977; Engler et 
al, 1978). Illness is also an important factor in the low T3 levels measured in 
elderly subjects (Davis, 1979), although also in healthy persons a negative cor-
relation between age and serum T3, but not T4 and rT3 has been found (Smeulers 
et al, 1979). Thus, in several studies, specific diseases have been reported to 
be associated with alterations in peripheral T4 metabolism. Among these are 
febrile conditions (Rastogi et al, 1976; Wartofsky et al, 1977; Maharajan et al, 
1978), myocardial infarction (Westgren et al, 1977e; Smith et al, 1978), diabetes 
mellitus (Naeye et al, 1978; Saunders et al, 1978; Pittman et al, 1979a,b), liver 
and kidney disease (see below). 
Normal or low serum T4, low T3 and high rT3 and TSH levels have been measur-
ed in patients with alcoholic cirrhosis (Copra et al, 1974; Nomura et al, 1975; 
Israel et al, 1979; Walfish et al, 1979). In acute hepatitis, changes in circul-
ating thyroid hormone concentrations are less pronounced (Hepner and Chopra, 
1979) and in chronic active hepatitis and primary biliary cirrhosis serum levels 
of T3 and T4 may even increase due to enhanced binding to serum proteins (Schuss-
ler et al, 1978). Serum binding is otherwise often impaired. Interestingly,serum 
T3 was found to increase in several cirrhotic patients on treatment with PTU, 
due to an improvement of liver function (Israel et al, 1979, see also Orrego et 
al, 1979). 
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Disturbances in T4 metabolism have also been observed in patients with 
renal failure. Serum r4 is normal or decreased, serum T3 decreased and serum TSH 
normal or elevated (Ramirez et al, 1976; Spector et al, 1976; Lim et al, 1977). 
The TSH response to TRH is usually blunted. Abnormalities were observed in 
patients on hemodialysis and those who were not, but amelioration was observed 
upon renal transplantation (Lim et al, 1977). On the average, serum T3 and TBG 
levels were decreased and urinary excretion of T3, T4 and TBG increased in 
patients with nephrotic syndrome (Afrasiabi et al, 1977). 
The changes in thyroid hormone metabolism in systemic illness have been 
shown to be due to decreased production rates of T3 from r4 and decreased elimin-
ation rates of rT3 (Nomura et al, 1975; ChopN, 1976; Lim et al, 1976; Pittman 
et al, 1979a,b), which reverted to normal on successful treatment of the dis-
ease, e.g. diabetes mellitus (Pittman et al, 1979a,b). In general, the decrease 
in serum T3 and the increase in rT3 are related to severity of disease as estim-
ated by several parameters such as body temperature, size of myocardial infarct-
ion, decrease in liver function, etc. (e.g. ljunggren et al, 1977; Smith et al, 
1978; Hepner and Chopra, 1979). The low serum T4 encountered in a substantial 
number of sick patients may be the result of decreased binding to serum, caused 
by a circulating inhibitor (Chopra et al, 1979a,b). It is doubtful whether alter-
ations in T4 metabolism are a consequence of enhanced cortisol secretion (Kall-
ner and Ljunggren, 1979; Ljunggren et al, 1979). 
2.4. Conclusions 
Several approaches have been used to assess the contributions of thyroidal 
secretion and peripheral conversion to the total production of T3, rT3 and lower 
substituted iodothyronines. These are i) measurement of serum concentrations of 
these compounds in subjects without appreciable thyroid function receiving sub-
stitution therapy with synthetic T4, ii) quantitation of radioactive metabolites 
in plasma after administration of labelled T4 under steady state conditions and 
iii) comparison of secretion rates with total turnover rates. For the latter, 
the amounts of iodothyronines secreted have been e.stimated knowing that thyroid-
al secretion accounts for all r4 delivered to the circulation and either i) 
assuming that secretion of these compounds is proportional to their content in 
thyroglobulin or ii) by direct assessment of arterio-venous gradients across the 
thyroid. 
These experiments have unequivocally demonstrated that a large proportion, 
i.e. about 80%, of circulating T3 and virtually all of circulating rT3 is derived 
from monodeiodination of T4 in peripheral tissues. Although the origin of the 
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Fig. 2.5. Effects of various conditions on serum levels, metabolic clearance 
rate (MCR) and production rate (PR) of T3 and rT3 (%of control) 
di- and monoiodothyronines has not been elucidated with similar conviction, it 
is likely that peripheral production is a major source for these compounds. 
Productions of r3 and rT3 from T4 are not random processes. Under a 
variety of conditions (summarized in Fig. 2.5.) conversion of T4 into T3 is 
diminished whereas conversion into rT3 does not change. Serum levels of rT3 
in these situations, however, increase owing to an impaired elimination. These 
findings are compatible with the hypothesis that the peripheral deiodination 
of T4 is mediated by two enzymes, i.e. a 5'-deiodinase converting T4 into T3 
and rT3 into 3,3'-T2, and a 5-deiodinase converting T4 into rT3 and T3 into 
3,3'-T2. Diminution of T3 production and rT3 degradation is then explained 
by a selective decrease in 5'-deiodinase activity. 
The in vivo observations have not yielded conclusive evidence with regard 
to the site of.thyroid hormone deiodination. The abnormalities found in liver 
and kidney disease may indicate that these organs play an important role in 
this respect. This is supported by the data obtained during the investigations 
of these reactions in tissue preparations as will be discussed in the next 
chapter. Further, evidence has been presented for the occurence of the con-
version of T4 into T3 in the pituitary and various brain regions. The contrib-
utions of these sites to the total production of T3 is probably negligible, 
notwithstanding their importance in the supply of the active hormone to local 
receptors. 
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3. THYROID HORMONE OEIODINATION - IN VITRO OBSERVATIONS 
3.1. Introduction 
The hypothesis that most of circulating r 3 is derived from monodeiodin-
ation of r4 in peripheral tissue has appealed to many investigators. It is 
not surprising then, that a lot of work has been done to reveal the principles 
involved and the mechanism of this reaction. Despite these efforts, relatively 
little progress has been made until recently, when in vitro studies have yield-
ed unequivocal information about the enzymatic nature of iodothyronine deiodin-
ation in tissue preparations. These investigations have already shed some 
light on the question of the mechanism of these reactions and the regulation 
of deiodinase activity in the organism. 
The reason for this success undoubtedly is the result of the introduct-
ion of reliable and specific radioimmunological techniques to measure the 
products of the deiodination reactions. Although in several studies deiodin-
ated products (e.g. T3) have been recovered from reaction mixtures containing 
tissue preparations and radioactive substrate (e.g. T4), most of the early 
studies have dealt with the production of iodide. In these latter investigat-
ions generally no specific products other than ill-defined "origin material" 
- referring to its chromatographic properties - have been observed. In the 
light of more recent studies, most of these results may be regarded as artific-
ial probably~tlithoutphysiological significance. Not only for historical reasons, 
but also since they have contributed to our understanding of the chemistry 
of thyroid hormone, these studies will be discussed in the next section. This 
is followed by an overview of results from mainly the recent literature, which 
allow a more reliable interpretation. 
3.2. Degradation of iodothyronines with release of iodide 
The generation of iodide on incubation of radioiodine labelled T4 with 
a variety of tissue preparations has been reported. Thus, deiodination has 
been observed using the perfused rabbit (Becker and Prudden, 1959) and rat 
liver (Flock and Owen, 1965), and slices, homogenates and subcellular fractions 
of rat liver, kidney, skeletal muscle and brain (Table 3.1.). Also, rat thyroid 
(Dawber et al, 1971) and tissues from frogs and tadpole (Dowling et al, 1964; 
Yamamoto, 1964a; Galton et al, 1965) have been studied. Deiodinative activity 
was associated with the particulate fractions (e.g. microsomes) of liver and 
kidney homogenates (Stanbury et al, 1960; Yamamoto et al, 1960; Wynn et al, 
1962; Nakagawa and Ruegamer, 1967), but with the supernatant fraction of 
skeletal muscle and brain (Tata, 1958, 1960; Lissitzky et al, 1961a,b). 
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Considerable attention has been given to the formation of the iodinated 
11 Drigin material 11 which often accompanied deiodination (Galton and Ingbar, 
1961; Plaskett, 1961; Lissitzky et al, 1961a,b; Wynn and Gibbs, 1962; Surks 
et al, 1969; Kozyreff et al, 1971). This material was found to contain iodine 
covalently bound to protein. This could be due to some form of transiodination 
involving the iodines of the phenolic ring, but it has also been shown to 
contain the intact substrate (Kozyreff et al, 1971) and breakdown products 
such as D1T (Plaskett, 1961; Wynn and Gibbs, 1962). It has been suggested 
that this type of reaction may also occur in vivo (Surks et al, 1969). 
The mechanism of non-specific deiodination has not been fully clarified. 
From the reported characteristic features of this process (Table 3.1.), one 
gets the impression that distinct reactions are involved. It has been suggested 
(Galton and Ingbar, 1963, 1964) that under certain conditions degradation of T4 
in tissue preparations may be mediated by peroxidase, since stimulation was ob-
served with H2o2 and the catalase inhibitors azide and 3-amino-1,2,4-triazole, 
and inhibition with catalase. Contradictory observations were made by Nakagawa 
and Rue_gamer (1967). The role of peroxisomes has not been investigated. Discord-
ant findings have also been reported with respect to the effects of thiols, 
ascorbate, p-chloromercuribenzoate and thiouracil. Breakdown of T4 may even 
occur in boiled tissues. Based on different sensitivities to heat Galton and 
Ingbar (1966) distinguished enzymatic and non-enzymatic components of tissue 
homogenates. In general, stimulation is seen with flavins and Fe2+, and inhibit-
ion with Hg2+ and cyanide. Except in brain and possibly muscle, T4 breakdown 
is oxygen dependent. 
Special mention must be made of the degradation of T4 by white blood 
cells. Deiodination and iodoprotein formation have been observed in intact 
cells (Klebanoff and Green, 1973; DeRubertis, 1974; Woeber, 1976a) and in 
homogenates (Kurland et al, 1960; Weeber, 1976b). Deiodinative activity is 
associated with the granule fraction (Weeber, 1976b), and is stimulated in 
phagocytosing leucocytes (e.g. Klebanoff and Green, 1973). Iodination of 
intracellular protein was also detected in cells incubated with iodide (e.g. 
Klebanoff and Clark, 1g77), especially after induction of phagocytosis. All 
these processes (i.e. iodination, de- and transiodination) are mediated by 
myeloperoxidase, which is located in the granules, and require H2o2, the 
production of which is stimulated by phagocytosis (e.g. Klebanoff and Green, 
1973). Iodination (and subsequent killing) of ingested microorganisms has 
Table 3.1. EFFECTS OF CONDITIONS ON THE DEGRADATION OF T4 (WITH RELEASE OF IODIDE) IN TISSUE PREPARATIONS AND 
TISSUE FREE INCUBATIONS 
Stimulation Inhibition No effect 
Liver and kidney Flavinsa, Fe2+b-d, thiolsc, 
ascorbatec, T4 in vivom, 
phenobarbital in vivor, 
Anoxiaa-f, heata,b,t,l, 
Hg2+c,f,m, cyanidea-d,f,m, 
thiolsm, ascorbatem,n, 
EDTAc,d,t,m, thiouracilP, 
azidea, catalase2 , p-chloro-
mercuribenzoatec,m. 
Flavinsa,m, heati-1 , 
thiolsa, thiouracilb,f, 
H 0 d,m catalased,m 
Ho x 'dz · 2 2 , az1 e , amlno-
triazole2. 
2 2 , ' 
azidem, p-chloromercuri-
benzoated,£. 
Skeletal muscle Flavinsg,h Fe2+h H 0 x 
' ' 2 2 ' 
Anoxia~ heatg,i, Hg2+g-i 
thiolsg, ascorbateg. 
Ana xi a1 . 
Brain 
Buffer 
T4 in vivoq. 
Flavins +light+ o2s-w, 
H2o2 + peroxidasex,y. 
' 2+. 0 Heat~' 0 , Hg ~'0 , cyanide . Ana xi a1 ' 0 • 
a b . c d e References: Yamamoto et al, 1960; MacLagan and Re~d, 1957; Stanbury et al, 1960; riynn et al, 1962; Sprott and 
MacLagan, 1955; fYamazaki and Slingerland, 1959; gLissitzky et al, 196la,b; hTata, 1960; 1 Tata, 1957; 
jLissitzky et al, 1959; kEtling and Barker, 1959; 1Galton and Ingbar, 1966; mNakagawa and Ruegamer, 
1967; nYamamoto, 1964b; 0 Tata et al, 1957; PBraverman and Ingba1.·, 1962; qTata, 1961; rSchwartz et al, 
1969; 5 Lissitzky et al, 196lc; tsuzuki et al, 1961; uGalton and Ingbar, 1962; vuorreale de Escobar et 
al, 1962,1963; wReim~'ein and Rall, 1965; xGalton and Ingbar, 1963; YNayrargue-Kodja et al, 1958; 
zGalton and Ingbar, 1964. 
:t 
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been suggested to perform the function of a host defense mechanism (Klebanoff, 
1967). In sepsis, cellular uptake and metabolism of T4 are accelerated (De-
Rubertis and Weeber~ 1973; see also chapter 2.3.). It has, therefore, been 
suggested that phagocytosing leucocytes may utilize thyroid hormone as a 
source of iodine for bactericidal activity (e.g. Klebanoff and Green, 1973). 
In many instances, r 4 and other iodothyronines have been found to be 
degraded in chemically defined media (Table 3.1.). Thus, 11 deiodination" was 
observed in mixtures containing flavins in the presence of oxygen and light. 
Flavin dependent deiodination is stimulated by inert proteins such as fibri-
nogen and albumin (Morreale de Escobar et al, 1962, 1963; Reinwein and Rall, 
1965) and inhibited by Cu2+ and Hg2+ (Galton and Ingbar, 1962). In this 
system the ether bond is split and DIT is formed (Lissitzky et al, 1961c, 
Suzuki et al, 1961). Deiodination also occurs in the presence of H2o2 or 
H2o2-generating systems, and is further stimulated by peroxidase (Mayrargue-
Kodja et al, 1958; Galton and Ingbar, 1963) or chelated metal ions (Reinwein 
et al, 1968). Also here, the ether bond has been found to be cleaved (Mayrargue-
Kodja et al, 1958). 
The above findings indicate that degradation of T4 may be observed in 
tissue preparations as well as tissue-free incubations, especially where 
conditions allow for the formation of free radical species. This degradation 
is an oxidative process and is characterized by iodide production, ether 
bond cleavage and iodination of protein (if present). Especially noteworthy 
in this respect are the studies by Wynn (1968) and Nakano and coworkers 
(Nakano et a 1 , 1971, 19 73; Us hi j ama et a 1 , 1973; Suwa and Nakano, 1975). 
These authors have linked T4 deiodination by microsomes with lipid peroxid-
ation. Both lipid peroxidation and deiodination are induced by Fe2+, which 
may be kept in the reduced state either enzymatically (NADPH dependent) or 
chemically (ascorbic acid dependent). Ferrous iron induces the formation of 
lipid, lipid alkoxy and lipid peroxy radicals, initiating a chain reaction 
characteristic for fatty acid autooxidation (Chow, 1979). Thyroxine inter-
feres with the propagation of this chain reaction by reacting with the 
alkoxy and peroxy radicals, and may be regarded as an antioxidant in this 
respect (Wynn, 1968; Suwa and Nakano, 1975). 
However, in the presence of peroxidase and H2o2, T4 enhances lipid 
peroxidation (Kumar et al, 1977). The common factor in all these observations 
may be the ability of r4 to form a phenoxy radical. In subsequent steps, the 
iodine atoms of the phenolic ring are eliminated as the radical (I-; Kumar 
et al, 1977) or as the anion (!-; Suwa and Nakano, 1975) and the ether bond 
is cleaved (see Fig. 3.1). 
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R-Q-OH + 1-, 1·, etc. 
I 
Fig. 3.1. Oxidative breakdown ofT via the phenoxy radical yielding DIT, 
iodide and other products~ 
Lipid peroxidation is a degenerative reaction, and the cell is well 
equipped with defense mechanisms which prevent damage from this process. The 
antioxidant potential of the cell comprises radical scavengers such as 
vitamin E and superoxide dismutase, while peroxide concentrations are kept 
at a minimum level by catalase and glutathione peroxidase (Chow, 1979). It 
is, therefore, likely that the type of deiodination described in this section 
is of limited physiological relevance, with the possible exception of r4 
degradation by leucocytes. 
3.3 Production of specific metabolites 
Production of radioactive T3 from radioiodine-labelled T4 by intact 
cells has been detected with the aid of chromatographic techniques. Using 
this method conversion has been shown to occur in several tissue preparations, 
e.g. rat kidney slices (Albright et al, 1954; Cruchaud et al, 1955; Balsam 
et al, 1978a), human kidney slices (Albright and Larson, 1959), rat liver 
slices (Green, 1976; Balsam et al, 1978a), perfused rat heart (Rabinowitz 
and Hercker, 1971), rat thyroid (Haibach, 1971; Green, 1978) and pituitary 
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fragments (Silva et al, 1978b; Cheron et al, 1979), human leucocytes (Kleba-
noff and Green, 1973) and cell cultures of human fibroblasts (Refetoff et al, 
1972), liver and kidney cells (Sterling et al, 1973) and rat pituitary tumors 
(Gershengorn et al, 1979). Using similar techniques, Papavasiliou et al (1977) 
noted conversion of rT3 into 3,3'-Tz in a rat pituitary tumor in culture. 
Noteworthy are further studies by Sorimachi and coworkers of the deiodination 
of several iodothyronines in monkey hepatocarcinoma cells in culture. These 
cells were found to be active in the 5-deiodination of r4 , r3, 3,3'-Tz and 
3,5-T2 and the 5'-deiodination of rT3 and 3' ,5'-T2. From the incubations 
3,3'-T2 and 3'-T1 were primarily recovered as sulfates. Interestingly, no 
conversion of T4 into T3 could be observed (Sorimachi and Robbins, 1977, 
1978a,b, 1979a,b; Sorimachi and Cahnmann, 1979). 
Radioactive substrates a"nd chromatographic analysis of the reaction 
products have also been employed in the analysis of the conversion of T4 
into T3 in homogenates and subcellular fractions of rat kidney (e.g. Chira-
seveenuprapund et al, 1978) and liver (Harris et al, 1978b; Balsam et al, 
1978b). 
Deiodination of unlabelled substrates (by quantitation of metabolites 
with radioimmunoassay) has been demonstrated to take place in various intact 
cell preparations. For instance, conversion of r4 in r3 has been detected 
in perfused rabbit kidney (Adlkofer et al, 1977) and rat liver (Hesch et al, 
1975; Jennings et al, 1979), isolated rat hepatocytes (Hesch et al, 1975; 
Van Noorden et al, 1979) and renal tubules (Heyma et al, 1978), rat pituitary 
tumor in culture (Melmed et al, 1979) and human leucocytes (Woeber and Maddux, 
1978). Production of rT3 from T4 by the kidney (Heyma et al, 1978) and 
leucocytes (Woeber and Maddux, 1978), and of 3,3'-T2 from rT3 by liver cells (M.H. Otten and T.J. Visser, unpublished observations) have similarly been 
observed. 
By far most of the observations of the enzymatic deiodination of iodo-
thyronines have been made using broken cell preparations, measuring the 
products with the aid of specific radioimmunological techniques. Most of 
these studies have employed rat liver and kidney homogenates and subcellular 
fractions thereof. In this system the following reactions have been followed: 
conversion of T4 into r 3 (e.g. Hesch et al, 1975; Visser et al, 1975a, 1976a; 
HUfner and Knopfle, 1976; Chopra, 1977; Kaplan and Utiger, 1978a), conversion 
of T4 into rT3 (e.g. Cavalieri et al, 1977; Hoffken et al, 1977; HUfner et 
al, 1977; Visser et al, 1978c, 1979a), conversion of rT3 and r 3 into 3,3'-T2 
(e.g. Chopra et al, 1978c; Hoffken et al, 1978a; HUfner and Grussendorf, 
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1978; Visser et al, 1978c, 1979a) and conversion of 3' ,5'-T2 into 3'-T1 
(Visser and Van Overmeeren, 1980a). 5'-Deiodination of T4 in rat pituitary 
homogenates has also been followed by radioimmunoassay of T3 (Silva et al, 
1978b; Kaplan, 1980). 
3.4. Localization of deiodinase activity 
There is general agreement that, irrespective of the substrate used, 
deiodinase activity is associated with the particulate fractions of tissue 
homogenates, predominantly with the microsomes (e.g. Hesch et al, 1975; 
Visser et al, 1976b). Deiodination by this fraction is stimulated by the 
addition of cytosol (Visser et al, 1976b; see Fig. 3.2.) suggesting the 
Fig. 3.2. 
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requirement for a soluble cofactor. Highest conversion rates of r4 into rT3 
were observed by Cavalieri et al (1977) in rat liver cytosol, but this finding 
may be due to a slight contamination of this fraction by microsomal protein 
in combination with -strangely enough- a relative lack of rT3 5'-deiodinase 
activity (see also Fekkes et al, 1979). Conversion of T4 into rT3 in homogen-
ates or microsomes is difficult to estimate due to the highly effective 
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breakdown of rT3 by 5'-deiodination (Hufner et al, 1977; Visser et al, 1978c). 
More recently, investigators have attempted to define more exactly the intra-
cellular location of deiodinase activity. Leonard and Rosenberg (1978a) ob-
tained evidence for a plasma membrane location for r4 5
1
-deiodinase activity 
in rat kidney homogenate. The same, was also suggested by Maciel et al (1979b) 
for the liver enzyme, although this was not supported by their own data. Auf 
dem Brinke et al (1979, 1980) and Fekkes et al (1979) found a clear associat-
ion between deiodinase activity and marker enzymes for liver endoplasmic 
reticulum. This was found to be true following both 5- and 51 -deiodinations. 
3.5. Characteristic features of enzymatic deiodination 
It is now well established that the deiodinations of iodothyronines are 
enzymatic processes. To certain limits, deiodinase activity is linearly related 
to the concentration of microsomal protein in the reaction mixture, and accumul-
ation of products is linear with time of incubation (e.g. Visser et al, 1979a). 
The factors involved with the conversion of T4 into lower substituted iodo-
thyronines are sensitive to heat. Heating tissue preparations for only 30 min 
at 56°C was sufficient to destroy deiodinase activity completely (Visser et 
al, 1975a). Several authors have reported on the inhibitory effect of SH 
group-blocking agents (see section 3.7). Moreover, it has been demonstrated 
repeatedly that 5- and 5'-deiodinase catalysed reactions obey Michaelis-Menten 
kinetics, where apparent Km values for most reactions in rat liver homogenate 
or microsomes vary between 1 and 10 ~M (Chopra, 1977; HUfner et al, 1977; 
Chopra et al, 1978c; Hoffken et al, 1978b; Kaplan and Utiger, 1978a; Kaplan 
et al, 1979; Visser et al, 1979a). However, the apparent Km of rT3 in the 
5'-deiodinase-catalysed conversion into 3,3'-T2 is substantially lower, i.e. 
10-7 - 10-8 M (Hufner et al, 1977; Chopra et al, 1978c; Kaplan and Utiger, 
1978a; Kaplan et al, 1979; Visser et al, 1979a). For 3' ,5'-Tz in the enzymatic 
5'-deiodination into 3'-T1 an intermediate apparent Km value (10-6 - 10-7 M) 
has been estimated (Visser and Van Overmeeren, 1980a; D. Fekkes, E van Over-
meeren and T.J. Visser, unpublished observations). Similar estimates of Km 
values for T4 and rT3 have been reported for the 5'-deiodinase from rat kidney 
(Chiraseveenuprapund et al, 1978; Kaplan et al, 1979). However, quite different 
figures have been published for the hepatocarcinoma (Sorimachi and Robbins, 
1979b) and anterior pituitary enzymes (Kaplan, 1980). 
The effect of pH on the several deiodinations has been studied extensively. 
In liver preparations, conversion of T4 into T3 has been found to be most 
effective at pH 6-7 (Cavalieri et al, 1977; Chopra, 1977; Hoffken et al, 1977; 
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H·Ufner et al, 1977; Visser et al , 1978c, 1979a). In first instance, production 
of rT3 from T4 was found to be optimal at pH 9-9.5 (Hoffken et al, 1977; 
HUfner et al, 1977). It was, however, observed that at more physiological pH 
values, rT 3 was degraded too rapidly into 3,3'-T2 to allow its direct measure-
ment. By following the production of 3,3'-T2 instead it was deduced that 5-
deiodination of T4 was most effective at pH 8 (HUfner and Grussendorf, 1978; 
Visser et al, 1978c, 1979a). This value is in agreement with that found by 
Cavalieri et al {1977), who studied this reaction in rat 1iver supernatant 
fraction. Conversion of r3 into 3,3'-T2, which is analogous to the conversion 
of r4 into rT3 (5-deiodination), has also been shown to be optimal at approx-
imately pH 8 (Chopra et al, 1978c; Hoffken et al, 1978a; Visser et al, 1978c, 
1979a). 
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Large discrepancies have been reported with respect to the effect of pH 
on the conversion of rT3 into 3,3'-T2 , which is analogous to the production 
of T3 from T4 (5'-deiodination). Optimal values for pH have been reported to 
amount to 8-9 (Chopra et al, 1978c), approximately 8 (HDfner and Grussendorf, 
1978), 7.7 (Gavin et al, 198Da), 7.3 (Hoffken et al, 1978a) and 6.5 (Visser 
et al, 1978c). It has, however, been shown that the effects of pH on product-
ion rates of 3,3'-T2 depend on the concentration of rT3 tested (Visser et al, 
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1979a; Visser and Van Overmeeren, 1980a). At low substrate concentrations, 
reaction rate is highest around pH 6.5, whereas with high rT3 concentrations, 
deiodination proceeds more rapidly at about pH 8. Strikingly similar obser-
vations have been made in the study of the conversion of 3' ,S'-T2 into 3'-T1 , 
also a 5'-deiodination (Visser and Van Overmeeren, 198Da; see Fig. 3.3). As 
far the 5'-deiodination, the apparent Km for rT3 is much lower and the Vmax 
much higher than the corresponding values for T4 (Visser et al, 1979a"). These 
kinetic parameters are different functions of pH depending on whether rT3 or 
T4 is substrate (Visser et al, 1979a; see Fig. 3.4.). 
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Fig. 3.4. Effect of pH on the kinetic parameters of enzymatic 5- and 5'-
deiodinations (means.:!:_ S.E.M .• n=3-5; from Visser et al, 1979a). 
Despite these differences, evidence has been obtained that both react-
ions are catalysed by a single enzyme (iodothyronine 5'-deiodinase). Thus, 
T4 is a competitive inhibitor of the 5'-deiodination of rT3 (Kaplan and 
Table 3.2. EFFECTS OF CONDITIONS ON ENZYf~TIC DEIODINATION OF !ODOTHYRONINES IN RAT LIVER AND KIDNEY PREPARATIONS 
Stimulation 
Thiolsa-j, anoxiab,k, 
EDTAa,k, diphenyl-
hydantoin in vivot, 
hyperthyroidismw,x,y. 
Inhibition 
Heate,k,p, NENd,k, H2o2 e,k, t-butylperoxided, 
iodoacetic acidm, silver and mercury ionsa,b,d, 
mercuri compoundsa,d,e, GSSGd, diamided,n,o, 
so3
2
-r, thiouracilj-m,p,q' dinitrophenolg,m, 
X-ray contrast agentsg, dexamethasone in 
vivoq,t,u, fastingq,u,v, diabetesu, 
hypothyroidismw,x,y. 
No or slight effect 
NAD(P)a,c,k,l, NAD(P)Ha,c,k,l, EDTAb,l, 
flavinsa,k, methimazoler,s, thiourear,s, 
tyrosinea,c,l, ~11Ta,c,1' DITa,c,l' 
dinitrotyrosinea,c,l, a-methyltyrosinec, 
k,l, propranololk, dexamethasone1'q, 
diphenylhydantoin1 , I-e,k,r, CN-e,k,r, 
SCN-r,s, N
3
-k,l,r, Fe2+q, Fe3+q, ascorbic 
acid1. 
References: avisser et al, 197Gb; bcavalieri et al, 1977; cHiifner et al, 1977; dChopra, 1978; eH0ffken et al, 
1978b; £Harris et a1, 1979 ; gKaplan et al, 1979; hLeonard and Rosenberg, 1978a; ivisser, 1979; jvisser 
et al, 1978c; kchiraseveenuprapund et al, 1978; 1chopra, 1977; mChopra et al, 1978c; nBalsam et al, 
1979a; °Kaplan, 1979a; Pvisser et al, 1975a; qKaplan and Utiger, 1978a; rVisser, 1980a; sLeonard and 
Rosenberg, 1978b; tHiifner and Kn0pf1e, 1976; uBalsam et a1, 1978b; vl!arris et al, 1978b; loJGrussendorf 
and Hiifner, 1977; xBalsam et al, 1978a; YKaplan and Utiger, 1978b, 
"' N 
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Utiger, 1978a; Visser et al, 1979a) and vice versa (Chopra, 1977; Kaplan 
and Utiger, 1978a), where K; and Km values were found to be equal under 
various conditions. Also 3' ,S'-T2 competitively inhibits the 5'-deiodination 
of T4 (Chopra et al, 1978a). Evidence may be obtained that conversion of r4 
into rT3 and of T3 into 3,3'-Tz is mediated by a separate enzyme (iodothyro-
nine 5-deiodinase). Kinetic parameters of both conversions showed to be 
similar functions of pH (Visser et al, 1979a; see Fig. 3.4.). Not only the 
relatively low level of 5'-deiodinase activity of monkey hepatocarcinoma 
cells, but also the finding that the inhibitory effect of T4 on the 5'-
deiodination of rT3 is negligible (K1 ~1a-S M) compared with its potent 
inhibition of the 5-deiodination of 3,5-T2 (Ki~1o- 8 M), strongly suggest 
that separate enzymes are involved in these processes (Sorimachi and Robbins, 
1979b). Based on differences in Km values with small variations in pH, Auf 
dem Brinke et al (1979) suggested that more than one enzyme catalyses the 
conversion of T4 into T3. The significance of these observations remains to 
be established. 
The characteristics of enzymatic deiodination of iodothyronines in 
homogenates and microsomal fractions of rat liver and kidney are summarized 
in Table 3.2. Converting activity is impaired in tissues from fasted and 
diabetic rats. Enzyme activities are decreased in hypothyroid, and increased 
in hyperthyroid animals. In general, concomitant changes are observed in the 
conversion of T4 into T3 and that of rT3 into 3,3'-T2 (Kaplan and Utiger, 
1978a,b; Kaplan et al, 1979). Properties of deiodinase activities in liver 
and kidney appear to be very similar (Kaplan et al, 1979). However, their 
regulation in vivo differs in some respects, judged from the effects of 
thyroid (Kaplan and Utiger, 1978b) and nutritional status (Kaplan et al, 
1979). A very interesting observation is that - in contrast to peripheral 
tissues - deiodinase activity in the pituitary is decreased in hyperthyroid-
ism, increased in hypothyroidism and unaffected by fasting (Cheron et al, 
1979; Kaplan, 1980). Also, Sorimachi and Robbins (1978b) found that deletion 
of nutrients from the incubation medium had no effect on phenolic ring de-
iodination by hepatocarcinoma cells, whereas non-phenolic ring deiodination 
was even accelerated. 
Addition of propranolol, a-methyltyrosine, dexamethasone or diphenyl-
hydantoin does not influence deiodinase activities of tissue homogenates. 
Propranolol, in high concentrations (>290 ~M), inhibits conversion of T4 into 
T3 by rat hepatocytes (Van Noorden et al, 1979), whereas lower concentrations 
also do not interfere with the formation of 3,3'-T2 from rT3 in this system 
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(M.H. Otten and T.J. Visser, unpublished observations). Liver and kidney 
homogenates from rats pretreated with dexamethasone show decreased T4 5'-
deiodinase activities. Treatment of fetal sheep with cortisol paradoxically 
enhances deiodinase activity of liver and kidney (Wu et al, 1978b). Pretreat-
ment of rats with diphenylhydantoin has a stimulatory effect (HUfner and 
Knopfle, 1976). 
3. 6 Cofactors 
Stimulation of T4 5
1
-deiodinase activity of rat liver homogenate was 
observed by the addition of NAO while NADH, NADP and NADPH were without 
effect (Visser et al, 1975a). The stimulatory effect by NAD could not be 
confirmed in a subsequent study (Visser et al, 1976b). A lack of effect by 
addition of any of these nicotinamide-adenine dinucleotides has also been 
reported by other authors (Chopra, 1977; Hlifner et al, 1977; Chiraseveen-
uprapund et al, 1978), although NADPH may stimulate T4-T3 conversion in 
tissue preparations of fasted (Balsam et al, 1979a) and hypothyroid (Balsam 
et al, 1979b) animals (see chapter 4). Flavins have been shown to have no 
effect on enzymatic deiodination, although addition to rat liver homogenate 
stimulated non-enzymatic production of T3 from T4. This was not observed 
upon exclusion of light (Visser et al, 1975a). 
During subcellular fractionation of rat liver homogenate T4 5'-deiodin-
ase was lost so that in none of the fractions obtained production of T3 could 
be detected. Only on combining the particulate fractions, in particular the 
microsomal fraction, with the 100 000 x g supernatant converting activity 
was recovered (Visser et al, 1976b). This has been confirmed by other investig-
ators (Balsam et al, 1979a,b; Kaplan, 1979a,b). These findings indicate that 
there is an absolute requirement for a soluble cofactor in the cytosol. In 
the investigation of the possible constitution of this factor it was found 
that cytosol could effectively be replaced by simple thiols such as dithio-
threitol (OTT), 2-mercaptoethanol and 2,3-dimercaptopropanolol, and it was 
suggested that reduced glutathione (GSH) is the endogenous cofactor (Visser 
et al, 1976b; see Fig. 3.5.). 
Since then a large number of reports has been published on the stimul-
ation of deiodinase activity in various tissue preparations by mercapto 
compounds. Thus, thiols stimulate both 5- and 5'-deiodinase activities of 
liver and kidney (Table 3.2.), leucocytes (Woeber and Maddux, 1978) and 
hepatocarcinoma cells (Sorimachi and Robbins, 1979b). Mercapto compounds 
also stimulate conversion of T4 into T3 in pituitary tumor cells (Melmed et 
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Fig. 3.5. Effects of 1 mM dithiothreitol (OTT), dimercaptopropanol (DMP) or 
mercaptoethanol (ME) on the conversion of T4 into T3 by rat liver 
microsomal fraction (from Visser et al. 1976b). 
al, 1979) and pituitary homogenates (Silva et al, 1978b; Kaplan, 1980). 
55 
Dithioerythritol (OTE) and OTT are the most potent stimulators of deiodin-
ase activity, while 2-mercaptoethanol and 2,3-dimercaptopropanol are less 
active, and GSH is clearly the least effective (Visser et al, 1976b; Cavalieri, 
1977; Chopra, 1978). 
It has recently been established that thiols are real cofactors in deiodin-
ation processes, since it has been demonstrated that there is an active part-
icipation of these compounds in these reactions. Thus, thiols act as the second 
substrate in the 5'-deiodination of r4 (Leonard and Rosenberg, 1978b) and of 
rT3 (Visser, 1979), reactions which are believed to follow a ping-pong mechanism 
(see section 3.8.). Therefore, the enzymatic deiodination of iodothyronines 
(Tin) is a reduction, where the reductive equivalents are supplied by thiol 
cofactors (R-SH): Tin+ 2 R-SH + Tin_ 1 + R-S-S-R +HI (note that Tin_ 1 contains 
missing H). 
3.7 Inhibitors 
Two classes of inhibitors of 5- and 5'-deiodinase-catalysed reactions 
have been studied in some detail. In the first category are the compounds 
which react more or less specifically with sulfhydryl groups. Conversion of 
T4 into T3 in tissue homogenates and subcellular fractions is inhibited by 
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addition of N-ethylmaleimide (NEM), H2D2, diamide, silver and mercury ions, 
mercury containing compounds such as p-chloromercuriphenylsulfonic acid, 
t-butylperoxide and oxidized glutathione (GSSG; Table 3.2.). Iodoacetic 
acid has been shown to inhibit formation of 3,3'-T2 from both T3 and rT3 in 
rat liver homogenate in a non-competitive fashion (Chopra et al, 1978c). 
Conversion of 3' ,S'-T2 into 3'-T1 is also blocked by the action of NEM on 
rat liver microsomes (Visser and Van Overmeeren, 1980b). After incubation 
with NEM, Ag+, Hg+ or p-chloromercuriphenylsulfonic acid, deiodinase activity 
was not restored by the subsequent addition of excess thiols, indicating the 
presence of essential cysteine residues in the enzyme(s) (Visser et al, 
1976b; Visser and Van Overmeeren, 1980b). The non-_competitive inhibition 
by iodoacetic acid may also point into this direction. 
The second group of compounds, which mainly consists of the thiouracil (TU) 
derivatives, appears to react also with an essential sulfhydryl group of the 
enzyme, but only after this has been oxidized during the deiodination process. 
Notably PTU has been reported to inhibit both 5- and 51 -deiodinations in a 
variety of tissue preparations, i.e. either intact cells (Cruchaud et al, 
1955; Larson et al, 1955; Green, 1976; Heyma et al, 1978; Woeber and Maddux, 
1978; Van Noorden et al, 1979) or homogenates and subcellular fractions 
(Table 3.2.). Inhibition has also been observed in tissue preparations from 
PTU-pretreated rats (Larson et al, 1955; Leonard and Rosenberg, 1978b; Balsam 
et al, 1978b; Kaplan et al, 1979). Sorimachi and Robbins (1979a,b) found only 
phenolic ring deiodination by hepatocarcinoma cells to be inhibited by PTU, 
whereas deiodination of the tyrosyl ring was unaffected. Generally, inhibit-
ory effects are observed with methimazole only at high concentrations (>1 mM), 
although inhibition occurred also at 10 ~M in leucocytes (Woeber and Maddux, 
1978). The structure-activity relationship of thioureylenes in the inhibition 
of 5 1-deiodinase activity has been investigated, and the low activity of 
methimazole was found to be due to the N1-methy1 group (Visser et al, 1979b). 
Inhibition by thiouracil and its derivatives is of the uncompetitive 
type (Chopra, 1977; Chopra et al, 1978c; Leonard and Rosenberg, 1978b; Visser, 
1979), and is competitively antagonized by OTT, methimazole and thiourea 
(Leonard and Rosenberg, 1978b; Visser, 1979, 1980a). A similar mode of inhibit-
ion is exerted by sulfite. However, its action is additive to that of methi-
mazole and thiourea (Visser, 1980a). It is of interest that also where the 
action of PTU in vitro is concerned, deiodination in the anterior pituitary 
has characteristics different from those in peripheral tissues. Inhibition of 
T4-T3 transformation could be detected neither in tissue fragments (Cheron et 
al, 1979) nor in homogenates (Kaplan, 1980). 
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The mutual competitive inhibition by iodothyronine substrates has been 
discussed in section 3.5. In addition, pretreatment of rats with large doses 
of rT3 resulted in a substantial lowering of T4-r3 converting activity of 
liver homogenates (Coiro et al, 1980). Tyrosine, MIT, DIT and dinitrotyrosine 
do not or only weakly inhibit iodothyronine deiodinase activity (see also 
Larson and Albright, 1961; Sorimachi and Robbins, 1979b). The latter is a 
specific inhibitor of iodotyrosine deiodinase (Haibach, 1971). However, 
dinitrophenol does lower iodothyronine deiodinase activity, although not in 
hepatoma cells (Sorimachi and Robbins, 1978a). Competitive inhibition by 
several radiographic contrast agents of r4-T3 and rT3-3,3'-T2 converting 
activity of liver, kidney (Kaplan et al, 1979) and pituitary homogenates 
(Kaplan, 1980) has been described. Judged from their structures (Fig. 2.3.), 
these compounds may be regarded as substrate analogues. 
A Inhibition by PTU 
is uncompetitivc 
with respect to 
substrate 
B Inhibition by PTU 
is competitive 
with respect to 
cofactor (e.g. OTT) 
1/V 
C Km and V max ore 1/V 
increo~ proportionally 
by on increase in 
cofactor concentration. 
1/S 
l/cofoctor 
1/S 
++ 
+ PTU 
++ 
+ PTU 
+ 
++ cofactor 
+++ 
Fig. 3.6. Kinetics of enzymatic 5 1 -deiodination; effect of PTU and cofactor. 
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3.8. Possible mechanisms of deiodination 
Key observations concerning the pathway of enzymatic 5'-deiodination are 
(see Fig. 3.6.): i) Lineweaver-Burk diagrams of iodothyronine substrate (TI
0
) 
concentration against monodeiodinated product (TI 0 _ 1) formation at various 
fixed concentrations of thiol compounds yield a set of parallel lines; ii) 
Lineweaver-Burk diagrams of Tin concentration against TI
0
_ 1 formation at 
various fixed concentrations of TU or its derivatives yield another set of 
parallel lines; iii) Lineweaver-Burk diagrams of thiol concentration against 
TI 0 _ 1 formation at various fixed concentrations of TU or its derivatives 
yield a set of lines which intersect on the 1;v axis (Leonard and Rosenberg, 
1978b; Visser, 1979). These results indicate that enzymatic 5'-deiodination 
follows a socalled ping-pong mechanism, a reaction involving two substrates 
and two products, which enter and leave the enzymatic cycle sequentially 
(Dixon and Webb, 1979). Thus, reaction of the first substrate (A) with the 
enzyme (E) yi e 1 ds an intermediate enzyme comp 1 ex ( E' ) concomitant with the 
formation of the first product (P). Reaction of the intermediate with the 
second substrate (B) results in the 
second product (Q; see Fig. 3.7.). 
generation of native enzyme and the 
E • A :;;;::::::::::'~ E ' • P 
A/ ~p 
E E' 
Q~ fs 
E·Q ~=o;:E'·B 
Fig. 3.7. Ping-pong mechanism of enzymatic reaction involving two substrates 
(A,B) and two products (P,Q). 
The findings suggest that TU reacts with the same intermediate as the 
thiol cofactor. Since other studies (see section 3.7.) had indicated that 
iodothyronine-deiodinating enzymes contain at least one essential cysteine 
residue, it was suggested (Leonard and Rosenberg, 1978b; Visser, 1979) that 
the intermediate was formed by conversion of a sulfhydryl group into a higher 
oxidation state. It has been shown that TU reacts more or less specifically 
with protein-sulfenyl iodides under formation of protein-thiouraci1 mixed 
disulfides (Cunningham, 1964; Jirousek, 1968; see Fig. 3.8.). 
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OH OH 
L~ 
P-SI+ HS N 
L~ P-S-5 N 
--HI 
Fig. 3.8. Reaction of thiouracil with protein-sulfenyl iodide (P-SI) yielding 
a protein-thiouracil mixed disulfide (according to Cunningham, 1964). 
As a working hypothesis, it has been proposed (Visser, 1979, 1980a,b) 
that thyroid hormone deiodination implies the formation of a deiodinase-
sulfenyl iodide (E-SI). Such a derivative is formed by transfer of an iodinium 
ion (!+) from the substrate to a sulfhydryl group of the enzyme (E-SH). To 
complete the cycle, the E-SI complex is subsequently reduced by cofactor 
(R-SH). It is also subject to reaction with thiouracil (U-SH) yielding a 
deiodinase-thiouracil disulfide (E-S-S-U; see Fig. 3.9.). 
E-SH·Tln ~ E-SI·Tin-1 
Tin/ HI \ Tln-1 
E-SH • > "'Z E-SI 
",, R-S-S-R 2 /(-SH U-SH 
U-SH~ 
' 
' HI 
'E-S-S-U 
Fig. 3.9. Pathway of enzymatic deiodination of iodothyronines (TI 0 ); the 
role of cofactor (R-SH) and inhibition by thiouracil (U-SH). 
Competitive attenuation of the inhibitory effects by TU with methimazole 
and thiourea suggests that all these compounds compete with cofactor for the 
E-SI intermediate. The small effect by methimazole and thiourea on deiodin-
ation compared with that on iodination points to a different structural 
requirement for inhibitors of these processes. The findings suggest that 
methimazole (M-SH) also forms a mixed disulfide with the enzyme on reaction 
with the SI group (E-SI + M-SH -> E-S-S-M +HI). This disulfide would be rapid-
ly reduced by cofactor (E-S-S-M + 2 R-SH -> E-SH + R-S-S-R + M-SH), whereas 
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the enzyme-thiouracil disulfide apparently is not. Amelioration of the inhibit-
ion by TU with methimazole may also be the result of a thiol-disulfide exchange 
(E-s-s-u + M-SH -> E-S-S-M + U-SH) followed by rapid reduction of the enzyme-
methimazole disulfide. It was found that methimazole is not a cofactor of 
deiodinase catalysed reactions (unpublished results), excluding reactions such 
as E-Sl + 2 t1-SH -> E-SH + M-S-S-M + HI and, therefore, E-S-S-M + M-SH -> E-SH + 
M-S-S-M. 
Finally, sulfite has similar effects on the kinetics of enzymatic deiodin-
ation, suggesting that it also is a dead-end inhibitor (Dixon and Webb, 1979), 
acting on the E-SI intermediate. This would yield a thiosulfate: E-SI + HS03 -r 
E-s-so3- +HI (Parker and Kharash, 1959; Visser, 1980a). The additive rather 
than competitive action of methimazole in the presence of sulfite may indicate 
that HS03- also reacts with the enzyme-thioureylene disulfide (E-S-S-U or 
E-5-S-M + HS03- + E-S-503- + U-SH or M-SH; Parker and Kharash, 1959; Visser, 
1980a). 
Although the hypothesis concerning the involvement of an E-SI complex in 
the deiodination of iodothyronines is attractive, the actual formation of such 
intermediate is far from established. Due to the extreme lability of such 
groups it would appear an almost impossible task to proof the validity of the 
model. Experiments, however, may be designed, by which circumstantial evidence 
for the proposed mechanism may be obtained. Apparently covalent binding of 
radioactive TU to the 5'-deiodinase, which only takes place in the presence 
of substrate (and, therefore, only after the formation of the E-SI intermediate) 
is one such piece of evidence (Visser and Van Overmeeren, 1979; Leonard and 
Rosenberg, 1980). Also the irreversible inactivation of the enzyme by TU which 
only occurs in the presence of substrate (Leonard and Rosenberg, 1978b, 1980; 
Visser and Van Overmeeren, 1980b) are in line with the hypothesis. In these 
inactive complexes, TU is probably linked to the enzyme via aS-S bond, as 
suggested by the finding that OTT not only prevents their formation but also 
regenerates free enzyme and thiouracil once these complexes have been formed. 
On the assumption that enzymatic deiodination of iodothyronines follows 
the pathway depicted in Fig. 3.9., there have been speculations on the molec-
ular mechanism of these reactions (Visser, 1979). Deiodination of the phenolic 
ring and that of the tyrosyl ring have several properties in common, i.e. 
stimulation by thiols and uncompetitive inhibition by TU (e.g. Chopra et al, 
1978c). This suggests a common underlying mechanism for both reactions, and 
thereby seems to dispose of one of the possibilities, which have been consider-
ed. This reaction mechanism was based on the observations by Hartmann and co-
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workers (Hartmann et al, 197la,b; see also Friedman, 1973) of the non-enzymatic 
deiodination of DIT by cysteine. Although formation of an E-SI complex by this 
mechanism is entirely feasible, this possibility was rejected since it requires 
the presence of a phenolic hydroxyl group in the ortho position to the iodine 
substituent. Therefore, deiodination of the tyrosyl ring is not possible (Vis-
ser, 1979). 
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Fig. 3.10. Mechanism of deiodination of 5-iodo-2'-deoxyuridylate by thymidylate 
synthetase (according to Wataya and Santi, 1975). 
A second possibility was considered more likely, which is related to the 
mechanism of action of thymidylate synthetase in the reductive deiodination of 
5-iodo-2'-deoxyuridylate (see Fig. 3.10.) as elucidated by Santi and coworkers 
(Wataya and Santi, 1975; Pogolotti and Santi, 1977; Garrett et al, 1979; see 
also Sander, 1977; Chikuma et al, 1978). Applying this model to the reductive 
deiodination of iodothyronines (see Fig. 3.11.) implicates a primary attack of 
an enzyme nucleophile (X) at the 6' (or the equivalent 2') position. This 
results in the formation of a covalent 5' ,6'-dihydrosubstrate-enzyme complex. 
Elimination of r+ in a concerted mechanism with the aid of an enzyme-thiolate 
anion yields the E-SI complex and monodeiodinated substrate. 
Any proposed mechanism of action of iodothyronine deiodinase is based 
mainly on speculation. The above model, however, suffices as a working hypo-
thesis as it can be verified by experimental testing. It is an attractive model 
since both phenolic and tyrosyl ring deiodination may occur via such a mechan-
ism. Moreover, it may explain why rT3 and 3' ,s•-r2 are better substrates for 
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Fig. 3.11. Possible mechanism of enzymatic 5- and 5'-deiodination. 
the 5'-deiodinase than T4 (Visser et al, 1979a; Visser and Van Overmeeren, 
1980a). Since 5'-deiodination is supposed to involve the reaction of an enzyme-
nucleophile with c6' (or c2'), bulky iodine substituents on c3 and c5 may inter-
fere with the formation of a proper contact between enzyme and substrate. Relief 
from steric hindrance by deletion of one or both of these iodine atoms may, 
therefore, account for the preferred reactions with rT3 and 3' ,5'-T2. To test 
the validity of the model, substrate analogues could be prepared- in analogy 
with thymidylate synthetase-catalysed reactions (t·1atsuda et al, 1978; Mertes 
et al, 1978; Brouillette et al, 1979) - which would arrest the catalytic cycle 
at the stage of the 5 1 ,6 1 -dihydrosubstrate-enzyme complex. The most obvious 
compounds to test would be nitrothyronine derivatives. Finally, to stress the 
speculative nature of the above discussion it is mentioned that even the 
stoichiometry of enzymatic iodothyronine deiodination with respect to cofactor 
oxidation has not been settled. 
The here described mechanism for iodothyronine-deiodinating enzymes is 
clearly different from that for iodotyrosine deiodinase. The latter is also a 
microsomal enzyme occurring in the thyroid as well as in the liver. It has been 
characterized as a flavoprotein, containing FMN, and reductive equivalents may 
be supplied either by NADPH through an electron carrier with its specific 
reductase, or directly by dithionite (Rosenberg and Goswami, 1979; Goswami and 
Rosenberg, 1979). 
Thyroid hormone deiodination is not mediated by tyrosine hydroxylase 
(Rokos and Scheiffele, 1979), nor by thymidylate synthetase (Visser et al, 
1978c). 
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Irrespective of the exact molecular mechanism of inhibition by TU, it is 
evident that coincubation with substrate is a prerequisite for inactivation of 
iodothyronine deiodinase. This offers the possibility to assess more directly 
which iodothyronines are substrate for a common enzyme. It was found that pre-
incubation of rat liver microsomes with TU and low concentrations of r4, rT3 or 
3' .s·-r2 resulted in the persistent and concomitant diminution of rT3 and 3' ,5'-
r2 5'-deiodinase activity (Visser and Van Overmeeren, 1980b). Preincubations 
with TU only or iodothyronines only or with TU in the presence of r
0 
or DIT 
were without effect. Lower concentrations of rT3 and 3' ,5'-Tz than of T4 were 
needed to achieve a similar degree of inactivation. As rT3 and 3' ,5'-T2 are 
also more readily deiodinated at the 5' position than T4, these findings lend 
support for the supposition that deiodination of substrate and, thus, iodo-
enzyme complex formation preceeds inactivation by TU. The results demonstrate 
that indeed T4, rT3 and 3' ,5'-T2 are substrates for a single 5'-deiodinase. 
Surprisingly, it was found that high concentrations of 3,5-T2 also assisted 
in the production of inactive enzyme-TU complexes. This indicates the possibil-
ity of one enzyme mediating the sequential breakdown of T4 by both 5- and 5'-
deiodination. The alternative explanation still is the two enzyme-concept 
implicating preference rather than selectivity of the 5- and 5'-deiodinase 
with respect to the position of the iodine atoms in the substrate (Visser and 
Van Overmeeren, 1980b). Up to now it has not been possible to separate 5- from 
5'-deiodinase activity in detergent extracts of liver microsomes (Fekkes et 
al, 1980). 
3.9. Conclusions 
With respect to the metabolism of iodoamino acids, three types of deiodin-
ative reactions may be distinguished: i) oxidative breakdown of iodothyronines 
with release of iodide, ii) enzymatic, reductive deiodination of iodothyro-
nines, and iii) enzymatic, reductive deiodination of iodotyrosines. In the 
presence of tissue components both enzymatic and non-enzymatic pathways are 
involved with the oxidative breakdown of T4. Similar degradation may, however, 
also occur in the absence of tissue preparations, provided that conditions 
allow for the generation of free radical species. The initial step is probably 
the formation of a phenoxy radical. Among the products are iodide, derived from 
the phenolic ring, and DIT. Iodination of protein, if present, has frequently 
been observed. The physiological significance of this reaction is considered 
minimal, because of mechanisms within the cell, which prevent the creation of 
the hazardous conditions necessary for this type of deiodination. Nevertheless, 
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quite extensive metabolism of T4 by such a mechanism may take place in vivo 
in phagocytosing leucocytes. 
The oxidative degradation of T4 has for a long time interfered with the 
detection of the specific conversion into T3 and rT3 and, subsequently, lower 
substituted iodothyronines in vitro. However, the introduction in recent years 
of reliable techniques to measure the specific metabolites has made it possible 
to study this second type of deiodination. Evidence has been presented that 
these reactions are enzymatic in nature. The enzymes are located in the endo-
plasmic reticulum of liver and, possibly, in the plasma membrane fraction of 
kidney homogenate. Mercapto compounds are required for deiodinase activity. 
Thiouracils are potent inhibitors of these reactions. Based on the kinetics of 
stimulation by thiols and inhibition by TU, a ping-pong mechanism has been 
indicated. According to the proposed model, the reductive deiodination of iodo-
thyronines is envisaged as a transfer of an iodinium ion from the substrate to 
a receptive group on the enzyme, followed by the reduction of this iodo-enzyme 
complex by thiol groups of the cofactor. The specific reaction of thioureylenes 
with sulfenyl iodides point to the formation of such an enzyme derivative: 
TI (substrate) + E-SH (enzyme) + TI 1 (first product) + E-SI (intermediate) n n-
E-SI+ 2R-SH (cofactor) -> E-SH + R-S-S-R +HI (second product)-
It has been shown that T4, rT3 and 3' ,5'-T2 are substrates for a common 
enzyme catalyzing the deiodination of the phenolic ring. However, 3,5-T2 also 
appeared to be deiodinated by this enzyme, though with less efficiency. This 
may indicate either that all possible deiodinations are mediated by a single 
enzyme or that two enzymes are required (iodothyronine 5- and 5'-deiodinase) 
which do not exhibit full specificity as far as the positions of the iodine 
substituents in the substrate are concerned. Deiodination of the phenolic ring 
(at low substrate concentrations) is optimal at slightly acidic pH, whereas 
non-phenolic ring deiodination proceeds maximally in a slightly alkaline milieu. 
As various manipulations affect deiodinase activity of isolated tissues in the 
same way as observed in the intact organism, it is concluded that these in vitro 
observations are representative for the physiological situation (see Table 3.3.). 
The third type of reaction concerns the enzymatic deiodination of iodo-
tyrosines. This is catalysed by a flavoprotein from thyroid and liver micro-
somes, where reductive equivalents are supplied by NADPH via an as yet un-
identified electron carrier and its specific reductase. 
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Table 3.3. EFFECTS OF VARIOUS IN VIVO AND IN VITRO TREATt~ENTS ON THE CONVERSION 
OF T4 INTO T3 IN THE INTACT ORGANISM AND IN LIVER HOMOGENATES" 
Treatment or condition 
Starvation 
Carbohydrate feeding 
Diabetes mellitus 
PTU 
Methimazole 
Dexamethasone 
Propranolol 
X-ray contrast agents 
rT 3 
a-Methyl tyrosine 
Diphenylhydantoin 
In vivo 
Body T4-T3 Tissue T4-T3 
conversion 
t 
conversion 
~ 
t 
t 
~ 
t 
In vitro 
Tissue T4-T3 
conversion 
at, increased; t, decreased; unaffected; - not tested or not applicable. 
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4. REGULATION OF THYROID HORr10NE DEIODINATION 
4.1. Introduction 
Several factors must be considered to play a role in the regulation of 
peripheral thyroid hormone deiodination, i.e.: changes in i) substrate avail-
ability, ii) concentration of active enzymes, iii) concentration of cofactor, 
iv) concentration of naturally occurring inhibitors, and v) pH. 
While the enzymatic mechanism of iodothyronine deiodination is still only 
partly understood and the basic question concerning the number of enzymes in-
volved has as yet not been resolved, several attempts have been made to identify 
the cause of a change in T4 metabolism. Most attention has been given to the ef-
fects of nutritional and thyroid status on deiodinase activity of tissue prepar-
ations. 
4.2. Effects of nutritional and thyroid status 
Several studies have demonstrated that the deiodinase activity of un-
supplemented rat liver homogenates is decreased during fasting (Balsam et al, 
1978b, 1979a; Harris et al, 1978b,c, 1979; Kaplan and Utiger, 1978a; Kaplan, 
1979a; Kaplan et al, 1979; Chopra, 1980; Gavin et al, 1980a,b). In contrast, 
no effect of fasting was observed in rat kidney homogenate (Kaplan et al, 1979) 
and pituitary fragments (Cheron et al, 1979). In addition, "fasting 11 was found 
to have no effect on the 5'-deiodination of rT3 in monkey hepatocarcinoma cells, 
whereas production of rT3 from T4 was even increased (Sorimachi and Robbins, 
1978a). Production of T3 from T4 by perfused rat livers from fasted rats was 
found to be normal if related to the amount of T4 taken up. The latter was found 
to be decreased (Jennings et al, 1979). 
In rats, prolonged starvation is accompanied by decreased T4 and T3 levels 
in the plasma. Hypothyroidism has been shown to lead to diminished deiodinase 
activities of the tissues, whereas hyperthyroidism results in enhanced activ-
ities (Larson et al, 1955; Grussendorf and HUfner, 1977; Balsam et al, 1978a, 
1979b; Harris et al, 1978b, 1979; Kaplan and Utiger, 1978b; Kaplan, 1979b). A 
notable exception is the converting activity of the anterior pituitary (Cheron 
et al, 1979; Kaplan, 1980). 
Several studies have indicated that the defect in rat liver 5'-deiodinase 
activity induced by a 2-days fast is related to changes in intracellular GSH 
concentrations. This was suggested from the findings that i) liver GSH content 
is decreased during fasting (Harris et al, 1979; Chopra, 1980) ii) there was no 
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difference between deiodinase activity of "fasted*' and 11 fed" homogenates if 
this was measured after addition of OTT (Harris et al, 1979; Chopra, 1980), 
iii) the activity of the microsomal fraction tested with exogenous thiols 
was not affected (Balsam et al, 1979a), iv) the potency of liver cytosol to 
support deiodination bj microsomes was diminished (Balsam et al, 1979a) and 
v) this diminished potency could not only be restored by the addition of GSH 
but also with NADPH (Balsam et al, 1979a). Noteworthy are also the findings 
by Kaplan et al (1979) who could not find an effect of fasting on deiodinase 
activity of rat kidney homogenates. In contrast to liver, kidney GSH content 
was found to be unaffected. 
General agreement exists that there is a direct influence of thyroid 
status on enzyme function rather than on GSH concentrations (Balsam et al, 
1979b; Harris et al, 1979; Kaplan, 1979b). Studies have been conducted to 
exclude that fasting-induced changes in peripheral thyroid,.,ormone metabolism 
are secondary to a decrease in thyroid function. In these studies, the effects 
of thyroid hormone administration during fasting were investigated. It was 
found that the decrease in tissue deiodinase activity by short-term (2 days) 
starvation was not reverted by hormone substitution (Harris et al, 1978b, 1979; 
Chopra, 1980). These results indicate different underlying mechanisms for the 
decreased 5'-deiodinase activity of liver in early fasting and hypothyroidism. 
However, during prolonged starvation an impairment of thyroid function appears 
to play an important role (Chopra, 1980). This may explain the disparity 
observed between tissue non-protein-SH content and deiodinase activity after 
3 or 4 days of fasting (Kaplan, 1979; Chopra, 1980; Gavin et al, 1980a). 
Thus, in the early phase of starvation, decreased peripheral production 
rates of T3 may be accounted for by a decline in the concentration of cofactor. 
In a later phase, tissue converting activity may be further impaired by a 
decrease in the number of enzyme units due to ensuing hypothyroidism. This 
dual mechanism is also apparent from the finding by Burger et al (1980), that 
refeeding rats following 6 days of starvation - in contrast to shorter periods -
did not induce an acute rise of serum T3. As fasting has no profound effects on 
thyroid function in man, this prolonged defect of peripheral thyroid hormone 
metabolism may be dissimilar in rats. 
Even in short-term fasting, reduction of intracellular GSH concentrations 
cannot be the sole cause for the decreased deiodinasc activity of rat liver. 
Although many studies have emphasized the importance of carbohydrate intake 
for optimal peripheral r3 production, protein depletion has been recognized 
as the predominant factor in the lowering of liver GSH content by fasting (Leaf 
and Neuberger, 1947; Edward and Westerfeld, 1952; Barford and Eden, 1956). 
More specifically, GSH levels are related to the intake of cysteine, cystine 
and methionine (Tateishi et al, 1977). This contradistinction is substantiated 
by the work of Gavin et al (1980b), who found that GSH concentrations were 
highest in rats fed a protein-rich diet, whereas deiodination was most effective 
in homogenates from rats fed glucose only. Moreover, fortifying the glucose diet 
with cysteine resulted in a rise of GSH levels, without a discernable effect on 
deiodination. 
It may be postulated that deiodinase activity is determined by the glu-
tathione sulfhydryl-disulfide ratio rather than by GSH levels per se (Fig. 4.1.). 
This is strengthened by the observation of an inhibitory effect of GSSG on 
tissue T4-T3 converting activity (Chopra, 1978), which may be due to the form-
ation of a mixed disulfide (E-S-SG) with an essential SH group. The activity 
of other enzymes (e.g. fructose-1,6-diphosphatase and glycogen synthetase) is 
also regulated by enzyme-glutathione mixed disulfide formation (Isaacs and Bink-
ley, 1977a,b). 
E-SH 
GSH 
Tin Tln-1 
\ /~ E-SI 
j-GsH 
/ltHI 
------E-5-SG 
Fig. 4.1. Possible regulation of thyroid hormone deiodination by GSH/GSSG ratio 
It has previously been suggested (Visser, 1978; Balsam et al, 1979a) that 
fasting-induced changes may be explained by a diminished production of NADPH in 
the hexose monophosphate shunt due to a lack of substrate (glucose). Since NADPH 
is a cofactor in the reduction of glutathione by glutathione reductase this will 
lead to a decrease in GSH levels (or the glutathione sulfhydryl-disulfide ratio) 
and, consequently, to a decrease in deiodinase activity (Fig. 4.2.). However, 
fasting does not induce a fall in liver NADPH concentrations (Greenbaum et al, 
1971; Isaacs and Binkley, 1977b). 
The following sequence of events may seem more likely. In fasting, glucagon 
secretion is increased which stimulates adipose tissue to mobilize fatty acids 
and the liver to oxidize these fatty acids. This results in increased product-
ions of H2o2 which is metabolised via glutathione peroxidase at the expense of 
GSH. The GSSG produced will then react with protein sulfhydryls to form mixed 
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NADPH GSSG T4f'rT3 
(D Glvtothione reductase 0 lodothyronine 5'-deiodino$C 
Fig. 4.2. The role of NADPH and GSH in thyroid hormone deiodination 
disulfides(Isaacs and Binkley, 1977b). 
In conclusion, it is suggested that oxidation of glutathione is an import-
ant factor in the decrease of tissue 5'-deiodinase activity as the underlying 
mechanism for a defect in the peripheral metabolism of T4 during dietary 
restrictions and perhaps also in systemic illness. For this it is necessary to 
assume that the deiodination itself is the rate limiting step in the peripheral 
conversion of thyroid hormone. An additional problem here is that not only 5'-
deiodinase activity but also the 5-deiodinase is dependent on the availability 
of sulfhydryl groups. Nevertheless, in the intact organism, fasting is associat-
ed with a selective decrease of 5'-deiodinase catalysed reactions, leaving the 
5-deiodination unaffected. 
The analogy between starvation and the effect of PTU in vivo is apparent. 
Administration of PTU evokes the manifestations of a selective decrease in 5'-
deiodinase activity, i.e. decreased serum r 3 and increased serum rT3 concentrat-
ions. Nevertheless, derivatives of TU have been shown to inhibit both types of 
deiodination in vitro. It has been demonstrated that addition of TU and a de-
crease in the concentration of thiol compounds have identical effects on the 
kinetics of enzymatic deiodination. Both manipulations interfere with the reduct-
ion of the E-SI intermediate (see previous chapter). It may of course be argued 
that the 5'-deiodinase is more sensitive to these manipulations than the 5-
deiodinase (if at all these are separate enzyme entities). Since there is not 
sufficient experimental evidence to support this assumption, this must remain 
purely speculative. 
Additional regulatory mechanisms for fasting-induced changes in the peri-
pheral metabolism of thyroid hormone have been suggested. Jennings et al (1979) 
investigated conversion of T4 into r3 with the perfused rat liver. They found 
that livers from fasted rats took up less r4 from the medium and produced less 
r3 as compared with livers from normally fed controls. If the production of r3 
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was related to the amount of T4 taken up by the liver, no abnormality could be 
observed. These authors concluded that the deiadination itself is nat the rate-
limiting step in the conversion of T4 into T3 but rather the transport of the 
substrate from the vascular to the intracellular compartment. A complicating 
factor in these studies was, however, the presence of glucose in the perfusion 
medium. Nevertheless, these findings suggest that variations in thyroid hormone 
transport through the plasma membrane play a part in the regulation of the 
peripheral r4 metabolism. This does not appear unlikely as it has been found 
that this transport is an active process, being dependent on intracellular ATP 
concentrations (Krenning et al, 1978, 1979, 1980). Cytoplasmic ATP is strongly 
diminished by fasting (Soboll et al, 1978). 
Reduced uptake of substrate can not be the sole explanation for the reduced 
conversion of T4 into T3 since in that case one would expect a concomitant re-
duction in the conversion of T4 into rT3, which also takes place intracellularly. 
Unless most rT3 is produced outside the liver, for which there is no experiment-
al evidence (see Fig. 4.3.). The hypothesis that changes in intracellular pH are 
also involved in the modulation of the deiodination processes has been put 
forward by the group of Hesch. In their view, changes in pH could have an 
effect either on the availability of substrate by influencing the binding to 
intracellular proteins (HOffken et al, 1977) or on the activity of the deiodin-
ating enzymes (Hesch et al, 1980). These authors suggest that in the latter 
situation a change in intracellular pH will result in a diminished degradation 
(by 5'-deiodination) of rT3. The accumulation of this inactive metabolite will 
in turn lead (by competitive inhibition) to a decreased conversion of T4 into r3. 
4.3. General conclusions 
It is generally conceived that T3 is the most active form of thyroid 
hormone. Besides the small amount secreted by the thyroid most of circulating 
T3 is derived from peripheral 5'-deiodination of T4. An alternative product, 
rT3, is obtained by 5-deiodination of T4. The biological potency of rT3 is 
negligible and so is probably the intrinsic activity of T4. The nature of 
thyroid hormone synthesis suggests that it is directed to keeping the level 
of inactive precursor at a constant level. The amount of active hormone produced 
is then regulated at the level of peripheral tissues, i.e. at the site of the 
target organs. Several clinical observations tend to suggest that indeed the 
amount of r3 produced is adjusted to the need which exists in specific circum-
stances. It appears that this is mainly achieved by. the regulation of 5'-deiodin-
ase activity. In vitro studies of the deiodination of iodothyronines, mainly 
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Fig. 4.3~ Possible mechanisms for normal (A) or decreased (B) production of r 3 {by 5'-deiodination from T4) and degradation of rT3 (by 5'-deiodin-ation into 3,3'-T ). 
I : 5- and 5'-deibdination take place in the same cell (tissue). 
Observations can only be explained by a selective decrease in 
5'-deiodinase activity. A general decrease in deiodinase activity 
or a decrease in substrate uptake will also result in a diminished 
rT production. 
II: s-3and 5'-deiodination take place in different cells (tissues). 
Observations can be explained by a defect in the 5'-deiodinating 
cell (tissue): decrease in deiodinase activity (a) or in substrate 
uptake (b). 
involving rat liver preparations, have therefore been performed to elucidate 
the molecular mechanism of this regulation. 
These in vitro studies have indicated that all possible deiodinations are 
enzymatic in nature, where the enzymes are located in the microsomal fraction 
(endoplasmic reticulum). The activity of these enzymes depends on the avail-
ability of thiols in the cytoplasmic fraction, and GSH is probably the endo-
genous cofactor. Circumstantial evidence has been presented that the entire 
sequential deiodination is catalysed by two enzymes, i.e. iodothyronine 5- and 
5'-deiodinase. It has, however, also been demonstrated that if this proves to 
be correct, the enzymes do not display full specificity with regard to the 
position of the iodine substituents in the substrate. It may, therefore, be 
quite possible that the 5'-deiodinase also mediates 5-deiodinations, though 
with low efficiency, and vice versa. Based on the effects of TU and variations 
in cofactor concentration on the kinetics of the 5'-deiodination, a model has 
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been developed in which the reaction is envisaged as consisting of two half-
reactions. In the first, there is a transfer of an iodinium ion from the sub-
strate to a sulfhydryl group of the enzyme. In the second half-reaction this 
intermediate iodo-enzyme complex is reduced by cofactor to free enzyme (ping-
pong mechanism). 
Armed with this rather poor knowledge of the deiodinating enzymes and the 
reactions they catalyse, attempts have been made to explain the observations of 
an altered metabolism in experimental conditions, notably during starvation. 
Most investigations have centered around the role of glutathione in the deter-
mination of deiodinase activity. They have revealed an association between the 
oxidation state of glutathione and the rate of S-deiodination during fasting. 
Several observations remain unexplained~ however~ which has led to the proposal 
of additional regulatory mechanisms. These involve changes in cellular uptake 
of T4 and changes in intracellular pH. Neither of these in itself can explain 
the observed alteration in thyroid hormone metabolism. This illustrates the 
complex nature of this matter and it seems pertinent that basic knowledge of 
the enzymes is increased, before definite answers on questions concerning this 
regulation can be given. A better understanding of the reactions will depend 
on the availability of pure enzyme preparations. 
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SUMMARY 
Thyroxine (T4) is the main secretory product of the thyroid gland and 
though a small amount of 3,3' ,5-triiodothyronine (T3) is also secreted, most 
of circulating T3 is produced by 5'-deiodination of T4 in peripheral tissues. 
Alternatively, 5-deiodination of T4 yields 3,3' ,5'-triiodothyronine (reverse 
T3, rT3). T3 is the only compound with significant biological activity. The 
amounts of r3 and rT3 produced from r4 in the body may vary depending on the 
pathophysiological situation. 
The aim of my studies described in the appendix papers was to obtain 
information about the characteristics and mechanism of thyroid hormone deiodin-
ation at the subcellular level. This would lead to a better understanding of 
the regulation of this process in the intact organism. 
In chapter 1 the biosynthesis of thyroid hormone and the role of peroxidase 
is described. Reactions resulting in the formation of iodothyronines, i.e. 
iodination and coupling of tyrosine residues, follow a radical mechanism and 
are inhibited by derivatives of thiourea, e.g. propylthiouracil (PTU). In 
addition, structure-activity relationships of iodothyronines as well as path-
ways for the metabolism of these compounds are considered, showing that both 
quantitatively and qualitatively deiodination is the most important transform-
ation of T4. 
Chapter 2 deals with the economy of thyroid hormone deiodination in physiol-
ogical conditions and the role of the diet and the effects of drugs. Under 
normal conditions approximately 80% of T3 and 95% of rT3 in the human body are 
produced by peripheral deiodination of T4. However, in several non-physiological 
situations (e.g. starvation, systemic illness and administration of drugs such 
as dexamethasone, propranolol, PTU and radiographic contrast agents) T3 form-
ation and rT3 degradation are impaired. Supposedly, these effects are due to 
a diminished 5'-deiodinase activity of the tissues. The supply and utilization 
of glucose appears to be important in this respect. 
Chapter 3 and the appendix papers concern the study of enzymatic 5- and 
5'-deiodination of several iodothyronines in tissue preparations, notably liver 
and kidney homogenates. I studied the conversion of T4 into T3 and rT3 and their 
further deiodination to 3,3'-diiodothyronine (3,3'-Tz) in rat liver homogenates 
and microsomal fractions. This included i) measurement of the metabolites with 
specific radioimmunoassays, ii) investigation of the number and properties of 
the enzymes involved with the sequential deiodination of T4, iii) the search for 
possible cofactors, and iv) attempts to elucidate the mechanism of deiodination. 
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It is demonstrated that a single enzyme mediates the 5*-deiodination of 
r4 ~ rT3 and 3' ,5'-T2. This same enzyme may also catalyse - albeit with low 
efficacy- the 5-deiodination of 3,5-T2. However, it seems likely that there 
exists a second enzyme being more specific for 5-deiodinations. Up to now 
efforts to separate 5- from 5'-deiodinase have been unsuccessful. 
Thyroid hormone-deiodinating enzymes require mercapto compounds for 
activity and are strongly inhibited by derivatives of thiouracil. From the 
kinetics of stimulation by thiols and inhibition by thiouracil it is concluded 
that enzymatic deiodination follows a ping-pong mechanism. This mechanism is 
thought to be composed of two half-reactions. In the first, an iodinium ion is 
transferred from the substrate to the essential sulfhydryl group of the enzyme, 
yielding monodeiodinated substrate and an enzyme-sulfenyl iodide complex. This 
enzyme intermediate is reduced in the second half-reaction by thiol groups of 
the cofactor with the formation of free enzyme and iodide. 
In chapter 4 an attempt has been made to relate in vivo observations of 
an altered thyroid hormone metabolism to the characteristic features of enzym-
atic deiodination. It is proposed that reduced glutathione is the endogenous 
cofactor and that a decrease in the glutathione sulfhydryl-disulfide ratio 
is responsible for the impairment of tissue 5'-deiodinase activity during 
fasting. This may be an indirect result of increased fatty acid oxidation in 
the liver cell in this situation. Additional regulatory mechanisms may involve 
effects on cellular uptake of substrate. 
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SAMENVATTING 
Schildklierhormoon stirnuleert het energieverbruik van de lichaamscellen 
(basaal metabolisme). Het door de schildklier geproduceerde hormoon bezit echter 
weinig biologische aktiviteit, omdat veel van de inaktieve voorloper thyroxine 
(T4)* en slechts weinig 3,3' ,5-trijoodthyronine (T3)* gesecerneerd wordt. r 3 is 
de enige vorm van schildklierhormoon met significante biologische aktiviteit. 
Een groat gedeelte van het circulerende r3 ontstaat bij de dejodering van r4 in 
de lever en de nieren. Bij dit proces kan oak 3,3' ,5'-trijoodthyronine 
* . ("reverse" r 3, rT3) gevormd worden, een metabol1et met verwaarloosbare hormo-
nale aktiviteit. 
Recent is aangetoond dat de hoeveelheid T4 die in r 3 dan wel rT3 wordt om-
gezet niet konstant is. Wellicht wordt dit bepaald door de behoefte van het 
lichaam aan meer of minder biologisch aktief schildklierhormoon. 
Mijn onderzoek had tot doel de eigenschappen van de enzymen te bestuderen 
die betrokken zijn bij de dejodering van schildklierhormoon en het mechanisme 
van de dejoderingsreakties op te helderen. Deze onderzoekingen zijn in de bij-
gevoegde publikaties beschreven. Met dit proefschrift werd beoogd: 
i) een literatuur-overzicht te geven betreffende de bestudering van de dejo-
dering van T4 in het intakte organisme; 
ii) mijn onderzoek en dat van anderen naar de werking van bovengenoemde enzymen 
te bespreken; 
iii) de manier waarop de dejodering van schildklierhormoon in het lichaam wordt 
geregeld te verklaren aan de hand van onder ii) verkregen resultaten. 
Sommige geneesmiddelen (verbindingen afgeleid van thiouracil) remmen zowel 
de aanmaak (jodering) als de afbraak (dejodering) van schildklierhormoon. Dit 
zou kunnen wijzen op mogelijke overeenkomsten tussen beide processen. Vandaar 
dat in hoofdstuk 1 wordt beschreven hoe de joodthyronines in de schildklier 
worden vervaardigd. 
Het schildkliereiwit thyroglobuline bevat meerdere exemplaren van het 
aminozuur tyrosine. Deze kunnen worden gejodeerd en vervolgens samengevoegd tot 
joodthyronines. Zowel de joderings- als de koppelingsreaktie worden uitgevoerd 
door hetzelfde enzym: het schildklier-peroxidase. Vroeger is verondersteld dat 
hierbij een bepaald jodium-enzym complex (zgn. sulfenyl jodide) wordt gevormd. 
Thiouracil zou met dit complex reageren en daarmee de vorming van het hormoon 
belemmeren. Dit lijkt echter niet waarschijnlijk. 
* het cijfer duidt op het aantal jodium atomen in het molecuul (zie figuur 1.5.) 
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Dat dejodering van het T4-molecuul een belangrijke reaktie is wordt nog 
eens onderstreept door de gegevens die verder in hoofdstuk 1 worden besproken. 
Het is waarschijnlijk zelfs zo dat elk effekt van r4 toediening aan mensen maar 
oak aan proefdieren te verklaren is doordat uit dit T4 in het lichaam het ak-
tieve r3 wordt gevormd. 
De herkomst van circulerend T3 en rT3 is op verschillende manieren onder-
zocht (hoofdstuk 2). De konklusie is dat ongeveer 80% van het T3 en zelfs 95% 
van het rT3 ontstaan bij de dejodering van T4 en, dus, dat slechts 20% van het 
r 3 en 5% van het rT3 direkt door de schildklier aan de bloedbaan worden afge-
scheiden. 
Dejodering van T4 gebeurt niet willekeurig. In diverse omstandigheden (ze-
als tijdens vasten, ziekten en in gevallen van 11 stress 11 ) maar oak na toediening 
van bepaalde medicamenten (waaronder weer het thiouracil) blijkt het T3-gehalte 
in het bloed verlaagd te zijn en het rT3-gehalte verhoogd, terwijl het T4 
meestal niet veel verandert. (Langere toediening van thiouracil leidt uiteraard 
ook tot een verlaging van de T4 spiegels). De lage T3 spiegels blijken het ge-
volg te zijn van een verminderde omzetting van T4 in T3. Echter de produktie 
van rT3 uit T4 blijkt niet veranderd te zijn. Oat het rT3-niveau in het bloed 
is verhoogd wordt veroorzaakt door een verminderde klaring van deze stof. 
Naar aanleiding van deze bevindingen heeft men verondersteld dat het enzym 
dat T4 in T3 omzet (5'-dejodase)* niet gelijk is aan het enzym dat de omzetting 
* van T4 in rT3 bewerkstelligt (5-dejodase) . Het lijkt echter waarschijnlijk dat 
het 5'-dejodase ook verantwoordelijk is voor de afbraak van rT3. De bovenge-
noemde veranderingen in.het metabolisme van schildklierhormoon kunnen dan worden 
verklaard door een slechter funktioneren van dit 5'-dejodase, terwijl het 5-
dejodase ongemoeid verder dejodeert. 
Het blijkt dat de Samenstelling van het dieet- vooral de hoeveelheid 
koolhydraat daarin - een belangrijke rol speelt in de regulatie van de aktivi-
teiten van deze dejoderende enzymen. Aangezien vooral bij lever- en nierpatien-
ten afwijkingen optreden in de spiegels van T3 en rT3 in het bloed, wordt ver-
ondersteld dat de dejoderingsreakties hoofdzakelijk in deze organen plaatsvinden. 
Sinds kort is het mogelijk de diverse dejoderingsreakties, die leiden tot 
de vorming en afbraak van T3 en rT3, te bestuderen in weefselpreparaten waarin 
de celstruktuur niet meer aanwezig is (homogenaten). Voor mijn onderzoek heb ik 
homogenaten van rattelever gebruikt (hoofdstuk 3 en bijgevoegde publikaties). 
De betrokken enzymen blijken niet vrij in de eel voor te komen, maar zijn ge-
* 5 en 5' duiden op de posities van de jodiumatomen die door het enzym worden ver-
wijderd (zie figuur 1.5.); deze zijn equivalent aan, resp., posities 3 en 3'. 
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bonden aan membraanstrukturen binnen de eel. Zuivering van deze enzymen is dan 
oak niet eenvoudig. Wel is komen vast te staan dat inderdaad een enzym (het 
5'-dejodase) verantwoordelijk is voor zowel de aanmaak van T3 (uit T4) als de 
afbraak van rT3. Tot nu toe is het echter nag niet mogelijk geweest echt te 
bewijzen dat bij de produktie van rT3 uit T4 een ander enzym (het 5-dejodase) 
betrokken is, hoe aannemelijk dit oak mag zijn. 
De enzymen die schildklierhormoon dejoderen werken alleen in aanwezigheid 
van een verbinding die SH-groepen bevat (cofactor). Dejodering wordt echter 
geblokkeerd door thiouracil. De manier waarop de cofactor de dejodering stimu-
leert en thiouracil deze remt doet vermoeden dat de dejoderingsreaktie als volgt 
verloopt: er wordt een jodium atoom in b.v. het T4-molecuul vervangen door een 
waterstofatoom waarbij T3 of rT3 ontstaat. Het jodiumatoom (of liever het I+ 
ion) wordt overgedragen op een SH-groep van het enzym waarbij hier wel (i.n 
tegenstelling tot de joderingsreaktie) een sulfenyl jodide (SI)-groep wordt 
gevormd. De SI-groep op het enzym wordt vervolgens weer omgezet in de oorspron-
kelijke SH-groep na reaktie met de cofactor. De remmende werking van thiouracil 
kan op deze manier worden verklaard door reaktie met een enzym-SI-complex. 
In hoofdstuk 4 wordt getracht met summiere gegevens betreffende de werking 
van deze enzymen een verklaring te geven voor de belnvloeding van de dejode-
ringsprocessen in het lichaam onder verschillende kondities. Vooral de tijdens 
vasten waargenomen veranderingen hebben veel aandacht gekregen. 
Dejoderingsenzymen zijn dus afhankelijk van SH-verbindingen. Aangezien 
gereduceerd glutathion de in hoogste concentratie voorkomende SH-verbinding in 
de eel is~ wordt aangenomen dat dit de fysiologische cofactor is voor deze 
reakties. Nu blijkt dat tijdens vasten de dejoderingsaktiviteit van de eel 
tegelijkertijd met de concentratie van gereduceerd glutathion afneemt. Het 
belang van voldoende koolhydraat in het dieet voor een optimale dejoderings-
aktiviteit van de eel is al genoemd. De concentratie van gereduceerd glutathion 
wordt echter eerder bepaald door eiwit-inname. Het is dan ook zeer waarschijn-
lijk dat meerdere faktoren een rol spelen in de regulatie van de dejoderings-
processen. 
Een intrigerend fenomeen blijft het feit dat tot nu toe alleen variaties 
in 5'-dejodase aktiviteit Zijn waargenomen in tegenstelling tot het konstant 
blijven van de 5-dejodase aktiviteit. De konklusie is dan oak voorlopig dat, 
wil men meer weten omtrent de regulering van de dejoderingsreakties in het 
lichaam, het noodzakelijk is een dieper inzicht te krijgen in de werking van 
de daarbij betrokken enzymen. Hiervoor is het nodig te beschikken over zuivere 
enzympreparaten. 
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Conversion of Thyroxine into Tri-iodothyronine by Rat Liver Homogenate 
By THEO J. VISSER, INEKE VANDER DOES-TOBE, ROEL DOCTER 
and GEORG HENNEMANN 
Department of Internal Medicine III and Clinical Endocrinology, Medical Faculty, 
Erasmus University, Rotterdam, The Netherlands 
(Received 18 Apri/1975) 
By using a highly specific radioimmunoassay the formation of tri-iodothyronine by the 
deiod.ination of thyroxine was studied in rat liver homogenate. Several observations sug-
gest that the reaction observed is enzymic in nature. Pre-heating the homogenate for 30min 
at 56°C completely abolished conversion of thyroxine into tri-iodothyronine; the compo-
nent of rat liver homogenate responsible could be saturated with substrate; iodotyrosines 
displayed competitive activity. Between oo and 37°C~ the tri-iodothyronine-production 
rate was positively correlated with incubation temperature. The addition of NAD+ 
enhanced conversion into triwiodothyronine, which suggests that an oxidative mechanism 
is involved. 5-Propylw2-thiouracil and 6-propyl-2-thiouracil, both known to prevent 
deiodination in vivo, greatly decreased the deiodination activity of rat liver homogenate. 
Since the discovery of 3,3',5-tri-iodothyronine in 
human plasma (Gross &Pitt-Rivers, 1952) an abund-
ance of evidence has been presented which clearly 
shows that in the circulation in humans (e.g. Pitt-
Rivers et al., 1955; Braverman et al., 1970; Pittman 
et al., 1971; Sterling et al., 1970) and rats (e.g. 
Schwartz eta!., 1971) it is mainly derived by the peri-
pheral deiodination of thyroxine. These observations 
have repeatedly been confirmed by studies in vitro on 
perfused rat heart (Rabinowitz & Hercker, 1971), 
cultured human liver and kidney cells (Sterling et al., 
1973), cultured human fibroplasts (Refetoff et al., 
1972) and human leucocytes (Klebanoff & Green, 
1973; Weeber & Ingbar, 1973). No clear evidence 
that an enzymic reaction is involved in the mechanism 
of this conversion is as yet at hand. In rats a role for 
peroxidase in thyroxine deiodination has been 
proposed (Galton & Ingbar, 1963; Dawber et a!., 
1971), as well as the involvement of reduced flavin 
nucleotide as a cofactor in the deiodination of di-
iodotyrosine (Rosenberg & Ahn, 1969). These two 
supposed enzymic processes, however, seem to be 
functionally separated (Haibach, 1971). Thyroxine 
deiodination, in the absence of any apparent tri-
iodothyronine generation, has been observed in rat 
skeletal-muscle homogenate stimulated by flavins 
(Tata, 1960), and in several other homogenized rat 
tissues (Galton & Ingbar, 1963). In these and several 
other studies only the formation of iodide and 
chromatographically immobile 'origin material' was 
observed. For instance, this was the case when 
deiodination was studied in chemically defined 
milieus, e.g. in the presence of peroxidase and Hz0.2 
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or H.20.2 alone (Galton & Ingbar, 1963: Dawber 
eta!., 1971), by the combination ofHzOz andehelatcd 
metal ions (Reinwein et al., 1968) or by iliumination 
of a solution containing FMN (Rcinwein & Rail, 
1966). Almost ail studies referred to have been per-
formed with radioactive iocline~Iabelled thyroxine 
and by chromatographic analysis of the reaction 
products. 
A different approach bas been undertaken by 
Hesch et al. (1974), who applied a specific radio-
immunoassay to detect tri-iodothyronine generation, 
when rat liver homogenate was incubated with 
thyroxine. We have extended these studies and the 
results arc the subject of the present paper. 
Experimental 
Materials 
L-Thyroxine (free acid), 3 ,3 ',5·tri·iodo-L -thyronine, 
3,5~di-iodo~L·thyroninc, 3,3',5-tri·iodothyroacetic 
acid, 3,3',5-tri-iodothyropropionie acid, 3,5-dinitro-
L-tyrosine, NAD+, NADH, NADP+ and NADPH 
were obtained from Sigma Chemical Co .. St. Louis, 
Mo., U.S.A .. L-Tyrosine. 3-iodo-L-tyrosine and 
3,5-di-iodo-L-tyrosine were from Calbiochcm A.G .. 
Lucerne, Switzerland. Tri-[1 ;:5I]iodo-L-thyroninc 
(specific radioactivity approx. 500J1Ci/J1g) was from 
Abbott Laboratories, North Chicago, Ill., U.S.A.; 
goat anti-(rabbit y-globulin) antiserum was from 
Antibodies Inc., Davis, Calif., U.S.A. 5-Propyl-2-
thiouraci\ was synthesized by the method described by 
Anderson eta!. (1945) by Dr. P. J. H. Eggels, Univer-
sity Hospital ''Dijkzigt', Rotterdam, The Netherlands. 
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Preparation of rat liver homogenate 
Ma1e Wistar rats weighing approx. 200g were used. 
After perfusion ln situ through the portal vein, rat 
liver was minced, washed and subsequently homo-
genized in 3 vol. of 0.25M-sucrose in 0.05M-Tris-HCI, 
pH7.4 (sucrose-Tris buffer) at 4"C. The homogenate 
was centrifuged for Smio at 2000g at zoe. The result-
ing pellet was discarded. 
The protein content of the homogenate was deter~ 
mined after solubilization in O.lM-NaOH by using 
the biuret method. 
Deiodlnati'cm studies 
Thyroxine and other substances were dissolved 
and diluted in sucrose-Tris buffer immediately before 
use and added in 10 .ul quantities for incubation with 
I rnl samples of homogenate. Control experiments 
were conducted in which thyroxine was incubated 
with sucrose-Tris buffer or with homogenate pre-
heated for 30m.in at 56°C. Since these controls yielded 
identical results, the former was subsequently omitted. 
At increasing time-intervals 200 .ui portions of the 
reaction mixtures were taken and added to 400 .ui of 
icewcold 95 %(v/v) ethanol. The precipitates were spun 
down (1500g, 15min) and the tri-iodothyronine 
concentrations were measured directly in lOO.ul por-
tions of the supernatants in duplicate. The recovery 
of added tri-[125I]iodothyronine amounted to 85.8 
±4.5% (mean± S.D., n = 22). 
Radioimnuuwassay for tri-iodothyronine 
The radioimmunoassay utilizes rabbit antiserum 
raised against a tri-iodothyronine-bovine serum 
albumin conjugate (Docter era!., 1972). In Table 1 the 
Table 1. Composition of radiolmmunoassay mixtures 
All reagents were dissolved in 0.05M-potassium phosphate 
buffer, pH7.4, containing 0.4% bovine serum albumin 
(dilution buffer). Antiserum, final dilution 1:20000 was 
dissolved in 2.5% normal rabbit serum in dilution buffer. 
Extracts of reaction mixtures were made as described in 
the Experimental section. 
Tri-{1 ~51]iodotbyronine, 
20pg 
Tri-iodothyronine 
standard 
64% (v/v) Ethanol 
Extract of reaction mixture 
Antiserum 
Dilution buffer 
Volume for 
standard curve 
(.ul) 
100 
100 
100 
100 
600 
Volume for 
samples 
(.ul) 
100 
100 
100 
700 
composition of the assay mixtures is shown. The 
mixtures were incubated for 16h at 4°C. In the assay 
lOO,ul of previously titred goat antjw(rabbit y-globu-
Iin) antiserum was subsequently added to each tube 
and the mixtures were kept for an additional16h at 
4°C. The tubes were centrifuged and the superw 
natants were subsequently aspirated. The pellets 
were counted for radioactivity in a Packard gamma 
spectrometer. Non-specific binding of tri-(12 si]-
iodothyronine to the precipitate was evaluated by 
preparing controls containing normal rabbit serum 
without antiserum. The amount of tri-[125J]iodo-
thyronine specifically bound to the antibody was ex-
pressed as a percentage of the radioactivity precipi-
tated in the tubes without added unlabelled triw 
iodothyronine, which was usualiy approx. 45% of 
the total amount of radioactivity. To calculate the 
triwiodothyronine content of unknown samples the 
standard curve was transformed into a logit-Iog plot 
(Feldman & Rodbard. 1972). 
Results and Discussion 
Radioi'mmunoassay 
Fig.1 shows a typical radioimmunoassay standard 
curve. The specificity of the antiserum used was 
assessed by estimating the relative affinity of various 
thyroid-hormone analogues for the antibody- (Table 
2). It is concluded that the antiserum is highly specific 
for triwiodothyronine, only 3.3',5-tri-iodothyroacetic 
acid displaying a significant cross-reactivity. When 
dilutions of ethanol extracts of the reaction mixtures 
were assayed, the curve for antibody~bound tri-
pzsi]iodotbyronine versus log(.ul of extract) (not 
detailed here) paralleled the standard curve. These 
tests establish the reliability of this assay for the 
100 
75 
2 50 
~25 
0 
,L0 ---~, o-=-o---:,-":oo"o---c:, o-':oo·o 
Tri-iodothyronine (pg) 
Fig. 1. Standard curve for the radioimmunoassay of trl-
iodothyroninc 
Conditions are detailed in the Experimental section and in 
Table 1. Ordinate values show the amount of tri-(12'1]-
iodothyronine bound (B) as a percentage of radioactivity 
precipitated without added unlabeiied tri-iodothyronine 
(B,). 
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Table 2. Cross-reactivity of thyroid~homwne analogues 
with anti-trl-iodothyronin.e antiserum 
Cross-reactivity is defined as the ratio of the concentration 
of tri-iodothyronine to the concentration of analogue 
both resulting in a 50% decrease of antibody-bound 
tri-[12SI]iodotbyroninc. 
CQmpound 
3,3' ,5-Tri-iodo-L-thyrooinc 
3,3' ,5,5'-Tctraiodo-L-thyronine 
3,5-Di-iodo-L-thyronine 
3,3',5-Tri-iodothyroacetic acid 
3,3' ,5-Tri-iodothyropropionic acid 
3-Iodo-L-tyrosinc 
3,5-Di-ioclo-L-tyrosinc 
3,5-Dinitro-L-tyrosine 
L-Tyrosine 
Cross-reactivity 
1.0 
<0.001 
0.003 
0.77 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
60 120 
Time of incubation (min) 
Fig. 2. Dependence of trl-lodothyronine accumulation on 
incubation time and temperature 
Portions (lrol) of rat liver homogenate (43mg of protein( 
ml) were made to react in duplicate with 1J1g of thyroxine 
at ooc (A), 22°C (•) and 3JOC (e). At the times indicated 
200pl samples were added to ice-cold ethanol (400,ul). The 
resulting mixtures were processed as detailed in the Experi~ 
mental section. 
measurement of the conversion of thyroxine into tri~ 
iodothyronine. 
Delodination studies 
Fig. 2 shows the accumulation of' tri-iodothyronine, 
when rat liver homogenate is incubated with 1 pg of 
thyroxine/ml (1.3 pM) at different temperatures. 
During the first 15 min of the reaction the rate of tri~ 
iodothyronine production was 2.5nM/min at 37°C, 
0.47nM/min at 22°C and only 0.16 nM/min at occ. No 
tri-iodothyronine generation was observed when the 
homogenate was pre-heated for 30min at 56°C, and 
when no thyroxine was added to the homogenate the 
amount of tri-iodothyronine formed was negligible. 
Vol. 150 
• 
010·---""10~0---~10~0~0---,.,10:-'000 
Thyroxine added (ng) 
Fig. 3. Depl!l!dence of tri-iodothyrom"nc--production rate on 
thyroxine concentration 
Portions (lml) of rat liver homogenate (5lmg of protein/ 
m.l) were made to react with amounts of thyroxine as indi-
cated in duplicate. After incubation for 15min at 37°C the 
reaction was stopped and the tri-iodothyronine generated 
was extracted by addition of etlunol as described in the 
Experimental section. 
The relationship between the rate of tri-iodothyro--
nine formation and the thyroxine concentration is 
shown in Fig. 3. Since an abundance of thyroxine-
and tri-iodothyronine-binding sites exists in rat liver 
homogenate (e.g. Tata. 1962; Visser et al., 1975), 
the free thyroxine concentration in the reaction sys-
tem is not known and the kinetics of the reaction 
studied cannot be characterized simply by the stan~ 
dard procedure for the estimation of the Michaelis 
constant. At concentrations of thyroxine above 
Spgjml (6.4,UM) no further increase in reaction rate is 
observed, however, and this suggests that either the 
catalysing system is saturated in these circumstances 
and/or the possible cofactors involved are only pre-
sent in limited concentrations. 
Experiments were conducted in which the effect of 
the addition of millimolar concentrations of nicotin-
amide-adenine d.inucleotides was studied (Table 3). 
The presence of NAD+ resulted in a significant en~ 
han cement of the deiodination, whereas the addition 
of NADP+ was without effect. An insignificant de-
crease in tri-iodothyronine production was observed 
when the incubations were performed in the presence 
of 1 mM-NADH or 1 rnM-NADPH. These results 
could indicate that an oxidative reaction is involved. 
In view of the role of flavins in deiodination reac-
tions (Rosenberg & A~ 1969; Tata, 1960; Reinwein 
& Rall, 1966) 1 mM-FAD was added to the reaction 
mixtures. This resulted in an approximately twofold 
increase in tri-iodothyronine generation. However, a 
considerable amount was also produced in the control 
tubes with pre-heated homogenate in the presence of 
FAD. When this experiment and the dctennination of 
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Table 3. Effect of possi'ble co/actors on the corwersion ofthyroxlne into tri-iodothyronine 
Incubations were performed at 37°C as outlined in the Experimental section, by using 1 pg of thyroxine/mi. Mean values 
±s.E.M. (number of experiments) are given for the amount of tri-iodothyronine formed in paired experiments conducted on 
separate occasions. Statistical analysis was with Student's paired t test. NS, Not significant (P>0.05). 
Tri-iodothyronine production (og) 
Incubation conditions 
Control 
+lmM-NAD+ 
Control 
+liDM-NADH 
Control 
+lmM-NADP+ 
Control 
+lmM-NADPH 
15min 
16.2±2.3 (4) 
21.8±2.2 (4)P<0.05 
18.7±0.9 (5) 
16.5±2.4(5)NS 
17.9± 1.3 (5) 
18.7±1.9 (5) NS 
14.7±2.3 (4) 
9.2±2.3 (4) NS 
30min 
26.5±5.0 (4) 
36.7±6.2 (4) P<0.025 
29.3±1.9(5) 
26.5 ± 3.6 {5) NS 
29.2±0.9 {5) 
31.6±2.0 (5) NS 
22.0±4.0 (4) 
12.3±3.0 (4) NS 
Table 4. Effect of addition ofthyrold-hormone analogues on 
the corwersion of thyra xinc into tri-iodothyronine 
For details sec legend of Table 3; incubation time I5min. 
Incubation conditions 
Control 
+l.ug of3-iodotyrosine 
Control 
+ IO.ug of 3-iodotyrosine 
Control 
+1.ug of 3,5-di-iodotyrosinc 
Control 
+lO.ug of 3,5-di-iodotyrosine 
Control 
+1.ug of 3.5-dinitrotyrosine 
+10pg of3,5-dinitrotyrosine 
Control 
+lpg of tyrosine 
+IO,ug of tyrosine 
Tri-iodothyronine 
formed (ng) 
21.0± 1.3 (3) 
18.9±1.3 {3) NS 
20.2± !.2 (4) 
9.4±2.6 (4)P<0.05 
18.3±1.5 (5) 
21.3± 0.9 {5) NS 
18.7±2.0(4) 
10.2±2-S (4) P<0.05 
18.9±1.3 {4) 
18.1 ± 1.2 (4) NS 
17.7±1.5 (4) NS 
19.2±1.6(5) 
19.3 ±0.9 (5) NS 
19.3 ± !.0 (5) NS 
tri-iodothyronine by radioimmunoassay were re-
peated inthedark, this enhancement with FAD totally 
disappeared. The results of experiments without 
added FAD. performed in the dark, were as under 
normal illumination. These findings are in accordance 
with the work of Reinwcin & Rail (1966), who 
detected thyroxine deiod.ination by illuminating a 
solution containing thyroxine, FMN and tracer 
amounts of certain cations. 
The reaction was investigated in the presence of 
different quantities of thyroid-hormone analogues 
known to be unreactive in the radioimmunoa<;say 
(Table 4). Of the compounds used only 3,5-di-
iodotyrosine and 3-iodotyrosine are potent inhibitors. 
affecting the reaction to a comparable extent. 3,5-
Dinitrotyrosine was tested since it is reported to 
be a specific di-iodotyrosine dehalogenase inhibitor 
(Haibach, 1971), and this enzyme is a constituent of 
rat liver homogenate (Rosenberg & Ahn, 1969). The 
Table 5. Effect of additiOn of propylthlouracil on the con-
version of thyroxine into tri-iodothyronine 
For details sec legend to Table 3; incubation time 15min. 
Incubation conditions 
Control 
+lO.UM-5-Propyl-2-thiouracil 
+ 1 OO.uM-5-Propyl-2-thiouracil 
Control 
+10.UM-6·Propyl-2-thiouracil 
+ 1 OO,uM-6-Propyl-2-thiouracil 
Tri-iodothyronine 
formed (ng) 
16.6±2.1 {4) 
5.5±1.1 (4)P<0.005 
4.3±0.9 (4) P<0.005 
17.0±2.6 (4) 
5.1 ±2.5 (4)P<0.005 
3.2±1.2 (4)p <0.001 
presence of this compound, however, did not affect 
the reaction, from which it is concluded that there-
action proceeds via a dciodinase different from di-
iodotyrosine dehalogenasc. Haibach (1971) also 
reported on the functional separation between di-
iodotyrosine deiodinase and thyroxine dciodinase in 
rat thyroid tissue. The addition of tyrosine to the 
incubation mixtures was without effect. 
6-Propyl-2-thiouraeil and 5-propyl-2-thiouracil, 
when administered to rats (Oppenheimer et al., 
1972; Bernal & Escobar del Rey, 1974) or humans 
(Hershman, 1964: Saberi et al., 1975; Geffner et al., 
1975), prevent peripheral deiodination of thyroxine 
and tri-iodothyronine besides displaying goitrogenic 
activity. Another goitrogen, methimazole, leaves the 
conversion of thyroxine into tri-iodothyronine un-
affected. These goitrogens exert their anti-thyroid 
activity mainly by inhibiting oxidative iodination of 
tyrosine by thyroidal peroxidase (Astwood, 1949). 
5-Propyl-2-thiouracil and 6-propyl-2-thiouracil were 
tested for their potential inhibitory effect on the de-
iodination. Table 5 shows that propylthiouracil 
strongly impairs the conversion of thyroxine into tri-
iodothyronine. Addition of methimazole in cquimolar 
concentrations was without effect (T. J. Visser & 
I. van der Does-TobC, unpublished work). From the 
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experiments involving NAD+, 5-propyl-2-tbiouracil 
and 6-propyl-2-thiouracil we suggest that thyroxine 
is deiodinatcd by rat liver homogenate, resulting in a 
production of tri-iodothyronine, by an oxidative 
mechanism. 
Preliminary experiments showed that the catalysing 
activity is predominantly associated with the micro-
somal fraction (T. J. Visser & I. van der Do.:::s-TobC, 
unpublished work). Whether the dciodination occurs 
at random_ resulting in a concomitant production 
also of 3,3',5'-tri-iodothyroninc, and whether 3,3'.5-
tri-iodothyroninc itself is also deiodinatcd by the 
same enzyme or exhibits some kind of product inhibi-
tion remains to be established. 
We arc grateful to Dr. P. J. H. Eggels for preparing 
5-propyl-2-thiouracil and to Mrs. C. Boot for expert 
sccrcto.rio.l o..ssisto.ncc. 
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Subcellular Localization of a Rat Liver Enzyme Converting Thyroxine into 
Tri-iodothyronine and Possible Involvement of Essential Thiol Groups 
By THEO J. VISSER, INEKE VANDER DOES-TOBJ:O, ROEL DOCTER and 
GEORGE HENNEMANN 
Department of Internal Medicine Ill and Clinical Endocrinology, Faculty of Medicine, 
Erasmus Utu'versity, Rouerdam, The Netherlands 
(Received 4 February 1976) 
Experiments with rat liver homogenates showed that on subcellular fractionation the 
ability to catalyse the conversion of thyroxine into tri-iodothyronine was lost. The 
activity could in part be restored by addition of the cytosol to the microsomal fraction. 
Both components were found to be heat labile. The necessity of the presence of cytosol 
could be circumvented by incorporation of thiol-group-<:ontaining compounds in the 
medium. Optimal enzymic activity was observed in the presence of dithiotbreitol and 
EDTA in medium of low osmolarity. By comparing the distribution of the converting 
enzyme over the subcellular fractions with a microsomal marker enzyme, glucose 6-
phosphatase, it was demonstrated that the former is indeed of microsomal origin. Finally. 
it was shown that thiol groups play an essential role in the conversion of thyroxine into 
tri-iodothyronine. 
Soon after the detection of 3,3',5~tri-iodothyronine 
in human plasma in 1952 by Gross & Pitt~Rivers, it 
was recognized that circulating tri~iodothyronine was 
in part derived from peripheral deiodination of 
thyroxine (Pitt~Rivers et a! .• 1955; Larson et al., 
1955). It was suggested that tri-iodothyronine is the 
principal biologically active hormone. with thyroxine 
as a large precursor pool enabling the body to main-
tain constant effective thyroid hormone concentra-
tions (Gross & Pitt-Rivers, 1954; Schwartz et a/., 
1971). This pro~hormone function of thyroxine has 
been substantiated by the finding that its affinity for 
the nuclear thyroid hormone receptor is small 
relative to tri~iodothyronine (Oppenheimer et al., 
1973; Samuels & Tsai, 1973; Docter et al., 1976). 
The study of the conversion of thyroxine into triM 
iodothyronine in vitro has been hampered by the 
occurrence of an apparently non-specific dciodination 
yielding reaction products other than tri~iodothyron~ 
inc (Tata, 1960; Stanbury eta!., 1960; Wynn et al., 
1962; Galton & Ingbar, 1963; Nakagawa & Rue-
gamer, 1967; Schwartz et al., 1969; Dawber eta!., 
1971). Other investigations by Larson et al. (1955), 
Rabinowitz & Hercker (1971), Sterling et al. (1973), 
Klebanoff & Green (1973) and Woebcr & Ingbar 
(1973) using tissue slices or isolated cc11s have 
unequivocally shown that production of tri-iodo-
thyronine as a result of mono-deiodination of 
thyroxine can be observed. 
These observations were extended by the applica~ 
tion of specific radioimmunoassu.ys for the measure-
ment of tri~iodothyronine on incubation of tissue 
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homogenates with thyroxine by Hesch et a!. (1975), 
Chirasevecnuprapund et a/. (1975) and Visser ct a!. 
(1975). The mechanism of the specific deiodination. 
however. remains unclear. We report in the present 
paper results of investigations that demonstrate that 
the conversion of thyroxine into tri-iodothyronine is 
catalyscd by an enzyme of the endoplasmic reticulum 
of rat liver tissue and that thiol groups are essential 
for this enzymic activity. 
Experimental 
Materials 
L-Thyroxine,p-chloromcrcuriphenyisulphonic acid 
and dithiothreitol were from Sigma Chemical Co., 
St. Louis, MO, U.S.A. 
Preparation of rat liver homogenate and Stt.hcel!ular 
fractionation 
The post-nuclear supernatant of rat (Wlstar) liver 
homogenate was prepared in 2501M~Tris/HC1, pH7.4. 
containing 0.25 M-sucrose as previously described 
(Visser eta/., 1975). This preparation was fractionated 
into mitochondrial, lysosomal, microsomal and cyto~ 
solic fractions by means of differential centrifugation 
essentially by the method of de Duvc et a/. (1955). 
The purity of the fractions thus obtained was evalu-
ated by analysis of several marker enzymes (de Duve 
et al., 1955). As a microsomal marker glucose 6-phos-
phatase (EC 3.1.3.9) was measured (de Duve eta/., 
1955). Protein was measured as described by Lowry 
eta!. (1951) with bovine serum albumin as standard. 
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Table 1. Tri-iodothyronine productlon en incubation of thyroxine (lp,M) with subcd/ular /ractlons tn 0.25M-sucrose/25mM-
Tris/HCl,pH7.4, at 37'''C 
The numbers in parentheses are the protein content (in mgjml) of the various fractions. 
Homogenatc(l4.8) 
Mitochondria!(l.45) 
Lysosomal(1.25) 
Microsomal(3.5) 
Fraction 
Cytosolic(9.7) 
Mitochondrial{I.45)+cytosolic(7.2) 
Lysosomal(l.25) +cytosolic(7 .2) 
Microsomal(3.5)+cytosolic(7.2) 
Tri-iodothyronine 
formed 
(pmolfml per 30min) 
14.9 
0.0 
0.3 
0.3 
0.3 
1.2 
1.4 
6.0 
Microsomal (after 30min at 56°C)(3.5)+cytosolic(7.2) 
Microsoma1(3.5)+cytosolic (after 30min at 56°C)(7.2) 
0.2 
0.0 
Table 2. Tri-icdothyrom'ne production on incubation of 
microsomal fraction (5.45mg ofproteinfm[) with thyroxine 
(l,uM) in 0.25M-sucrosej25m.M-Tris/HC/, pH7.4, at 37°C 
after a preincubation for 30min at 0°C in the presence or 
absence ofthiol-grou]rcontaining compounds 
Addition 
Tri-iodothyronine 
formed (pmol/ml) 
Incubation time (min) . . . 15 30 
None 0.4 0.8 
1 rnM-Dithiothrcitol 16.3 27.6 
1 roM-2,3-Dirnercaptopropanol 7.3 11.9 
I rnM-P..Mercaptocthanol 6.9 13.3 
Table 3. Tri-iqdothyronine production on incubation of 
thyroxine (lfJM) with microsomo.l preparations (3.Smg of 
proteinfml) in Tris buffered media (pH7.4) of different 
Dithio-
threitol 
(mM) 
0 
0 
I 
I 
5 
5 
5 
5 
5 
compositionsat37°C 
EDTA Sucrose KCI 
(mM) (M) (M) 
0 0.25 0 
5 0.25 0 
0 0.25 0 
5 0.25 0 
0 0.25 0 
0 0.25 0.4 
0 0 0 
5 0 0 
5 0 0.4 
Conversion studies 
Tri-
iodothyronine 
formed 
(pmol/ml per 
30min) 
0.5 
5.1 
30.8 
49.2 
33.9 
26.3 
30.2 
61.3 
19.9 
Thyroxine (l.Onmol in a final volume of 1 ml), w:tS 
incubated with various subcellular fractions scs-
pended in buffers of different composition as indi-
cated. The reaction was stopped by the addition of 
2vol. of95% (v/v) ethanol and the tri-iodothyronine 
produced was measured by radioimmunoassay 
(Visser et al., 1975). The thyroxine preparation used 
showed a relative displacement potency in this radio-
immunoassay of less than 0.1 %, which represents 
maximal values for contamination with tri-iodo-
thyronine as well as for actual cross-reaction of 
thyroxine. 
Results 
Although conversion of thyroxine into tri-iodo-
thyronine by rat liver homogenate could readily be 
demonstrated (Visser et a!., 1975) this catalytic 
activity was apparently lost on subsequent fractiona-
tion (Table 1). Activity could, however, in part be 
restored by combining the cytosol with the micro-
somal fraction and to a lesser degree with the other 
particulate preparations. The active factor present in 
the soluble fraction as well as that in the particles was 
found to be heat labile. Heating either cytosol or the 
particulate components for 30min at 56°C strongly 
decreased the converting activity displayed by the 
combination of the fractions concerned. 
In the course of these experiments we noticed that 
on standing at ooc for approx. 4h the homogenate 
lost over 50% of its converting activity. In addition a 
decrease in activity occurred when the homogenate 
was dialysed for a short time; 5ml of homogenate, 
dialysed against 2 litre of 0.25 M-sucrose/25 mM-
Tris/HCI, pH7.4, for 30min at ooc, possessed only 
45% activity compared with non-dialysed material. 
It was observed that the requirement for cytosol 
could be circumvented by including a thiol-group-
containing compound in the reaction mixture, 
namely ft-mercaptoethanol, 2,3-dimercaptopropanol 
or dithiothreitol, with the latter being far the most 
effective (Table 2). 
Table 3 demonstrates to what extent tri-iodo-
thyronine accumulated, when thyroxine was incu~ 
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bated with microsomal preparations suspended in 
media varying in sucrose, EDTA, KCI and ditbio~ 
threitol concentrations. Obviously conditions are 
optimal if both EDTA and dithiothreitol are present. 
KCI (0.4M) inhibited the reaction. 
In the presence of 1 ffiMwditbiotbreitol and 5 mM:-
EDTA. treatment at 56°C for 30min still abolished 
the catalytic activity of the microsomal fraction with 
respect to thyroxine conversion. This was not caused 
by accelerated oxidation of added dithiothreitol or 
cysteine residues in the microsomal proteins; it was 
rather a matter of denaturation, since subsequent 
addition of dithiothreitol failed to induce activity. 
To investigate the possible involvement of thiol 
groups, triRiodothyronineRdirected deiodination of 
Table 4. Tri-iodothyronine production on incubation of 
thyroxine (l,uM) with microsomal fraction in 25mM-Trisj 
HCl/1 mM-dithiothrdtol/5 mM-EDT A,pH7 .4, at 37~ C in the 
presence of thiol-group-blocklng reagents or eN-
Addition 
None 
3 mM-:P-Chloromercuriphenyl-
sulpbonic acid 
3tnM-Ag"" 
3InM-Hg"" 
lmM-KCN 
Tri-iodothyronine 
formed(%) 
100 
0,6 
2.0 
2.7 
97 
Table 5. Tri-iodothyronine production on incubation of 
thyroxine (1 f,LM.) with microsomal fraction in 25mM-Trisf 
HCI/1 mM-dithiothreitol/SmM-EDTA, pH7.4, at 31'C in 
the presence of possible cofactors 
Addition 
(lmM) 
None 
NAD+ 
NADH 
NADp+ 
NADPH 
Tri-iodothyronine 
formed(%) 
100 
115 
94 
105 
78 
thyroxine was studied by incubating it with a micro-
somal preparation preincubated with agents known to 
become covalently linked to cysteine residues (Table 
4).In the presenceofp-ehloromercuriphenylsulphonic 
acid, Hg+ or Ag"", tri-iodothyronine generation was 
almost completely suppressed. This decrease in 
activity was not due to reactions with dithiothreitol 
and the consequent decrease in its effective concentra-
tion, but rather to substitutions at the thiol groups of 
the enzyme. Experiments were performed in which 
the preincubation with the cysteine-directed inhibi-
tors was followed by a second preincubation in the 
presence of excess of dithiothreitol and in no case was 
any restoration of activity observed. Table 4 also 
shows that addition of KCN to the reaction mixture 
did not affect the amount of tri-iodothyronine 
generated from thyroxine, rendering the involvement 
of a prosthetic haem group unlikely. 
The monodeiodination of thyroxine by the 
microsomal fraction was investigated in the presence 
of millimolar concentrations of nicotinamide-adenine 
dinucleotides (Table 5). In no single instance was any 
enhancement of the reaction rate observed. 
In Table 6 the subcellular distributions of the conw 
verting enzyme (assayed under optimal conditions 
with respect to EDTA and dithiothrcitol concentra-
tions) and glucose 6-phospbatase are compared. The 
highest tri-iodothyronine production rate is observed 
with the microsomal fraction. 
Discussion 
Our observations suggest that rat liver homogenate 
contains a diffusible factor, the presence of which is a 
prerequisite for the conversion of thyroxine into tri-
iodothyronine. The loss of activity on keeping the 
homogenate at low temperatures could indicate that 
the factor(s) involved are inactivated either by 
proteolytic breakdown or, more likely~ by oxidation 
due to exposure to air. The latter possibility was 
supported by the finding that inclusion of 1 IDM-dithio-
threitol in the incubation mi'<ture enhanced the 
production of tri-iodothyronine from thyroxine as 
Table 6. Spf:cijic activitlesof g/uCQse 6-phosphatase and of the enzyme converting thyroxlne into tri-iodothyronine in subcellular 
fractions 
Tri-iodothyronine production was studied with thyroxine (lf,LM.) in 0.25M-sucrose/25mM-Tris/H0/3mM-dithiothreito1/ 
3m.'1-EDTA, pH7.4, at 37°C. 
Vol.l57 
Fraction 
Homogenate 
Mitochondrial 
Lysosomal 
Microsomal 
Supernatant 
Glucose 6-phosphatase 
(J.anol of phosphate/min per 
mg of protein) 
0.102 
0.036 
0.181 
0.200 
0.002 
Thyroxine-S' -deiodinase 
(pmol of tri-iodothyronine/min 
per mg of protein) 
2.90 
1.73 
4.34 
6.46 
0.11 
Q 
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catalysed by the homogenate. In addition, the 
decrease in activity on aging of the homogenate was 
less rapid in the presence of dithiothreitol than in its 
absence. Further, it induced converting activity by the 
microsomal fraction. The results of experiments 
described in the present paper are in favour of the 
assumption that the enzyme is highly sensitive to 
oxidation. Apparently a condition for the enzyme to 
display converting activity is that cysteine residues 
are present in the reduced state. The stimulation by 
cytosol in the experiments described in Table 1 may 
have been affected by endogenous glutathione 
although we cannot firmly exclude additional actions 
of the supernatant fraction. 
The only comparable study on the occurrence of 
the conversion in the presence of rat liver microsomal 
fraction is that by Hesch et al. (1975). Since these 
investigators did not incorporate rcductants such as 
thiols in their media, the conversion rate they 
reported is very low. Under comparable circum-
stances they observed that less than 0.1% of the 
thyroxine added was deiodinated to tri-iodo-
thyronine, whereas we found approx. 6% (Table 3). 
The results described here may also be compared 
with observations in other laboratories (e.g. Stanbury 
et a!., 1960; Wynn et a!., 1962; Nakagawa & Rue-
gamer, 1967) on the deiodination of thyroxine by rat 
liver microsomal fraction, apparently without con-
comitant tri-iodothyronine production. Although 
these studies are conflicting on several points, 
especially with regard to the properties of the cata-
lysing factor involved in this reaction, they all have 
in conunon that eN- brings about a diminution of 
the degradation of thyroxine. We, however, found that 
eN- did not decrease the conversion (Table 4). The 
explanation for this phenomenon could be that rat 
liver microsomal fraction catalyses the deiodination 
of thyroxine in two different ways: one, a non-specific 
eN--sensitive deiodination leading to products other 
than tri-iodothyronine and a second, eN--insensitive 
dciodination specifically producing tri-iodothyron-
ine. Green (1975) reached the same conclusion. 
Neither of these two activities is, however, identical 
with iodotyrosine deiodinase (Schwartz et al., 1969; 
Rosenberg & Ahn. 1969; Haibach, 1971; Visser eta!., 
1975). 
Several coenzymes separately tested with the 
microsomal fraction did not result in an enhancement 
of tri-iodothyronine production (Table 5), although 
we observed a small, but significant, increase in con-
verting activity by the addition of NAD+ to the 
homogenate (Visser et al., 1975). The reason for this 
remains unclear. Assuming that. besides tri-iodo-
thyronine, r- is the only product. the reaction under 
investigation is clearly a reduction: thyroxine+ 2H ->-
tri-iodothyronine+ ID. In our particular situation 
dithiothreitol might supply the reducing equivalents. 
Weare grateful to Dr. H. R. Scholte of the Department 
of Biochemistry I of our Faculty for invaluable advice, 
especially concerning the subcellular fractionation, and 
to Mrs. C. Boot for skillful secretarial assistance. 
References 
Chirasevcenuprapund, P., Buergi, U., Goswarni, A. & 
Rosenberg, I. N. (1975) (Abstr.) Program Int. Thyrold 
Conf. 7th, Boston, p.75, Excerpta Medica, Amsterdam 
Dawber, N. A., Galton, V. A. & Ingbar, S. H. (1971) 
Endocrinology 88, 144-148 
de Duve, C., Pressman, B. C., Gianetto, R., Wattiaux, R. 
&Appelmans, F. (1955) Biochem. J. 60, 604-716 
Docter, R., Visser, T. J., Stinis, J. T., van den Hout-
Goemaat, N. L. & Hennemann, G. (1976) Acta Endo-
crino/. (Copenhagen) 81, 82-95 
Galton, V. A. & Ingbar, S. H. (1963) Endocrinology 73, 
596-605 
Green, W. L. (1975) (Abstr.) Program Int. Thyroid Conf 
7th Boston, p.74, Excerpta Medica, Amsterdam 
Gross, J. & Pitt-Rivers, R. (1952) Lancet i, 439-441 
Gross, J. & Pitt-Rivers, R. (1954) Recent Pro g. Horm. Res. 
10, 109-115 
Haibach, H. (1971) Endocrinology 88, 918-923 
Hesch. R. D., Brunner, G. & SOling, H. D. (1975) Clin. 
Chim. Acta 59, 209-213 
K.lebanoff, S. J. & Green, W. L. (1973) J. Clin. Invest. 52, 
60-72 
Larson, F. C., Tomita. K. & Albright, E. C. (1955) 
Endocrinology 51. 338-344 
Lowry, 0. H., Rosebrough, N.J., Farr, A. L. & Randall, 
R. J. (1951) J. Bioi. Chern. 193, 265-275 
Nakagawa, S. & Ruegamer, W. R. (1967) Biochemistry 6, 
1249-1261 
Oppenheimer, J. H., Schwartz, H. I., Dillman, W. & 
Surks, M. I. (1973) Biochem. Biophys. Res. Commun. 
55,544-550 
Pitt-Rivers, R.. Stanbury, J. B. & Rapp, B. (1955) J. Clin. 
Endocrinol. Metab. 15, 616-620 
Rabinowitz, J. L. & Hercker, E. S. (1971) Science 173, 
1242-1243 
Rosenberg, I. N. & Ahn. C. S. (1969) Endocrinology 84, 
727-737 
Samuels, H. H. & Tsai, J. S. (1973) Proc. Nat!. Acad. Sci. 
U.S.A. 70. 3488-3492 
Schwartz. H. L.. Kozyreff. V .. Surks, M. I. & Oppen-
heimer, J. H. (1969) Nature (London) 221, 1262-1263 
Schwartz, H. L., Surks, M. I. & Oppcnhcimcr,J. H. (1971) 
J. Clin. Invest. 50, 1124-1125 
Stanbury, J. B.. Morris, M. L., Corrigan, H. J. & Lassiter, 
W. E. (1960) Endocrinology 67. 353-362 
Sterling. K .• Brenner, M.A. & Saldanha. V. F. (1973) 
Science 179, 1000-1001 
Tata, J. R. (1960) Biochem. J. 71, 214-226 
Visser, T. J., van der Docs-Tobe, I., Docter, R. & Henne--
mann, G. (1975) BIOchem. J. 150, 489-493 
Woeber, K. A. & Ingbar, S. H. (1973) J. Clin. Invest. 52, 
1796-1803 
Wynn, J., Gibbs, R. & Royster, B. (1962) J. Bioi. Chern. 
237, 1892-1897 
!976 
Biochem, J. (1979) 179,489-495 
Printed in Great Brltain 
Kinetics of Enzymic Reductive Deiodination of Iodothyronines 
EFFECT OF pH 
By THEO J. VISSER, DURK FEKKES. ROEL DOCTER and GEORG HENNEMANN 
Department of!memal Medicine II! and Clinical Endocniro!ogy, Medical Faculty. Erasmus 
University, Rorterdam, The Netherlands 
(Receiced 14 Nocember 1978) 
5' -Deiodination of thyroxine (yielding 3,3',5-tri-iodothyronine: reaction I) and of 3,3',5'-
tri-iodothyronine (yielding 3.3' -di-iodothyronine; reaction II) and 5-deiodination of 
thyroxine (yielding 3,3',5'-tri-iodothyronine; reaction Ill) and of 3.3'.5-tri-iodothyronine 
(yielding 3,3'-di-iodothyronine; reaction IV) as catalysed by rat liver microsomal fraction 
were studied at pH 6.5. 7.2 and 8.0. It was found that: (I) the Km of reaction I was relatively 
independent of pH (approx. 3 JIM), whereas Vwas highest at pH 6.5 (63 pmol of 3,3',5-tri-
iodothyroninejmin per mg of protein); (2) the Km of reaction II was lowest at pH 6.5 (0.035 
,UM). but Vwas highest at pH8.0 (829pmol of 3.3'-di-iodothyronine/mm per mg of pro-
tein); (3) thyroxine inhibited reaction II competitively; K 1 values were identical at pH 6.5 
and 8.0 (1 ,UM): (4) for both reactions III and IV Km was lowest and Vwas highest at pH 8.0. 
The results are compatible with the view that reactions I and II are mediated by a single 
enzyme (iodothyronine 5'-deiodinase) and that reactions III and IV are catalyscd by a 
second enzyme (iodoth)Tonine 5-deiodinasc). 
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Deiodination is the main pathway by which 
thyroxine is metabolized in vh·o (Cavalieri & Rapo-
port. 1977; Burman. 1978). Studies in cirro have 
demonstrated that reductive deiodination of iodo-
th)Tonines is enzymic in nature and involves thiol 
compounds. Reduced glutathione is probably the 
endogenous cofactor (Visser, 1978). The primary 
products in this cascade of reactions are the metaboli~ 
callyactive form oft he hormone 3.3',5-tri~iodothyro­
nine (tri-iodothyronine) and the inactive isomer 
3.3' ,5' -tri-iodothyronine (reverse tri-iodothyronine). 
Both have been observed in citro to be further de~ 
graded to 3.3'-di-iodothyronine (di~iodothyroninc; 
see Scheme 1 ). Evidence has been presented which 
suggests that all possible intermediates in the sequen-
tial deoidination of thyroxine are indeed generated 
(Rudolph a a/., !978; Sakurada era/., 1978). 
Vo1.179 
We suggested that two enzymes. i.e. iodothyronine 
5(3)- and 5'(3')-deiodinase. are responsible for the 
entire deiodination of thyroxine (Visser, 1978). This 
was mainly based on the pH-dependence of the 
several reactions and on clinical findings. The concept 
3,3',5-tri-iodothyronine 
(tri-iodothyronine) 
I 
3,3' ,5,5'-Tetraiodothyronine 
(thyroxine) 
3.3' ,S'~tri-iodothyronine 
(reverse tri~iodothyronine) 
3,3' -di-iodothyronine 
(di-iodothyronine) 
Scheme 1. Two pathways for the sequential deiodination of thyroxine to di~iodothyronine 
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is supported by the observations of competitive 
inhibition of reaction I by reverse tri-iodothyronine 
(Chopra. 1977; HUfner et a!., 1977; Kaplan & 
Utiger, 1978) and of reaction II by thyroxine (Kaplan 
& Utiger, 1978). As both kc~t. and Km may vary with 
pH, one cannot adequately characterize the pH-
dependence of an enzyme-catalysed reaction with 
measurements at a single substrate concentration. 
In the present study, therefore. we measured the effect 
of pH on VandKm for each of the four dciodination 
reactions. Rat liver microsomal fraction was used as 
the source of the enzymes (Visser et a/., 1976). 
Evidence was obtained suggesting that reactions I 
and II are mediated by a single enzyme (iodothyronine 
5' ~deiodinase), although the interaction of reverse 
tri~iodothyronine with the enzyme is quite different 
from the reaction with thyroxine. 
Experimental 
Preparation of rat liver microsomal fraction 
in 25 mM~Tris/HCl/3 mM~EDTA/3 mM~dithiothreitol, 
pH7.4 (Visser eta/., 1976), and analysis of deiodin· 
ation (Visser et a!., 1978) were done essentially 
as described before. Reaction mixtures consisted 
of 0.066M-sodium phosphate, 3mM~EDTA. 3mM~ 
dithiothreitol, pH6.5, 7.2 or 8.0, and substrate and 
microsomal fraction in the concentrations indicated. 
The final volume was 0.25 mi. Reaction was initiated 
by addition of microsomal fraction and incubation 
was carried out at 37'C. Reaction was stopped by 
addition of 1 ml of 1.25% of the detergent Brij 35 
(Sigma Chemical Co., St. Louis. MO. U.S.A.) in 0.06 M-
barbitone/0.15M~NaCljO.l% bovine serum albu~ 
min, pH8.6, kept at ooc. This concentration of Brij 
has been shown to destroy enzymic activity com~ 
pletely and afforded a 100% recovery of iodothyro~ 
nines. The method circumvents the use of volatile 
ethanol (e.g. Visser eta!., 1978) for the preparation of 
the extracts. In control experiments microsomal 
fraction was added after the Brij solution. 
The amounts of product generated and of sub~ 
strate remaining were measured in 50 .ul of the extracts 
by means of specific radioimmunoassays (Visser 
eta!., 1978). Standards were prepared in 1% Brij in 
0.06M-barbitone/0.15M~NaCl/O.l% bovine serum 
albumin, pHS.6. 
The amount of iodothyronine measured in the 
control experiment was subtracted from that pro-
duced in the complete reaction mixture. Both 
incubations and radioimmunoassays were performed 
in duplicate. 
The protein content of the microsomal fraction 
was measured after solubilization of 0.1 M~NaOH, 
by using the method of Lowry et a/. (1951) with 
bovine serum albumin as a standard. The sources of 
the various materials used are given in a previous 
paper (Visser eta!., 1978). For the determination of 
Km and Vvalues the straight lines of double~reciprocal 
plots were drawn by the least~squares method 
applied to unweighted means. 
Results 
Dependence of reaction rares on concentrarion of 
microsomal protein 
Fig. 1 demonstrated that at pH7.2 the production 
of tri-iodothyronine and di·iodothyronine from 
thyroxine and of di-iodothyronine from tri~iodo­
thyronine was linear with the concentration of the 
microsomal fraction in the reaction mixture up 
to approx. 0.1 mg of protein/mi. Conversion 
of reverse tri~iodothyronine into di·iodothyronine 
reached a maximum at approx. 0.02mg ofprotein/ml, 
owing to exhaustion of substrate under these con-
ditions. The amount of reverse tri-iodothyronine 
degraded was equal to the amount of di-iodothyro-
nine produced. Less than 10% of added thyroxine, 
tri~iodothyronine and di·iodothyronine (O.Ol.uM) 
was degraded by up to 0.7 mg of microsomal protein/ 
mi. Similar findings were obtained at pH 6.5 and 8.0. 
In further experiments 70pg of protein/ml was used 
in the study of reactions I. III and IV and 3.5,ug of 
protein/ml for reaction II. 
Reaction 1: 5'~delodination of rhyroxine 
Double-reciprocal plots of tri~iodothyronine pro-
duction rate as a function of thyroxine concentration 
10.0 
--
( 20 
9. 7.5 I / 5 ' " I " , 0 ., I 5 0 0 ~ 5.0 .c 
~ I 2 0 I -~ " ~ / ~ I 
./ 
/ ~ i5 2.5 I / ~ 
I / 
.•· 
-~ 
I 4:.---· ~ 
¥-" 
0 
0 0.05 0.10 0.15 
Protein (mg/ml) 
Fig. l. Accumulation of trl-iodothyronlne (e) and of di~ 
iodothyronine ( 0) from l f.I.M-thyroxlne and of di·iodothy-
roninefrom 0.5.uM-tri-iodothyronine (.&}and [rom O.OI,uM~ 
reoerse tri-iodothyronine (L) as a function of microsomal 
protein concentration at pH7.2 
For experimental details see the text. Incubation time 
was 6min. 
1979 
KINETICS OF ENZYMIC DEIODINATION OF IODOTHYRONINES 49I 
at three pH values arc shown in Fig. 2. Apparently, the 
r..:action obeys ordinary Michadis~Menren kinetics 
with Km values ofapprox. 3 pM. being somewhat lower 
at pH 7.2than at pH 6.5 and 8.0 (Table 1 ). Thek~ .. ,. of 
the reaction is strongly influenced by pH. as illus-
trated by a 5-fold dccn:asc in V if pH is increased 
from 6.5 to 8.0. 
Reaction If: 5'-deiodination of reccrse tri-iodothyro-
nine 
Fig. 3 shows the dependence of di-iodothyronine 
production on the concentration of reverse tri-
iodothyronine at various pH values. Apparently, 
this reaction also follows Michaclis-Mcntcn kinetics. 
Increasing the pH from 6.5 to 8.0 effected a 7-fold 
increase in Km and a 2.5-fold increase in V (Table J). 
Reaction Iff: 5~deiodinarion of thyro;.:ine 
To obtain an accurate estimate of the rate of 5~ 
deiodination of thyroxine the amount of reverse lri-
::;- 400 
" ' o--~ -~ 
~ '[ 300 
~ ~ 
.S ~ 2 : 200 
.2~ 
0 -= 
] ~ 100 
• .!, 0 ' 
r::: E ' 
'::::5' 
-0,5 0 0.5 1.0 1.5 2.0 2 5 
1/IThyroxinel (,uM 1) 
Fig. 2. Linea·eaDer-Burk plot oft he conversion of thyroxine 
into td-iodothyronine at pH6.5 (o), 7.2 (0) and 8.0 (4) 
For experimental details see the text. Microsomal 
protein concentration was 0.07mg/ml, and incubation 
time 12min. Results are means ±S.D. of five experi-
ments, 
iodothyroninc converted into di-iodothyroninc has 
to be taken into account (sec also Visser e1 a!., 1978). 
The implications of this procedure are illustrated in 
Figs. 4 and 5. At pH6.5 no significant accumulation 
of reverse tri-iodothyronine was observed, whereas 
at pH 8.0 approximately equal amounts of reverse 
tri-iodothyronine and di~iodothyronine were found 
(Fig. 4). Production of di-iodothyronine by the 
pathway via tri-iodothyronine is negligible (see 
below and Visser et a!., 1978). If the sum of the 
concentrations of reverse tri-iodothyronine and di-
iodothyroninc was taken as a measure of 5-deiodin-
ation of thyroxine, til is reaction was found to follow 
Michaelis-Menten kinetics (Fig. 5). Values for Km 
were calculated to be approx. 2-3J1M, being highest 
at pH 6.5 {Table 1 ). The V of this reaction is highest 
at pHS.O, being about twice the value at pH6.5 
(Table 1). 
~ , 5 r 
g,;..., 
-~ -~ 15.0 
] ~ 12.5 
0 0 
.5 Ci) § E 10.0 
:;., ;; 
~ ~ 
~ ·§ 7.5 
·-:::::, 0 E s.o 
~ 0 
-:= 
2.5 
// 
///I 
J/ 
-40 -30 -20 ·-10 0 10 20 30 40 50 
!/!Reverse tri-iodothyronine! (pM- 1) 
Fig. 3. Lineweaver-Burk p/ol of the conversion of reverse 
tri~iodothyronine into di-iodothyronine at pH6.5 (o), 7.2 
(C) and 8.0 (.t.) measured with a specific radioimmunoassay 
for the falter 
For experimental details sec the text. Microsomal 
protein concentration was 3.5pgjml, and incubation 
time 12min. Results are means ±S.f..M. of four experi-
ments. 
Table I. Parameters of iodothyronine 5- and 5' -deiodinase-cata!ysed reactions in rat liver microsomal fraction 
Mean values ±S.D. are given with the numbers of experiments in parentheses. 
K. (J<M) V (pmol/min per rng of protein) 
Reaction pH ... 6.5 7.2 8.0 6.5 . 7.2 8.0 
5'-Deiodination of 
thyroxine (5) 2.9±0.6 2.3 ± 0.5 3.0±0.6 . 63±25 30±17 13±7 
reverse tri-iodothyronine (4) 0.035±0.010 0.064 ± 0.008 0.23±0.06 342± 169 559±230 829±425 
5-Deiodination of 
thyroxine (3) 3..3± 1.3 1.9±0.4 1.8±0.3 13±6 18±5 24±2 
tri-iodothyronine (5) 7.8±0.9 6.2±0.2 4.7± 1.1 21±9 36±7 42±19 
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Reaction IV: 5-deiodination of tri-iodothyronine 
Conversion of tri-iodothyronine into di-iodothy-
ronine was also found to be a saturable process (Fig. 
6). The Km for this reaction was larger than for the 
other reactions. and was highest at pH6.5. V was 
'"' ____ _] 
0 
2.5 5.0 7.5 10.0 
IThyroxinel CuM) 
Fig. 4. Di-iodothyronine (a) and recerse tri-iodothyronine 
(b) production rates as a function of thyroxine concenrration 
at pH6.5 (o). 7 ."2 {0) and 8.0 (4) 
For experimental details see the text. Microsomal 
protein concentration was 0.07 mgjml, and incubation 
time 12.min. Results are me.1.ns ±s.o. of three experi-
ments. 
20 
0 2.5 5.0 7.5 
I Thyroxine I (.uM) 
10.0 
similar to that of reaction III. in both magnitude 
and dependence on pH. 
Inhibition of 5'-deiodination of reverse tri-iodothyro-
nine by thyroxine 
The effect of thyroxine on the conversion of 
reverse tri-iodothyronine into di-iodothyronine was 
studied at pH6.5 and 8.0. The results demonstrate 
that at both pH values thyroxine inhibits this reaction. 
competitively (Fig. 7). From the change in apparent 
700 
600 
-0.25 0 0.25 0.50 0.75 1.00 
!/[Tri-iodothyronine] CuM" 1) 
Fig. 6. Lineweaver-Surk plot of the conversion of tri-
iodothyronine into di-iodothyronine at pH6.5 (e). 7.2 (0) 
and 8.0 (4) 
For experimental details see the text. Microsomal 
protein concentration v.as 0.07mg,/mJ,and incubation 
time 12min. Results arc means ±s.o. of five experi-
ments. 
700 
'" 
-1.0 0 0.5 1.0 1.5 z.o 2.5 
1/IThyroxinel (pw 1) 
Fig. 5. Direct (a) and double-reciprocal (b) plot of the sum of di-iodorhyronine and reverse tri-iodothyronine production rates as a 
function of thyroxine concentration at pH6.5 (e), 7.2 (0) and 8.0 (4) 
For experimental details see the text and the legend to Fig. 4. Results are means ±S.D. of three experiments. 
1979 
KINETICS OF ENZYMIC DEIODINA TION OF IODOTHYRONINES 493 
Km for reverse tri-iodothyronine the Kt value for 
thyroxine was calculated to be approx. I t.JM at both 
pH6.5 and 8.0 (Table 2). 
Discussion 
Studies in vitro of the enzymic reductive deiodin-
ation of iodothyronines have yielded apparently 
-50 
-s.o 
'"' 
25 0 25 
!/[Reverse tri-iodothyronine] (pM- 1) 
15 
lbl 
l/ .' 
j / T • .- • 
Ji/ 
2.5 
/ 
/ 
/ 
!/[Reverse tri-iodothyronine] (.uM- 1) 
so 
J 
5.0 
Fig. 7. Lineweaver-Burk plot of the conversion of reverse 
tri-iodothyronine into di-iodothyronine at (a) pH6.5 and 
(b) at pH8.0 in the absence (•) and presence o/(0) 2.5,uM-
or (a) 5 JiM-thyroxine 
For experimental details see the text. Microsomal 
protein concentration was 3.5 pgjml, and incubation 
time 15min. Results are means ±S.D. of three experi-
ments. 
conflicting results for the optimum pH of these 
reactions. Several possibilities may explain these 
discrepancies. In rat liver homogenate or microsomal 
fraction, pH may affect the rate of deiodination 
indirectly by changing the availability of substrate, 
owing to alterations in binding to non~enzyme con-
stituents of these preparations (HOffken eta!., 1977). 
To obtain a true evaluation of the effect of pH on 
reaction rates. all added substrate must be free to 
interact with the enzyme concerned. It is conceivable 
that the dependence of deiodinase activities on pH 
may also be influenced by the nature of the cofactor 
used, e.g. the pK of its thiol group. Enzymic deiodin~ 
ation of iodothyronines as a function of pH may 
further depend on the concentration of substrate 
tested, since Km and kcat. may be affected indepen-
dently. We therefore decided to study the variation in 
these parameters in a narrow pH-range comprising 
most reported optimum values. Under the conditions 
used in the present study. reaction rates were propor-
tional to the microsomal protein concentration in the 
presence of dithiothreitol. Gross non-specific binding 
of substrate to the membranes is therefore excluded. 
If such binding did occur, then an increase in micro~ 
somal protein concentration would result not only in 
increased enzyme concentration but also in de~ 
creased substrate availability (Visser et a!., 1978). 
However, deviation from linearity was observed 
only above 0.1 mg of protein/ml. 
Reaction I (5'-deiodination of thyroxine) is re-
ported to be optimal at pH6.0 (H6ffken eta!., 1977) 
or pH7.0 (Chopra, 1977). The Km for this reaction 
is variously reported as 1.6,uM (Hilfner et al., 1977), 
2.5,uM (Chopra, 1977) and 7.7 ,uM (Kaplan & Utiger, 
1978). It is demonstrated (Table 1) that reaction 
velocity as a function of pH at sub-saturating con-
centrations of substrate is determined by kcat.· 
For reaction II (conversion of reverse tri-iodothy-
ronine into di·iodothyronine). reported values of 
Km and optimum pH vary considerably. The data 
presented in Table 1 may at least in part explain these 
apparent discrepancies. It was found that both Km 
and Vwere highly dependent on pH; Km was lowest 
at pH 6.5 and V was highest at pH 8 .0. Since the 
effect of pH on Km is predominant. the rate of di-
iodothyronine formation at low substrate concen-
Table 2. Estimation of the K1 of the inhibition by thyroxine oft he conversion of reverse tri-iodnthyronine into di~iodothyronine 
K1 values were estimated by using the equation: apparent Km = Km (1 + [I]/K1), w~erethe apparentKmis-1/intercepton 
the abscissa in the Lineweaver-Burk plot (see Fig. 6) and [I] the concentration of the inhibitor. 
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Concn. of thyroxine (.uM) pH 
2.5 
5.0 
Apparent Km of reverse 
tri~iodothyronine (.uM) 
6.5 
0.025 
0.080 
0.13 
8.0 
0.23 
0.77 
1.4 
K1 of thyroxine (.uM) 
6.5 
L1 
1.1 
8.0 
L1 
1.0 
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trations as used previously (Visser et al.. 1978) 
should be highest in a slightly acidic medium, as 
indeed we have found. At relatively high concen-
trations of reverse tri-iodothyronine as used by 
HG.fner & Grussendorf (1978) and Chopra et a!. 
(1978), reaction velocities would be expected to 
follow kcat.· Both groups of investigators reported. 
in accordance with this conclusion, that conditions 
were optimal at approx. pH 8.0. The magnitude of the 
Km at pH7.2, 0.064pM (Table 1). is in excellent 
agreement with the value published by Chopra et af. 
(1978). i.e. 0.065 JlM. The value of this parameter at 
pH7.5 as reported by Kaplan & Utiger (1978) is 
substantially lower (7.5nM). This may be due to the 
differences in techniques, as these authors studied 
the disappearance of substrate on reaction of reverse 
tri-iodothyronine with whole rat liver homogenate. 
It should be emphasized, since the reaction follows 
a Ping Pong mechanism, that not only V but also Km 
is a function of cofactor concentration (sec below). 
This may also apply to the other reactions. 
Little is known about the conversion of thyroxine 
into reverse tri-iodothyronine (reaction III). Hilfner 
et a!. (1977) and HOffken et al. (1977) showed that 
accumulation of reverse tri-iodothyronine on incu-
bation of thyroxine with rat liver homogenate or 
microsomal fraction was highest at pH9-9.5. It has 
been demonstrated that this is mainly due to the fact 
that the high rate of reverse tri-iodothyronine re-
moval (reaction II) occurs at a lower pH (Hilfner 
et al., 1977; Visser et a!., 1978). If this reaction was 
taken into account, 5-deiodination of thyroxine was 
found to be optimal at pH8.0 (Visser et al., 1978), 
which has also been observed by Cavalieri et a!. 
(1977). The latter investigators studied reaction III 
in rat liver cytosolic fraction. This preparation con-
tains little enzyme activity. but studies involving its 
use are apparently not hampered by reverse tri-
iodothyronine-degrading activity (Cavalieri et a! .. 
1977). The results in Table 1 are in agreement with 
the data of Cavalieri et al. (1977) and Visser et al. 
(1978), since Km is lowest and Vis highest at pH8.0. 
Formation of di-iodothyronine from tri-iodothy-
ronine (reaction IV) has been shown to proceed 
maximally at pH8.0 (Chopra et al., 1978; Visser 
et al., 1978). This appears to be due to the low Km 
and high Vat this pH (Table 1 ). The magnitude of the 
Km at pH7.2 as found in the present study, 6.2,uM, is 
equal to the value published by Chopra era/. (1978), 
i.e. 6Jl.M. 
It has been suggested that the sequential deiodin-
ation of thyroxine is mediated by two enzymes, i.e. 
iodothyronine 5- and 5'-deiodinase (Visser, 1978). 
This hypothesis was based mainly on the finding that 
the reactions involving 5'-deiodination of thyroxine 
or reverse tri-iodothyronine showed a similar pH-
dependence (Visser et a/., 1978) and on the com-
petitive inhibition by reverse tri-iodothyronine of 
reaction I (Chopra, 1977; Hllfner eta!., 1977; see also 
Kaplan & Utiger, 1978). More recent observations 
support this concept in that it has been shown that 
reaction II is inhibited competitively by thyroxine 
(Kaplan & Utiger. 1978). Clinical observations are 
in line with this hypothesis, since in several situ.:~.tions 
production of tri-iodothyronine and degradation of 
reverse tri-iodothyronine in peripheral tissues are 
simultaneously diminished (Schimmel & Utiger. 
1977). We also showed that reactions involving 5-
deiodination of thyroxine or tri-iodothyronine 
exhibit similar pH profiles (Visser et al., 1978). This 
is confirmed in the present paper by the demonstra-
tion of a similar dependence on pH of both Km and 
V of these reactions (Table 1). 
The present study, however, reveals that the 
influence of pH on the kinetic parameters of the 5'-
deiodination reaction is dependent on the substrate 
used. We therefore thought it of importance to study 
the mutual inhibition by the substrates of reactions 
I and II at pH6.5 and at pH8.0. Since reverse tri-
iodothyronine is rapidly degraded under conditions 
where the deiodination of thyroxine is investigated, 
these studies were limited to the effect of thyroxine on 
the 5'-deiodination of reverse tri-iodothyronine. 
Despite the large variation in Km for the latter, the 
K 1 for thyroxine was identical at pH 6.5 and 8.0 
(Table 2). In concordance with Kaplan & Utiger 
(1978). the value of the K 1 for thyroxine was close to 
the Km for this compound in reaction I. It is con-
cluded. therefore, that 5'-deiodination of thyroxine 
as well as of reverse tri·iodothyronine is mediated by 
a single enzyme. 
These results strongly suggest that the presence of 
an iodine substituent at C-5 interferes with the inter-
action of the substrate with the 5'-deiodinase. Not 
only is the magnitude of Km greatly increased and 
that of V diminished, but the dependence on pH of 
these parameters is changed considerably. 
Recent investigations point to a Ping Pong mech-
anism (Laidler & Bunting, 1974) for reaction II and 
possibly for the deiodination of iodothyronines in 
general. Such a mechanism is supported by the 
following observations. (1) A decrease in the con-
centration of cofactor results in a proportional 
decrease in Km and V of reaction II (T. J. Visser. 
unpublished work). (2) Inhibition by thiouracil is 
uncompetitive with respect to substrate (Chopra 
eta! .. 1978). (3) Inhibition by thiouracil is competi-
tive with respect to cofactor (T. J. Visser. unpublished 
work). Thiouracil has been shown to react specifically 
with su\phenyl iodides. yielding mixed disulphides 
(Cunningham, 1964). and iodothyronine deiodinases 
contain essential thiol groups (Visser, 1978). Thus 
the reaction pathway may be regarded as a trans-
iodination and the subsequent reduction of an iodo-
enzyme complex (sulphenyl iodide) by cofactor. The 
magnitude of both V and Km would be dependent on 
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which step in this pathway is rate~ limiting (Laidler & 
Bunting, 1974}. 1t is conceivable that in reaction I the 
rate~ limiting step is different from that in reaction II. 
This may explain the difference in behaviour of both 
Vand Km of these reactions with respect to variations 
in pH. 
The present investigations have been carried out with 
financial aid from the Netherlands Organisation for the 
Advancement of Pure Research (ZWO). The technical aid 
of Marleen Krieger and Ellen van Overmecrcn is appreci-
ated. Thanks are also due to Corry Boot for expert 
secreturial assistance. 
References 
Burman, K. D. (1978) Merab. Clin. Exp. '27. 615-630 
Cavalieri, R. R. & Rapoport. B. (1977) Annu. Rev. Med. 
28,57-65 
Cavalieri. R. R.. Gavin, LA., Bui, F.. McMahon, F. & 
Hammond, M. (1977) Bi'ochem. Biophys. Res. Commun. 
79,897-902 
Chopra. I. J. (1977) Endocrinology 101.453-463 
Chopra, I. 1., Wu, S. Y., Nakamura. Y. &Solomon. D. H. 
(1978) Endocrinology 102, 1099-1106 
VoL 179 
Cunningham. L. W. (1964) Biochemistry 13,1-629-1634 
HOffkcn. B., KOdding, R. & Hesch, R. D. (1977) Clin. 
Chim. Acta 78, 261-266 
HUfner, M. & Grussendorf. M. (1978) C!in. Chim. Acta 
85, 243-251 
HUfner, M., Grusscndorf, M. & Ntokalou, M. (1977) 
Clin. Chim. Acta 78,251-259 
Kaplan. M. M. & Utiger. R. D. (1978)/. Clin.Invest. 61, 
459-471 
Laidler. K. 1. & Bunting, P. S. (1974) The Chemical 
Kinetics of En::yme Action, 2nd cdn., Clarendon Press, 
Oxford 
Lowry. 0. H .. Rosebrough, N. 1 •• Parr. A. L & Randall, 
R. 1. (1951) J. Bioi. Chern. 193, 265-275 
Rudolph. M .. Sakurada, T .• Fang, S. L.. Vagcnakis. A. G .. 
Braverman, L. E. & Ingbar. S. H. (1978) J. C!in. 
Endocrinol. Metab. 46, 923-928 
Sakurada, T., Rudolph, M., Fang, S. L. Vagenakis, A. G .. 
Braverman, L. E. & Ingbar, S. H. (1978) J. Clin. 
Endocrino!. Merab. 46,916-922 
Schimmel, M. & Utiger. R. D. (1977) Ann. Intern. Med. 
87. 760-768 
Visser, T. 1. (1978) Mol. Cell. Endocrino!. 10,241-247 
Yi~ser, T. 1 .. van dcr Doe.<;~Tobi&, I.. Docter. R. & Benne-
mann, G. (1976) Biochem. J. 157. 479-482 
Vh>scr. T. J .• Fekkes. D .. Docter, R. & Hennemann, G. 
(1978) Biochem. J. 174, 221-229 
302 
Biochimica et Biophysica Acta, 569 (1979) 302-308 
© Elsevier/North~Holland Biomedical Press 
BBA 68792 
MECHANISM OF ACTION OF IODOTHYRONINE-5' -DEIODINASE 
THEO J. VISSER 
Department of Internal Medicine III and Clinical Endocrinology, Medical Faculty, 
Erasmus University, Rotterdam (The Netherlands) 
(Received December 28th, 1978) 
Key words: !odothyronine; De iodination; Thiouracil: Ping-pong mechanism; Uncompetitive 
inhibition: Thiol cofactor 
Summary 
Production of 3,3' -di-iodothyronine (3,3' -T 2 ) from 3,3' ,5' -tri-iodothyronine 
(reverse T 3, rT 3) as catalysed by rat liver microsomal fraction was measured 
with a specific radioimmunoassay. The effect of the addition of 2-thiouracil 
and of varying concentrations of cofactor (dithiothreitol) on the kinetic param-
eters of this reaction were studied. It was found that thiouracil is an uncompe-
titive inhibitor with respect to substrate and a competitive inhibitor with 
respect to cofactor. The effect of a decrease in the concentration of cofactor 
was similar to the effect of addition of thiouracil, i.e. a proportional decrease in 
Km and V. The results strongly suggest that enzymatic 5' -deiodination cf iodo-
thyronines follows a ping-pong mechanism, which may be envisaged as a trans-
iodination and the subsequent reduction of the iodo-enzyme complex by 
cofactor. The intermediate is probably a sulfenyl iodide form of the enzyme, 
which reacts with thiouracil to yield a mixed disulfide. 
Introduction 
The observation that 2-thiouracil derivatives inhibit both enzymatic oxida-
tive iodination of thyroglobulin in the thyroid [1] and enzymatic reductive 
deiodination of thyroid hormones in peripheral tissues [2] is intriguing. It sug-
gests that thiouracil reacts with a similar intermediate in both processes. It has 
been proposed that in thyroid peroxidase catalysed iodinations the formation 
of an enzyme-sulfenyl iodide is involved [ 3-7]. Thioureylenes react selectively 
with -SI [ 4,6,7] groups yielding mixed disulfides. It has been shown that 
thyroid l).ormone-deiodinating enzymes (iodothyronine-5- and -5' -dciodinase) 
contain essential sulfhydryl groups [8-10]. Mercapto compounds such as 
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dithiothreitol, 2-mercaptoethanol and reduced glutathione are cofactors in this 
deiodination [8] (Eqn. 1, where Tin and Tin-1 are substrate and mono-
deiodinated iodothyronine, respectively). 
Tin + 2 R-SH ~. Tin-1 + R-S-S-R +HI (1) 
These findings suggest that a sulfenyl iodide intermediate is involved in both 
iodination and deiodination of thyroid hormones. To test this hypothesis the 
kinetics of the conversion of 3,3',5'-tri-iodothyronine (reverse T 3 , rT3 ) into 
3,3'-di-iodothyronine (3,3'-T,) (as a model for 5'-deiodinase catalysed deiodina-
tions) were analysed. The results strongly suggest that this reaction follows a 
ping-pong mechanism. It is shown that thiouracil inhibits the 5' -deiodination of 
rT 3 uncompetitively with respect to substrate and competitively with respect to 
cofactor (dithiothreitol). These findings are consistent with the formation of a 
-SI intermediate. 
Materials and Methods 
Conversion of rT 3 into 3,3' -T 2 was studied as previously described [11,12]. 
In short, 0.01-1 pM rT 3 was reacted with rat liver microsomal fraction (3.5-7 
pg of protein) in 0.25 ml 0.066 M sodium phosphate, containing 3 mM EDTA 
and 0.2-10 mM dithiothreitol (pH 6.5 or pH 8.0). In experiments dealing with 
the effect of thiouracil, this compound was added at a final concentration of 
0.5 or 1 pM. After incubation for 15 min at 37°C, the reaction was halted by 
the addition of 1 ml 1.25% of the detergent Brij-35 in 0.06 M barbital, 0.15 M 
NaCI, 0.1% bovine serum albumin (pH 8.6) at 0°C. The amount of 3,3'-T, pro-
duced was determined radioimmunologically in 50 pi of the extract [13]. The 
sensitivity of this assay is approx. 1 pg (2 fmol) 3,3'-T,jtube. Cross-reactivities 
by 3,3',5-tri-iodothyronine, rT 3, 3,5- and 3',5'-di-iodothyronine are all less than 
0.05%, and by 3- and 3' -iodothyronine approx. 1%. Both incubation and radio-
immunoassay were performed in duplicate. The data shown are taken from 
representative experiments, which were repeated at least once with similar 
results. 
Dithiothreitol, Brij-35 and thiouracil were obtained from Sigma Chemical 
Co., St. Louis, MO, U.S.A.; rT3 and 3,3'-T, were purchased from Henning 
GmbH, Berlin, F.R.G. 
Results 
Both pH 6.0-6.5 [11] and pH 8.0 [14,15] have been reported to be 
optimal for the conversion of rT3 into 3,3'-T,. These apparently conflicting 
results are explained by the finding that, in the range 6.5-8.0, Km as well as V 
increase with pH; from 0.035 to 0.23 pM and from 0.34 to 0.83 nmol3,3'-T2 / 
min/mg protein (37°C), respectively [12]. The present investigations were, 
therefore, carried out both at pH 6.5 and 8.0. It has been assessed that all sub-
strate added is free to interact with the enzyme by showing a linear relation 
between conversion rate and microsomal protein concentration [ 12]. 
It was found that both at pH 6.5 and 8.0 the degree of inhibition by 
thiouracil of the conversion of rT 3 into 3,3' -T 2 increased with substrate concen-
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Fil!;. 1. Lincweaver-Burk plot of tht' amount of 3,3'-T2 produced versus initial rTJ concentration in the 
absence (•) and the presence of 0.5 (O) and 1 (.t.) p.M thiouracil at (a) pH 6.5 or (b) pH 8.0. The concen-
tration of dithiothrcitol was (a) 1 or (b) 2 ml\1. 
tration. This is indicated by virtually parallel lines in the Lineweaver-Burk plot 
of the amount of 3,3' -T, produced versus initial rT 3 concentratin at different 
concentrations of thiouracil (Fig. 1), which is characteristic for uncompetitive 
inhibition [ 16]. Inhibition by thiouracil was obviated by increasing concentra-
tions of dithiothreitol. Double-reciprocal plots of the amount of 3,3'-T, pro-
duced versus dithiothreitol concentration at different concentrations of 
thiouracil demonstrate (Fig. 2) that inhibition by thiouracil is competitive with 
respect to cofactor both at pH 6.5 and 8.0. Addition of up to 1 mM uracil did 
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Fig. 2. Lineweaver-Burk plot of the amount of 3,3'-T2 produced versus dithiothreitol concentration in the 
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6.5 or (b) pH 8.0. The concentration of dithiothreitol was 0.2 (•} or 1 (0) mM. 
not affect 3,3'-T, production rate (Visser, T.J., unpublished observations). It 
was observed that decreasing the concentration of dithiothreitol resulted not 
only in decreased V values but also was there a proportional decrease in Km. 
This is shown by the parallel lines in the Lineweaver-Burk plot of the amount 
of 3,3' -T 2 produced versus initial rT 3 concentration at different concentrations 
of dithiothreitol both at pH 6.5 and 8.0 (Fig. 3), which strongly suggests a 
ping-pong mechanism [16] for this reaction. 
Discussion 
The finding that inhibition by thiouracil of the 5' -deiodination of rT 3 is 
uncompetitive with respect to substrate (Fig. 1) is in accordance with data 
published by Chopra et a!. [14] on the effect of 6-n-propyl-2-thiouracil. 
Chopra also found that conversion of thyroxine (T4 ) into 3,3' -5-tri-iodo-
thyronine (T 3 ) by rat liver homogenate is inhibited uncompetitively by propyl-
thiouracil [9]. These observations indicate that thiouracil derivatives react with 
an intermediate in the enzymatic deiodination of iodothyronines [16]. The 
finding that the inhibition by thiouracil is competitive with respect to cofactor 
(Fig. 2) is in line with a report by Leonard and Rosenberg in abstract form 
[17] on the effect of propylthiouracil on the 5'-deiodination of Ta in rat 
kidney tissue preparations. It is, however, in conflict with a previous com-
munication from this laboratory [11], where it was noted that the degree of 
inhibition by propylthiouracil of the deiodination of several iodothyronines in 
rat liver homogenate was similar whether or not incubations were carried out in 
the presence of exogenous cofactor (dithiothreitol). The reason for this 
apparent contradiction remains unclear but, obviously, the degree of inhibition 
by thiouracil derivatives will depend on the reaction conditions such as the 
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type and concentration of cofactor and the concentration of substrate. 
The effects of thiouracil on the kinetic parameters of the 5' -deiodination of 
rT 3 (Fig. 1) are similar to the effects of a decrease in the concentration of 
dithiothreitol (Fig. 3), i.e. a proportional decrease in Km and V. 
It is concluded that conversion of rT3 into 3,3'-T, follows a ping-pong 
mechanism involving the formation of an intermediate which is reduced by 
dithiothreitol to the native enzyme. The intermediate may also react with 
thiouracil yielding an inactive complex. The importance of the sulfur in thio-
uracil is illustrated by the finding that uracil is devoid of inhibitory activity. It 
has been suggested that, beside the well-documented reaction of thiourea and 
thiouracil with sulfenyl iodides [ 4,6], thiourea may also react with -S-S-
groups [ 3]. However, it has been shown that the reaction rate of thiouracil 
with disulfides is negligible compared with its reactivity towards sulfenyl 
iodides [ 4,6]. Reaction of thiouracil with sulfenyl iodides is much faster than 
the reaction of thiols with -SI groups [ 4]. In our study a significant effect of 
0.5 11M thiouracil was observed in the presence of over 1 mM dithiothreitol. 
Therefore, our results strongly suggest that an enzyme sulfenyl (E-8•) group-
probably a sulfenyl iodide - is formed during 5' -deiodination of iodo-
thyronines. 
Because of the similarity in enzymatic 5- and 5' -deiodination -both are 
stimulated by mercapto compounds and inhibited by thiouracil derivatives-
a general reaction pathway is proposed (Eqns. 2 and 3). 
Tin + E-SH ~ Tin · E-SH -> ~ ~ E-SI + Tin-1 
E-SI + 2 R-SH ~ E-SH + R-S-S-R + HI 
(2) 
(3) 
The formation of a non-covalent, iodothyronine-enzyme complex (Tin · E-SH) 
is followed by a displacement reaction, which may include generation of one or 
more distinct intermediates. Monodeiodinated iodothyronine (Tin-d is 
released and an enzyme-sulfenyl iodide (E-SI) is formed (Eqn. 2). The latter is 
reduced to the native state by cofactor (Eqn. 3). E-SI may also react with thio-
uracil (X-SH) yielding a mixed disulfide (E-S-8-X) (Eqn. 4). 
E-SI + X-SH ~ E-S-S-X + HI (4) 
In both latter reactions the second product (r-) is released. Free enzyme is 
obtained from E-S-S-X by reaction with cofactor [ 6] (Eqn. 5 ). 
E-S-S-X + 2 R-SH -> E-SH + R-S-S-R + X-SH (5) 
It should be emphasized that reactions 3 and 5 involve two thiol groups of the 
cofactor. In our case these are supplied by one molecule dithiothreitol. 
A corollary of the present study is that the substrate is not directly reduced 
by the cofactor. Rather, the catalytic process is characterized by two reactions: 
transiodination (Eqn. 2) and subsequent reduction of the iodo-enzyme com-
plex by cofactor (Eqn. 3 ). 
Reminiscent of the work of Hartman et al. on non-enzymatic deiodination 
of di-iodotyrosine by cysteine [18-20], enzymatic 5' -deiodination may 
proceed by addition of a proton to cs' yielding (1). This is facilitated by the 
electron-donating effect of a dissociated phenolic hydroxyl group. An enzymic 
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sulfhydryl group may then assist the elimination of r+ by forming a sulfenyl 
iodide. This model, however, does not account for the finding that rT 3 is a 
much better substrate for the 5'-deiodinase than To, the Km being 40-fold lower 
and the V being 20-fold higher at pH 7.2 and 37° C [12]. 
Another possible mechanism of action of iodothyronine-5' -deiodinase is 
related to that of thymidylate synthetase in the dehalogenation of 5-bromo-
and 5-iodo-2'-deoxyuridylate (IdUMP) (Ref. 21, see also Refs. 10, 11). This 
implies a primary attack of an enzymic sulfhydryl group to c'' yielding a 
covalent enzyme-5' -6' -dihydrosubstrate complex W. The elimination of r+ may 
100' H I 1 "l e , S - E § 
'A' 
0 
1~1 
OH 1¢H ~ ;,_, 
H H 
0 
2 
then be accomplished in a concerted mechanism as shown or with the aid of a 
second sulfhydryl group yielding an E-SI complex. Steric hindrance by bulky 
substituents on both C3 and C5 in T 4 may interfere with the approach of the 
enzymic sulfhydryl group to c''. Release of steric hindrance by deletion of one 
of these iodine atoms on the tyrosyl ring may account for the preferred reac-
tion with rT 3• Also one can envisage 5-deiodination to occur by this mechanism 
and not by the former because of the absence of the activating hydroxyl group 
on the tyrosyl ring. 
Because of the similarities between the structures of Id UMP, iodothyronines 
and 5-n-propyl-2-thiouracil -another strong inhibitor of the deiodination of 
thyroxine [2,22] -it was previously hypothesized [10,11] that the latter 
might inhibit the conversions competitively with respect to substrate. This 
appears to be ruled out by the present study. 
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Summary 
Previous studies have demonstrated that thiouracil inhibits the 5' -deiodina-
tion of 3,3' ,5' -triiodothyronine uncompetitively with respect to substrate and 
competitively with respect to cofactor (thiol compounds). This paper shows 
that sulfite is also a strong inhibitor of this reaction showing a dose-dependent 
effect between 1 }.LM and 1 mM. The mode of inhibition is similar to that 
described for thiouracil. Dose-dependent inhibition was also observed with 
thiosulfate (0.01-1 mM), iodide and thiocyanate (both greater than 1 mM). No 
effect was exerted by up to 10 mM cyanide and up to 100 mM azide. 
Methimazole and thiourea were weak inhibitors above 0.1 mM but inhibition 
did not reach completion. These experiments were carried out in the presence 
of 1 mM dithiothreitol. The effect of thiouracil was found to be competitively 
obviated by methimazole and thiourea. However, the effeft of sulfite and that 
of methimazole or thiourea were additive. It is proposed that an enzyme-
sulfenyl iodide is formed during deiodination (ping-pong mechanism). This 
sulfenyl iodide may be reduced by cofactor to yield native enzyme. It may also 
react with thioureylenes, yielding mixed disulfides, or with sulfite, yielding a 
thiosulfate. The enzyme-methimazole disulfide is apparently less stable than 
the enzyme-thiouracil complex. It is suggested that sulfite also reacts with the 
enzyme-thioureylene disul!ide. 
Introduction 
2-Thiouracil (1) derivatives and 2-mercapto-1-methylimidazole 
(methimazole; 2) are used in the treatment of hyperthyroidism. 
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Scheme I. Structures of thiouracil and methimazole. 
These drugs interfere with the biosynthesis of thyroxine by inhibiting thyroid 
peroxidase activity [1]. Of these compounds only the thiouracil derivatives have 
an additional effect on the deiodination of thyroid hormone in peripheral tis-
sues [1]. It has been shown that thiouracil derivatives uncompetitively inhibit 
the 5' -deiodination of thyroxine, yielding 3,3' 5-triiodothyronine (triiodo-
thyronine) [2], and of 3,3' ,5'-triiodothyronine (reverse triiodothyronine), 
yielding 3,3' -diiodothyronine (diiodothyronine) [3,4]. Thyroid hormone-
deiodinating enzymes contain essential sulfhydryl groups and thiol compounds 
are required for activity [ 5]. Thiouracil has been shown to react selectively 
with sulfenyl iodides forming mixed disulfides [ 6]. It was, therefore, proposed 
that deiodination follows a ping-pong mechanism implying the intermediate 
formation of an iodo-enzyme complex where the essential -SH group is 
converted into a -SI group [ 4]. In the uninhibited reaction this E-SI complex is 
subsequently reduced by cofactor [ 4]. The present study was undertaken to 
test this hypothesis by investigating the effects on the 5' -deiodination of 
reverse triiodothyronine by agents such as sulfite known to react with a sulfenyl 
sulfur. In addition, the interaction of methimazole and thiourea with the 
enzyme inhibited by thiouracil or sulfite was studied. The results demonstrate 
that the mode of inhibition by sulfite is similar to that previously shown for 
thiouracil [ 4]. However, inhibition by thiouracil is competitively obviated by 
methimazole and thiourea, whereas the effects of the latter compounds and 
that of sulfite are additive. 
Methods 
The conversion of reverse triiodothyronine into diiodothyronine by rat liver 
microsomal fraction in the presence of dithiothreitol was measured essentially 
as described previously [7]. In short, usually 0.1 J.LM reverse triiodothyronine 
was incubated in 0.25 ml 0.05 M phosphate containing 3 mM EDTA, 1 mM 
dithiothreitol (unless indicated otherwise) and other substances to be tested 
(pH 6.5) with 7 11g of microsomal protein/ml for 20 min at 37•c. The reaction 
was stopped by the addition of 1 ml 0.06 M barbitone buffer containing 0.1% 
bovine serum albumin and 0.1% SDS (pH 8.6). The amount of diiodothyronine 
produced was measured with a specific radioimmunoassay in 50 J1.) of the 
extract [ 8]. The reaction was started by the addition of microsomes. 
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Deiodinase activity was corrected for non-enzymic production of diiodo-
thyronine as measured in extracts of control incubations. In the controls, 
microsomes were added after the barbitone-SDS buffer. Usually, the amount of 
diiodothyronine produced in the absence of enzyme was negligible (less than 
5%) compared with that generated enzymically. Incubation and radioimmuno-
assay were performed in duplicate. 
Results 
At the concentration of microsomes used there is no significant binding of 
reverse triiodothyronine to non-enzymic constituents of this fraction and 
degradation of diiodothyronine is negligible [7]. Alterations in diiodothyronine 
accumulation by test substances either via an effect on substrate availability or 
via an effect on the stability of the product are, therefore, excluded. A dose-
dependent inhibition of diiodothyronine production was observed with 0.01-
10 ).LM thiouracil, 1 ).LM-1 mM sulfite, 0.01-1 mM thiosulfate and 1-100 mM 
iodide or thiocyanate (Fig. 1). Deiodinase activity was also lowered by 
methimazole and thiourea at concentrations above 0.1 mM. Inhibition by these 
compounds reached a plateau of only approx. 50% despite increasing their con-
centration above 10 mM. No effect was observed with up to 10 mM cyanide 
and up to 100 mM azide. A 50% reduction in deiodinase activity was obtained 
with 0.3 ).LM thiouracil, 0.02 mM sulfite, 0.2 mM thiosulfate and 20 mM thio-
urea, iodide or thiocyanate but not with even higher concentrations of 
methimazole. 
The effect of addition of 0.04 or 0.1 mM sulfite on the kinetics of the reac-
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Fig. 1. Inhibition of the conversion of :reverse triidothYtonine into 3,3' -diiodothyronine by various com-
pounds. The following substances were tested: ..,. , thiouracil (TU); •. so~; o, s 2or; •. C; 6., seN-; o, 
thiourea, and •. methimazole (MMI). For details see Methods. Results are means of 3-8 closely agreeing 
experiments. 
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tion was investigated. This resulted in virtually parallel displacements of the 
Lineweaver-Burk plot of the deiodination rate versus reverse triiodothyronine 
concentration (Fig. 2). This indicates that inhibition by sulfite is largely 
uncompetitive with respect to substrate. Increasing the concentration of 
dithiothreitol alleviated the effect of sulfite although not completely. Analysis 
by means of a double-reciprocal plot of diiodothyronine production rate versus 
dithiothreitol concentration revealed that the reaction of sulfite with the 
enzyme was largely competitive with cofactor (Fig. 3). These conclusions were 
supported by Dixon plots [9] of Figs. 2 and 3. In addition, it was found that 
the replots [9] of the 1/v axis intercepts in Fig. 2 and of the slopes in Fig. 3 as 
a function of so;- concentration were linear. 
In the experiments shown in Fig. 4 addition of 0.4 or 1 1-LM thiouracil alone 
resulted in a suppression of deiodinase activity by 52 and 70%, respectively. 
However, inhibition declined to 44 and 44%, respectively, in the presence of 
increasing concentrations of methimazole. This is virtually the maximum level 
of inhibition obtained with methimazole alone, i.e. 38%. The effects of thio-
uracil are, therefore, competitively obviated by methimazole. 
Addition of 0.04 or 0.1 mM sulfite suppressed diiodothyronine production 
rate by 59 and 72%, respectively (Fig. 5 ). Now, in the presence of methimazole 
inhibition was further increased to a maximum of 79 and 87%, respectively. 
Inhibition by methimazole alone in this case was at the maximum 48%. The 
effects of sulfite appear, therefore, to be additive to that of methimazole. In 
the experiments described in Figs. 2-5 very similar findings were obtained by 
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Fig. 4. Inhibition of the conversion of reverse triiodothyronine into 3,3'-di.iodothyroninc by the simul-
taneous addition of thiou.xacil (TU) and methimazole (MMI). TU was tested at concentrations of 0 (•). 
0.4 (.ol.) and 1 (•) ,uM. For deta.i.ls see Methods. Results axe means of four closely agreeing experiments. 
Fig. 5. Inhibition of the conversion of reverse triiodothyronine into 3,3' -triiodothyronine by the simul-
taneous addition of SO~ and methimazole (MMI). so~- was tested at concentrations of 0 (•). 0.04 (A) 
and 0.1 (•) mM. For details sec Methods. Results ate means of two closely agreeing experiments. 
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using 0.4 and 1 mM thiosulfate instead of sulfite and 1-100 mM thiourea 
instead of methimazole. 
It was found that the effects of the combined additions of thiouracul and 
sulfite, of thiouracil and iodide or of thiouracil and thiocyanate, tested in 
various proportions, were larger than the effects excerted by these compounds 
alone. 
Discussion 
When this study was in progress Leonard and Rosenberg [10] also reported 
on the effect of 6-propylthiouracil on the 5' -deiodination of thyroxine by rat 
kidney microsomal preparations. These investigators found that the inhibitory 
effect of thiouracil and propylthiouracil was attenuated by dithiothreitol, 
methimazole and thiourea but not by thiocyanate. They, however, noted a full 
restoration of deiodinase activity by 1 mM thiourea or methimazole, which in 
themselves did not inhibit triiodothyronine production. This discrepancy with 
our observation may be related to the differences in experimental conditions 
such as the choice of substrate and enzyme preparations, and the concentra-
tions thereof, difference in dithiothreitol concentrations (0.1 mM [10] or 
1 mM) and the absence [10] or presence (this paper) of air oxygen. In essence, 
nevertheless, their findings are in agreement with those presented by us previ-
ously [ 4] and in the present paper. 
It has been demonstrated by Leonard and Rosenberg [10] and by us [ 4] 
that enzymic 5' -deiodination follows a ping-pong mechanism. Reaction of the 
first substrate (iodothyronine) with the enzyme results in the formation of an 
intermediate enzyme-complex, which by reaction with the second substrate 
(thiol cofactor) is converted back into native enzyme. Since it has been shown 
[ 5] that iodothyronine-deiodinating enzymes contain essential cysteine 
residues it is quite conceivable that during deiodination a sulfhydryl group is 
being oxidized. In consideration of the high reactivity of thiouracil towards 
sulfenyl iodides compared with ordinary disulfides [ 6] the formation of an 
E-SI complex in the catalytic cycle was implied [ 4]. The findings that thio-
uracil inhibits this reaction uncompetitively with substrate [2-4,10] and 
competitively with cofactor [ 4,10] support this hypothesis. They demonstrate 
that thiouracil reacts only with an intermediate in the deiodination process, 
being also the site of reaction with cofactor (see Fig. 6). It is not excluded, 
however, that inhibition by thiouracil is due to a reaction with some other 
form of sulfenyl sulfur such as an activated (protonated) disulfide [11-15]. To 
test this possibility the effect of several agents known to react with protein 
disulfides was investigated. 
An intriguing observation was the high reactivity of SOl- in contrast to the 
inactivity of CN-. Cyanide is at least as reactive as SOl- towards both 
disulfides [11-13] and sulfenyl iodides [6]. It should, however, be kept in 
mind that the present experiments were carried out in the presence of 1 mM 
dithiothreitol. The products of the reaction of sol- and eN- with both a 
sulfenyl iodide and a disulfide are a thiosulfate and a thiocyanate, respectively. 
The difference in effect of sulfite and cyanide on the production of diiodo-
thyronine may well be due to differences in the rate of regeneration of the 
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sulfhydryl group from these products by dithiothreitoL Iodide and thiocyanate 
were found to be weak inhibitors of 5'-deiodinase activity (Fig. 1). 
Inhibition by sulfite is largely uncompetitive with substrate and competitive 
with cofactor. Thus, while belonging to an entirely different class of com-
pounds, the mode of inhibition of the 5' -deiodination of thyroid hormone by 
SOt is similar to that by thiouracil. These findings provide further evidence for 
the formation of an enzyme-sulfenyl group (E-S•) in this reaction. 
Alleviation of the inhibitory activity of thiouracil by methimazole may be 
due either to competition of these compounds for the sulfenyl group in the 
intermediate enzyme complex [ 6] (Fig. 6, Reactions 2 and 3) or to reaction of 
methimazole with the enzyme-thiouracil mixed disulfide. The reaction rate 
especially of methimazole but also that of thiourea with I)-lactoglobulin 
sulfenyl iodide are much higher compared with thiouracil [ 6]. This is in 
contrast with the results presented in this paper. It is shown that inhibition at 
saturating concentrations of methimazole is far from complete. This suggests 
that the mixed disulfide of enzyme with methimazole is rapidly reduced by 
cofactor (Fig. 6, Reaction 5). Recent studies on the structure-activity relation-
ship of thioureylenes have shown that the low activity of methimazole is 
primarily due to the methylation of N1 [16]. 
The mode of inhibition by Sol- is very similar to that of thiouracil. The 
different behaviour of methimazole with the sor -inhibited enzyme compared 
with its action in the presence of thiouracil was, therefore, unexpected. It has 
been reported that besides methimazole other compounds such as so;- react 
with I)-lactoglobulin-thiouracil disulfide [17]. This suggests that inhibition by 
sulfite is not prevented by methimazole but that reaction with so~- may even 
be accelerated by prior formation of the enzyme mixed disulfide with 
methimazole (Fig. 6, Reactions 3 and 6). It should be noted that in the pres-
ence of sulfite there is minor irreversible loss of enzyme activity, which is not 
overcome by increasing dithiothreitol concentrations (Fig. 3). It is not 
excluded, therefore, that the effects observed with the simultaneous addition 
of SOl- and methimazole may be accounted for to some extent by this action 
of sulfite. 
Fig. 6 is shown in an .attempt to clarify the several observations described in 
T-1 +E-SH---+T-1 1 +·/E-SI/ n · n-
CD 2 R-SH E:Sr~---------------+ n HI+ E-SH + R-S-5-R 
@ X1-SH HI+ E-S-S-X 1} @) 2 R-SHt J 
r;-, ~ (] 2 R-SH 0 ~-SH HI+ E-S-S-~ @ ou3 .j, 
0 $032- - -c...::___.,_ ____________ __. I + E-S-S0
3 
Fig, 6. Possible interactions of thiouracil (X1·SH), methimazole (Xz-SH) and so§ with iodothy:ronine 
5'-deiodinase. Unaltered thiouracil and methimazole are released in reactions 5 and 6. Simil.arly, un-
altered SO~- is a product of Reaction 7. T-In• iodothy:ronine. 
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this paper. Recent studies in our laboratory are compatible with this view, since 
it has been found [18] that binding of radioiodinated propylthiouracil to rat 
liver microsomal fraction is induced specifically by substrates of the iodo-
thyronine-5' -deiodinase. This binding is prevented competitively by dithio-
threitol, unlabelled propylthiouracil, methimazole and sulfite. Since, 
apparently, Reaction 5 for the enzyme-thiouracil mixed disulfide and Reac-
tion 7 are slow compared with Reaction 1 (Fig. 6), thiouracil and sulfite may 
be regarded as dead-end inhibitors. This is substantiated by the finding of linear 
replots of Figs. 2 and 3 [9]. 
In conclusion, the present study provides further evidence that an enzyme-
sulfenyl group, probably a sulfenyl iodide, is formed during 5' -deiodination of 
iodothyronines. In view of the lability of -SI groups in aqueous media [6] it 
will, however, be a difficult task to prove the actual formation of such a deriva-
tive of the 5' -deiodinase. 
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SUBSTRATE REQUIREMENT FOR INACTIVATION OF !OOOTHYRONINE 5'-DEIOD!NASE ACTIVITY 
BY THIOURACIL 
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SUMMARY 
Preincubation of rat liver microsomal fraction with 1 vM 2-thiouracil and 
either 0.01-1 ~M 3,3' ,5'-triiodothyronine, 0.01-1 ~M 3' ,5'-diiodothyronine, 
0.1-10 ~M thyroxine or 0.1-10 uM 3,5-diiodothyronine led to a persistent, 
progressive and concomitant decrease in subsequently assayed 3,3' ,5'-triiodo-
thyronine and 3' ,5'-diiodothyronine 5'-deiodinase activity. Preincubation with 
thiouracil alone, with iodothyronines alone or with thiouracil and 10 uM 
thyronine or 3,5-diiodotyrosine had virtually no effect. The results indicate 
that (1) a previously proposed ping-pong mechanism for thyroid hormone deiodin-
ation, involving the formation of an enzyme-sulfenyl iodide intermediate, is 
correct; (2) thyroxine, 3,3' ,5'-triiodothyronine and 3',5'-diiodothyronine are 
substrates for a common 5'-deiodinase; (3) this 5'-deiodinase is not fully 
specific as regards the position of the iodine substituents in the substrate, 
since it also appears to catalyse the 5-deiodination of 3,5-diiodothyronine. 
INTRODUCTION 
The main route of mefabolism of the iodoamino acids, iodotyrosines and 
iodothyronines, is by means of deiodination. In both instances the enzymatic 
reaction is a reductive process, yet different types of enzymes are involved. 
Deiodination of iodotyrosines is catalysed by a mictosomal enzyme complex, 
which uses reductive equivalents supplied by NADPH (Goswami and Rosenberg, 
1977). Iodothyronine deiodinase act~vity is also located in the microsomal 
fraction of several tissues, but present evidence indicates that it constitutes 
a single enzyme, where reductive equivalents are supplied by thiols (Visser et 
al, 1976; Fekkes et al, 1980). 
In the deiodination of 3,3' ,5,5'-tetraiodothyronine (thyroxine; T4) two 
types of reaction may be distinguished, i.e. deiodination of the phenolic ring 
(5'-deiodination), yielding 3,3',5-triiodothyronine (T3), and deiodination of 
the tyrosyl ring (5-deiodination), yielding 3,3' ,5'-triiodothyronine (rT3). 
Both T3 and rT3 are subject to further degradation by both 5- and 5'-deiodin-
ation. Of all occurring iodothyronines T3 is biologically the most active~ 
suggesting that deiodination of T4 is a possible site for the regulation of 
thyroid hormone activity at the level of peripheral tissues. It has been 
suggested (Visser, 1978) that 5- and 5'-deiodinations are mediated by separate 
enzymes (iodothyronine 5- and 5'-deiodinase). As yet no direct evidence has been 
presented to support this hypothesis. On the contrary, subcellular fractionation 
(Fekkes et al, 1979) and analysis of detergent extracts of microsomes with 
various techniques (Fekkes et al, 1980) have failed to separate 5- and 5'-
deiodinase activity. 
Recent findings (Leonard and Rosenberg, 1978, 1980; Visser, 1979, 1980) 
suggest that deiodination follows a ping-pong mechanism. This involves the 
transfer of an iodinium ion from the substrate to a sulfhydryl group of the 
enzyme leading to the formation of an enzyme-sulfenyl iodide (E-SI) complex. 
The E-SI intermediate is subsequently reduced by mercapto compounds (cofactor) 
to free enzyme. The enzyme is inhibited by derivatives of 2-thiouracil (TU) as 
these compounds react with the E-SI intermediate forming an enzyme-TU mixed 
disulfide (dead-end complex). This is supported by the finding that inhibition 
by TU is uncompetitive with substrate and competitive with cofactor. Thus, TU 
reacts with the enzyme only after formation of the E-SI intermediate and, 
therefore, only if substrate is present. This appears to be true as binding 
of radioactive TU to rat liver microsomal fraction is specifically induced 
by substrates of the 5'-deiodinase (Visser and Van Overmeeren, 1979; Leonard 
and Rosenberg, 1980). Moreover, the persistent inactivation of T4 5'-deiodinase 
activity by TU requires the presence of T4 (Leonard and Rosenberg, 1978, 1980). 
Results from previous experiments have suggested that the 5'-deiodination 
of several iodothyronines is mediated by a single enzyme. Thus, rT3 is a 
competitive inhibitor of the 5'-deiodination of T4 and vice versa where apparent 
Km and Ki values were found to be identical (Kaplan and Utiger, 1978; Visser et 
al, 1979a). Furthermore, the effect of pH on the 5'-deiodination of rT3 and 
3' ,5'-diiodothyronine (3' ,5'-T2)was found to be very similar (Visser and Van 
Overmeeren, 1980). Based on the above reaction model the possibility of a single 
enzyme catalysing the 5'-deiodination of the different iodothyronines has now 
been tested more directly. 
5'-Deiodinase activity of rat liver microsomal fraction was inactivated 
by coincubation with TU and rT3, 3' ,5'-T2, T4 or, though to a lesser extent, 
also with 3,5-T2 but not with 3,5-diiodotyrosine (DIT) or thyronine (T0). These 
results indicate that T4, rT3 and 3',5'-T2 are indeed substrates for a cowmen 
5'-deiodinase. The specificity of this enzyme, however, is not complete since 
it also appears to catalyse, though with lesser efficiency, the deiodination of 
3,5-T2. 
MATERIALS AND METHODS 
Materials 
L-Thyronine, 3,5- and 3' ,5'-diiodo-L-thyronine, 3,3' ,5'-triiodo-L-thyronine, 
L-thyroxine and 3,5-diiodo-L-tyrosine were of the highest purity available and 
were purchased from Henning Berlin GmbH, Germany. 2-Thiouracil, N-ethylmaleimide 
and D,L-dithiothreitol·were obtained from Sigma Chemical Co., St. Louis, MD, USA. 
Methods 
Rat liver microsomal fraction was prepared essentially as described (Visser 
et al, 1976). Aliquots of this preparation (final protein concentration 400 ~g/ 
ml) were incubated at 37°C with 1 ~M TU and various concentrations of iodoamino 
acids or T0 in 0.05 M phosphate, 3 mM EDTA, 0.1 mM dithiothreitol (OTT), pH 6.5. 
After 30 min the reaction mixtures were diluted 10-fold by the addition of 0.05 
M phosphate, 3 mt~ EDTA, pH 6.5, at 0° C. In control experiments, microsomes were 
incubated without iodoamino acids or T0 which were added only after the dilution 
of the reaction mixtures. The resulting suspensions were kept at 0° C until the 
assay of 5'-deiodinase activity. For this, aliquots of the mixtures were incub-
ated at 37° C with equal volumes of 0.05 M phosphate, 3 mM EDTA, 2 mM OTT, 
pH 6.5, containing 2 ~M 3' ,5'-T2 or 0.05 ~M rT3. After 15 min the reaction was 
stopped by the addition of 9 volumes 0.06 M barbitone, 0.15 M NaCl, 0.1% bovine 
serum albumin, 0.1% sodium dodecyl sulfate, pH 8.6, at room temperature. In 
controls, substrate was added only after the sodium dodecyl sulfate-buffer. The 
products formed (3'-iodothyronine and 3,3'-T2, respectively) were measured in 
duplicate by specific radioimmunoassays in 50 ~1 of the extracts (Visser et al, 
1979a; Visser and Van Overmeeren, 1980). 
In a similar type of experiment microsomes were preincubated for 30 min 
at 37° C with 1 mM N-ethylmaleimide (NEM) and 0.1-1 "M 3' ,5'-T2. The reaction 
mixtures were now diluted with 0.05 M phosphate, 3 mM EDTA, 2 mM OTT, pH 6.5, 
to block unreacted NEM. The subsequent assay of 5'-deiodinase activity with 
3',5'-T2 as the substrate was performed as described above. 
RESULTS 
Preincubation of rat liver microsomal fraction with thiouracil alone or 
with iodothyronines alone did not affect the 5'-deiodination of rT3 or 3' ,5'-
T2 in the second incubation. However, coiricubation of microsomes with 1 ~M TU 
and either 0.01-1 "M rT3, 0.01-1 "M 3' ,5'-T2 , 0.1-10 "t~ T4 or 0.1-10 "M 3,5-T2 
resulted in a persistent and progressive loss of rT3 5'-deiodinase activity 
(Fig. 1). After incubation of microsomes with TU in the presence of 10 uM r0 
or DIT, rT3 5'-deiodinase activity was found to be 91 ~ 9% and 80 ~ 7% (mean 
~S.D., n=6) of the control value, respectively. The presence of as little as 
0.01 uM rT3 or 3'~5'-T2 in the preincubation resulted in a loss of 60% of enzyme 
activity in both cases. The addition of 0.1 uM T4 or 1 uM 3,5-T2 to the reaction 
mixtures during the preincubation led to an persistent decrease in 5'-deiodinase 
activity by 40% and 60%, respectively {Fig. 1.). Under the conditions tested, 
maximum inhibition was obtained with 0.1 ~M rT3 or 3' ,5'-T2, 1 ~M T4 and 10 ~M 
3,5-T2 and amounted to approximately 80%. 
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Fig. 1. Effect of preincubation of rat liver microsomal fraction with 1 ~M TU 
with or without varicus concentrations of rT3, 3' ,5'-T2, T4 or 3,5-T2 
on the subsequent assay of rT3 5'-deiodinase activity. For details see 
text. Results are expressed as percentage of control and are given as 
mean+ S.D. (n=4-8). 
Figure 2 shows that coincubation of microsomes with 1 uM TU and increasing 
concentrations of 3' ,5'-T2, T4 or 3,5-T2 led to a progressive, parallel loss of 
rT3 and 3' ,5'-Tz 5'-deiodinase activity. Irrespective of the substrate used in 
the second incubation, virtually maximum(approximately 70%) inhibition was 
reached again using 0.1 "M rT3 or 3',5'-T2, 1 "M T4 or 10 "M 3,5-T2. 
Even after the subsequent addition of excess OTT, 3' ,5'-T2 5'-deiodinase 
activity was found to be greatly inhibited following the reaction of microsomes 
with 1 mM NEM. Compared with the control experiment, where NEM was added only 
after the OTT, only 4-5% of deiodinase activity was left. The presence of 0.1 or 
1 ~M 3' ,5'-T2 during the preincubation did not protect against the inhibitory 
activity of NEf~. This resulted only in an increase in the subsequent 5'-deiodin-
ation of 3' ,5'-T2 to 7-8% of the control. 
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Fig. 2. Effect of preincubation of rat liver microsomal fraction with 1 ~M TU 
with or without various concentrations of 3' ,5'-T?, T4 or 3,5-T2 on the 
subsequent assay of rT3 (D) and 3' ,5'-T2 (a) 5'-d~iodTnase activity. For details see text. Results are expressed as percentage of control 
and are given as mean+ S.D. (n=4-8). 
DISCUSSION 
The conditions for the experiments described in the previous section were 
chosen such that concentrations of TU and iodothyronines were high enough in 
the first incubation to ensure a proper interaction with the enzyme. After 
dilution, the concentrations of these compounds wou1d need to be decreased as 
much as to prevent the interference with the subsequent assay of deiodinase 
activity. Previous studies had shown that 0.1 and 1 ~M TU inhibit enzyme activ-
ity by 25 and 75%, respectively, in reaction with mixtures containing 0.1 ~M 
rT3 (substrate) and 1 mM OTT (cofactor) at pH 6.5 (Visser et al, 1979b). In 
the present experiments, the mixtures contained 1 ~r1 TU and 0.1 mM OTT in the 
first, and 0.05 ~M TU and 1 mM OTT in the second incubation. At pH 6.5 in the 
presence of 3 mM OTT, apparent~ values for T4, rT3 and 3' ,5'-T2 are 3, 0.04 
and approximately 0.1 ~M. respectively. Oeiodination rates of rT3 and 3' ,5'-T2 
are also much higher compared with T4 (Visser et al, 1979a; Visser and Van Over-
meeren, 1980; D. Fekkes, E. van Overmeeren and T.J. Visser, unpublished work). 
The concentrations of 3',5'-Tz and T4 were at the most 1, 1 and 10 ~Min the 
first, and 0.05, 0.05 and 0.5 ~M, respectively, in the second incubation. In 
the presence of saturating concentrations of substrate in the second incubation, 
the small amount of iodothyronine carried over from the first incubation would, 
therefore, not interfere with the estimation of enzyme activity. These consider-
ations were borne out by the findings that enzyme activity measured after in-
cubation of microsomes with TU alone or with iodothyronine alone was not differ-
ent from the control experiment. 
It has been shown previously that only in the presence of substrate the 
reaction of TU with the 5'-deiodinase leads to a persistent inactivation of the 
enzyme (Leonard and Rosenberg, 1978; 1980; Visser, 1979). This is probably the 
result of the formation of an enzyme-TU mixed disulfide by reaction of TU with· 
an enzyme-sulfenyl iodide (E-SI) intermediate. We now have demonstrated that 
preincubation of rat liver microsomal fraction with TU and low concentrations 
of rT3, 3' ,5'-T2 or T4 results in a decrease in the subsequently assayed 5'-
deiodinase activity. These findings not only confirm the proposed mechanism 
of inhibition by TU, but also prove that indeed these iodothyronines are sub-
strates for a common 5'-deiodinase. This is substantiated once more by the 
observation that the effects on 5'-deiodinations of both rT3 and 3' ,5'-T2 were 
very similar depending on the conditions during the preincubation. The specific-
ity of the inactivation process is illustrated by the finding that the inhibit-
ory activity of TU is not or virtually not expressed in the presence of high 
concentrations of T0 or DIT. Moreover, the relative activity of T4, rT3 and 
3' ,5'-T2 in the induction of dead-end complex formation by TU mirrors their 
performance as substrates for the 5'-deiodinase. This is further support for 
the concept that compounds which assist in the inactivation of the 5'-deiodinase 
by TU are also substrates for this enzyme. 
Thus, there appears to be an absolute requirement for the presence of sub-
strate in the persistent inactivation of the 5'-deiodinase by TU. Unexpectedly, 
3,5-T2 also fulfilled this requirement, despite the absence of iodine sub-
stituents in the 3' and 5' positions. These results lead to the inevitable 
conclusion that 3,5-T2 is also deiodinated by the same enzyme which mediates 
the 5'-deiodination of other iodothyronines. Both 5- and 5'-deiodinations may, 
therefore, be catalysed by the same enzyme. Whether this reflects that only 
a single enzyme is involved in the entire sequential deiodination of thyroxine 
remains to be investigated. Published observations of the deiodination of 
thyroid hormone in vivo and in vitro are best explained by the two-enzyme 
hypothesis. If this hypothesis proves to be correct our results indicate that 
these enzymes have no absolute specificity. Recent studies have also shown that 
at high concentrations 3,5-T2 is a competitive inhibitor of the 5'-deiodination 
of 3' ,5'-T2 (D. Fekkes, E. van Overmeeren and T.J. Visser, unpublished work). 
The experiments involving NEM were also intended to give information on 
the substrate specificity of the 5'-deiodinase. If the enzyme-sulfhydryl group 
actively involved in the deiodination process, were the only one exposed to the 
environment, one would anticipate that occupation of the active site with sub-
strate would prevent NEM from blocking this group. In that case it would be 
possible to test by an entirely different approach which iodothyronines are 
substrates fo·r a common enzyme. The results once again demonstrate that thyroid 
hormone-deiodinating enzymes contain one or more essential cysteine residues. 
The failure of 3' ,5'-T2 to protect against the inactivation by NEM may suggest 
that the catalytic thiol group is not shielded sufficiently by the substrate 
under the conditions tested. It may also indicate that essential sulfhydryl 
groups are also located outside the active site of the enzyme. 
In conclusion, the present results demonstrate that 3,5-T2 is deiodinated 
by the enzyme catalysing the 5'-deiodination of other iodothyronines. The 
results at least indicate that thyroid hormone deiodinating enzymes do not 
display full specificity with respect to the position of the iodine atoms in 
the substrate. 
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